Code of Practice on Reproductive Technology & Embryo Research

Council on Human Reproductive Technology
August 2007
Code of Practice on Reproductive Technology & Embryo Research

Council on Human Reproductive Technology
August 2007

(Softcopy of this Code is available at http://www.chrt.org.hk)
<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapterholds</td>
<td></td>
</tr>
<tr>
<td>I. Introduction</td>
<td>1</td>
</tr>
<tr>
<td>- Preamble</td>
<td></td>
</tr>
<tr>
<td>- Application of the Code</td>
<td></td>
</tr>
<tr>
<td>- Interpretation of the Human Reproductive Technology Ordinance and Promulgation of the Code</td>
<td></td>
</tr>
<tr>
<td>II. Staff</td>
<td>3</td>
</tr>
<tr>
<td>- General</td>
<td></td>
</tr>
<tr>
<td>- Person Responsible</td>
<td></td>
</tr>
<tr>
<td>- Licensee</td>
<td></td>
</tr>
<tr>
<td>- Medical Practitioners</td>
<td></td>
</tr>
<tr>
<td>- Nursing Staff</td>
<td></td>
</tr>
<tr>
<td>- Staff Engaged in Scientific/Laboratory Services</td>
<td></td>
</tr>
<tr>
<td>- Counsellors</td>
<td></td>
</tr>
<tr>
<td>- Fitness to Practise</td>
<td></td>
</tr>
<tr>
<td>III. Facilities and Equipment</td>
<td>5</td>
</tr>
<tr>
<td>- General Standard of Clinical and Laboratory Facilities</td>
<td></td>
</tr>
<tr>
<td>- Minimum Requirements for RT Centres offering IVF Services</td>
<td></td>
</tr>
<tr>
<td>- Storage Facilities for Gametes and Embryos</td>
<td></td>
</tr>
<tr>
<td>- Counselling Facilities</td>
<td></td>
</tr>
<tr>
<td>IV. Assessment of Clients, Donors and Welfare of Children</td>
<td>7</td>
</tr>
<tr>
<td>- Assessment of Clients</td>
<td></td>
</tr>
<tr>
<td>- Proper Counselling</td>
<td></td>
</tr>
<tr>
<td>- Assessment of Donors of Gametes and Embryos</td>
<td></td>
</tr>
<tr>
<td>- Persons Considered Unsuitable as Donors</td>
<td></td>
</tr>
<tr>
<td>- Payment to Donors</td>
<td></td>
</tr>
<tr>
<td>V. Information to Clients and Donors</td>
<td>10</td>
</tr>
<tr>
<td>- General</td>
<td></td>
</tr>
<tr>
<td>- Information to Clients</td>
<td></td>
</tr>
<tr>
<td>- Information to Donors of Gametes or Embryos</td>
<td></td>
</tr>
</tbody>
</table>
Consent
- Informed Consent
- Consent of Husband in Cases of Donor Insemination
- Consent to Use of Gametes and Embryos
- Consent to Storage of Gametes and Embryos
- Consent Forms

Counselling
- General
- Counselling for Potential Clients of RT Services
- Counselling for Clients where Donated Gametes or Embryos are to be Used
- Counselling for Clients Undergoing Infertility Treatment
- Counselling for Potential Donors of Gametes or Embryos

Treatment Method
- General Standards
- Embryonic/Fetal Reduction
- Pre-implantation Genetic Diagnosis

Use of Gametes and Embryos
- Collection of Gametes or Embryos
- Screening and Selection of Gametes or Embryos
- Local Transfer of Gametes or Embryos between Licensed Centres
- Importation of Gametes or Embryos
- Limitation on Number of Times Donated Gametes or Embryos may be Used
- Limitation on Number and Source of Eggs or Embryos that may be Placed in a Woman
- Fresh Ovum Donation
- Exportation of Gametes or Embryos

Storage and Disposal of Gametes and Embryos
- Security
- Ensuring Quality of Gametes and Embryos
- Disposal of Gametes and Embryos
- Maximum Storage Period for Gametes or Embryos
- Storage of Embryos for Married Persons Only
Storage of Gametes or Embryos for Cancer Patients or Other Patients
Post-humous Arrangement
General Principles for Storing Gametes and Embryos

XI. Research

Basic Principles
Prohibitions in Connection with Embryos
Use of Embryos for Research
Use of Human Embryonic Stem Cell for Research
Use of Fetal Ovarian or Testicular Tissue
Genetic Manipulation
Prohibition Against Commercial Dealings
Terms of Reference and Membership of Institutional Research Ethics Committee

XII. Surrogacy

XIII. Gender Selection

XIV. Record Keeping and Information Management

Accuracy and Confidentiality of Information
Keeping of Record
Submission of Information to Council
Disclosure of Information in Register A
Access to Information
Handling of Personal Data under the Personal Data (Privacy) Ordinance
Disclosure of Personal Information

XV. Handling of Complaints

Complaints against RT Centres
Breach of Code of Practice

References

Glossary of Abbreviations in the Code and Common Terms Used in RT
### Appendices

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendix I</td>
<td>Guidelines for Screening of Potential Gamete/Embryo Donors Against Infectious Diseases</td>
<td>43</td>
</tr>
<tr>
<td>Appendix II</td>
<td>Guidelines for Payment to Donors</td>
<td>45</td>
</tr>
<tr>
<td>Appendix III</td>
<td>Ethical Guidelines on Pre-implantation Genetic Diagnosis (PGD)</td>
<td>47</td>
</tr>
<tr>
<td>Appendix IV</td>
<td>Guidelines for Local Transfer of Gametes or Embryos between Licensed Centres</td>
<td>50</td>
</tr>
<tr>
<td>Appendix V</td>
<td>Guidelines on Disposal of Gametes or Embryos</td>
<td>52</td>
</tr>
<tr>
<td>Appendix VI</td>
<td>Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects</td>
<td>53</td>
</tr>
<tr>
<td>Appendix VII</td>
<td>Ethical Guidelines for Human Embryonic Stem Cell Research</td>
<td>58</td>
</tr>
<tr>
<td>Appendix VIII</td>
<td>Sex-linked Genetic Diseases</td>
<td>62</td>
</tr>
<tr>
<td>Appendix IX</td>
<td>Records to be Kept and Maintained by Licensed Centres</td>
<td>63</td>
</tr>
<tr>
<td>Appendix X</td>
<td>Fact Sheet on Disclosure of Information Related to Provision of Reproductive Technology Procedure</td>
<td>65</td>
</tr>
<tr>
<td>Appendix XI</td>
<td>Information Sheet on Personal Data Collected in Connection with Provision of Reproductive Technology Procedure / Donation</td>
<td>67</td>
</tr>
</tbody>
</table>

### Annexes

<table>
<thead>
<tr>
<th>Annex</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annex I</td>
<td>Supplementary Code of Practice on Reproductive Technology – Artificial Insemination by Husband (AIH)</td>
<td>69</td>
</tr>
<tr>
<td>Annex II</td>
<td>Sample Consent Forms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consent Form (1)  Freezing and Storage of Gametes (for own subsequent use)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consent Form (2)  Freezing and Storage of Embryos (for married couples’ own use)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consent Form (3)  Anonymous Donation of Sperm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consent Form (4)  Anonymous Donation of Eggs (Oocytes)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consent Form (5)  Anonymous Donation of Embryos</td>
<td></td>
</tr>
</tbody>
</table>
Consent Form (6)  Donor Insemination
Consent Form (7)  In Vitro Fertilization/Gamete Intra-Fallopian Transfer/Embryo Transfer (including frozen/thawed embryo)
Consent Form (8)  Designated Donation of Sperm
Consent Form (9)  Designated Donation of Eggs (Oocytes)
Consent Form (10)  Designated Donation of Embryos
Consent Form (11)  Disposal of Stored Embryos
Consent Form (12)  Surrogacy Arrangement
Consent Form (13)  Use of Reproductive Technology Procedures for Purposes of Gender Selection on Medical Ground
Consent Form (14)  Artificial Insemination by Husband (AIH)
Consent Form (15)  Disclosure of Personal Data in Connection with Reproductive Technology Procedure / Donation
Consent Form (16)  Checking on Previous Record of Donation of Gametes
Consent Form (17)  Checking on Previous Record of Donation of Embryo(s)

Annex III  Data Collection Forms

DC Form 1  Reproductive Technology Treatment Form (for treatment NOT involving donor gametes or embryos)
DC Form 2  Reproductive Technology Treatment Form (for RT treatment involving donor gametes or embryos [other than DI])
DC Form 3  Donor Insemination Treatment Form
DC Form 4  Pregnancy Outcome Form
DC Form 5  Donor Information Form (for gamete donors)
DC Form 6  Donor Information Form (for embryo donors)
DC Form 7  Artificial Insemination by Husband (AIH) Treatment Form

Annex IV  Annual Statistics

AS Form 1  In Vitro Fertilization and Embryo Transfer
AS Form 2  Gamete Intra-Fallopian Transfer
AS Form 3  Zygote Intra-Fallopian Transfer/Pronuclear Stage Tubal Transfer
AS Form 4  Frozen-Thawed Embryo Transfer
AS Form 5  Intra-Cytoplasmic Sperm Injection
| AS Form 6 | Use of Reproductive Technology for Surrogacy Arrangement |
| AS Form 7 | Use of Reproductive Technology for Gender Selection to Avoid Sex-linked Diseases |
| AS Form 8 | Others |
| AS Form 9 | Artificial Insemination by Husband (AIH) |
| AS Form 10 | Storage of Gametes / Embryos |
CODE OF PRACTICE ON REPRODUCTIVE TECHNOLOGY AND EMBRYO RESEARCH

CHAPTER I — INTRODUCTION

Preamble

1.1 The Council on Human Reproductive Technology (the Council) was established under section 4 of the Human Reproductive Technology Ordinance (Cap. 561) (the Ordinance) in April 2001. It takes a multidisciplinary approach and provides a framework to ensure the safe and informed practice of reproductive technology (RT) in a way which respects human life, the role of the family, the rights of service users and the welfare of children born through RT.

1.2 Under section 8 of the Ordinance, the Code of Practice on Reproductive Technology and Embryo Research (the Code) has been produced in consultation with, and provides detailed guidelines for RT service providers and embryo researchers.

1.3 The Code provides guidance for good practice, as described in subsequent chapters, which aim to support proper clinical and scientific procedures, to safeguard the health and interests of service users and to protect the welfare of children born through RT. Professionals concerned should still follow the codes of practice and professional ethics of their individual disciplines. The Code is not meant to supersede these.

Application of the Code

1.4 The Code came into effect on 1st August 2007. The Code will be reviewed and updated as necessary to keep up with developments in RT. Although a failure on the part of any person to observe any provision of the Code shall not of itself render the person liable to any proceedings, the Council, which is the licensing authority for RT services and embryo research, shall take into account any observance of or failure to observe the provisions of the Code when considering granting, renewal, variation, revocation or suspension of licences. The person may also become liable to legal or disciplinary proceedings if the act of non-observance also constitutes a breach of any statutory provision and / or code of conduct of any profession and/or civil duty of care.

Interpretation of the Human Reproductive Technology Ordinance and
Promulgation of the Code

1.5 All personnel involved in the provision of RT procedures or embryo research are advised to familiarize themselves with the Ordinance. Reference should be made to the Ordinance for definitions of specific terms.

1.6 The Code must be construed in a manner consistent with the

1 s.8(6) of the Human Reproductive Technology Ordinance (the Ordinance)
2 s.8(3) of the Ordinance
3 s.9 of the Ordinance

Code of Practice on RT & Embryo Research
provisions of the Ordinance.

1.7 Since artificial insemination by husband (AIH) is regarded as a relatively simple RT procedure, the Council considers that a simpler code is sufficient when AIH is being performed. The Supplementary Code of Practice on Reproductive Technology – Artificial Insemination by Husband (AIH) (attached herewith as Annex I and forms part and parcel of the Code) is prepared for compliance when AIH is performed by a RT service provider (whether or not other RT procedures are provided by the same service provider). However, when RT procedures other than AIH are performed by the RT service provider, he should comply with the provisions of the Code.
CHAPTER II — STAFF

General

2.1 As required by the Ordinance, no person shall carry on RT activities and embryo research except pursuant to a licence.  

Person Responsible

2.2 The "person responsible", in relation to a licence, refers to the individual specified in the licence as the individual under whose supervision the activities authorised by the licence shall be carried on. 

2.3 It shall be the duty of the person responsible to ensure that -

(a) the other persons to whom the licence applies are of such character, and are so qualified by training and experience, as to be suitable persons to participate in the relevant activity authorised by the licence;
(b) proper equipment is used;
(c) proper arrangements are made for the keeping of gametes and embryos and for the disposal of gametes and embryos that have been allowed to perish;
(d) proper practices are used in the course of that activity; and
(e) the conditions of the licence are complied with.

2.4 The person responsible should ensure that this Code is made known to all staff involved.

Licensee

2.5 The "licensee", in relation to a licence, is the holder of the licence as defined in the Ordinance. 

2.6 It is the duty of the licensee to ensure that the person responsible discharges his/her duty. The discharge of the duty by the person responsible should not be prejudiced if the licensee and the person responsible are the same person. 

Medical Practitioners

2.7 The overall clinical responsibility for RT procedures should be held by registered medical practitioner with relevant training and experience and with post-graduate qualifications recognised by the Hong Kong College of Obstetricians and Gynaecologists or the Hong Kong College of Surgeons, and recognised as an accredited specialist in Obstetrics & Gynaecology or

---

4 s.13 of the Ordinance  
5 s.2(1) of the Ordinance - interpretation of the term “person responsible”  
6 s.24(1) of the Ordinance  
7 s.24(3) of the Ordinance  
8 s.2(1) of the Ordinance - interpretation of the term “licensee”  
9 s.23(3) and s.24(2) of the Ordinance  
10 a medical practitioner registered in accordance with s.14 of the Medical Registration Ordinance (Cap. 161)
Reproductive Medicine under the Specialist Register of the Medical Council of Hong Kong. Centres performing intravaginal or intracervical insemination only are exempted from this requirement.

2.8 Medical staff in a training capacity shall only carry out such procedures under supervision.

Nursing Staff

2.9 All nursing staff employed by RT centres must be registered nurses or enrolled nurses under the Nurses Registration Ordinance (Cap. 164) and be appropriately trained for the duties they carry out.

Staff Engaged in Scientific/Laboratory Services

2.10 The person in charge of a RT laboratory should have an appropriate scientific or medical degree, plus a period of experience in a RT laboratory sufficient to qualify him/her to take full charge of the laboratory.

2.11 Scientific or laboratory staff should have a degree or higher qualification in a relevant discipline, plus a period of experience sufficient to qualify them to perform the duties of the respective RT procedures.

Counsellors

2.12 Counselling may be provided by doctors, nurses, social workers, clinical psychologists or other persons with suitable experience and/or qualifications as appropriate. Please refer to Chapter VII for details on counselling services.

Fitness to Practise

2.13 In the case of medical practitioners, reference should also be made to guidance laid down by the Medical Council of Hong Kong on fitness to practise.
CHAPTER III — FACILITIES AND EQUIPMENT

General Standard of Clinical and Laboratory Facilities

3.1 The person responsible must secure that proper facilities and equipment are used and maintained.\(^{11}\)

3.2 Backup and emergency support facilities for each technique practised should be available at RT centres, equivalent to those which are standard practice in other specialties and appropriate to the degree of risk involved.

3.3 A laboratory manual and logbook must be properly kept and maintained and be available for inspection by persons authorised by the Council.

Minimum Requirements for RT Centres Offering IVF Services

3.4 The minimum facilities and equipment required for RT centres offering in vitro fertilization (IVF) services include the following -

(a) laboratory facilities for semen analysis at least up to the specifications laid down in the World Health Organisation’s (WHO) current laboratory manual for examination of human semen, including light microscopes with phase-contrast optics, a haemocytometer, counting chambers, and the necessary reagents for determining sperm viability and morphology;

(b) a completely separate laboratory for handling gametes and embryos, which should be equipped with carbon dioxide incubator, safety cabinet with dissection microscope, inverted microscope, programmable freezer and liquid nitrogen tank, micromanipulator, refrigerator, upright microscope, centrifuge and other necessary equipment;

(c) culture media and purified water, which can either be bought ready made or be prepared in the laboratory. The water should be sterile and deionised;

(d) hormonal assay facilities, which should either be available at the RT centre or provided if required by another laboratory closely linked to it;

(e) ultrasound equipment, which should be readily available in the RT centre for monitoring ovarian function and may include a probe attachment to be used for ultrasonically guided retrieval of ova through the vagina;

(f) a laboratory properly set up and equipped for the purpose of oocyte collection, vacuum aspiration of the follicles and embryo transfer;

(g) facilities for resuscitation should be available for the procedure of oocyte collection. A properly equipped operating theatre is required if general anaesthesia is used for oocyte collection. Facilities for emergency laparotomy must be made readily available.

\(^{11}\) s.24(1)(b) of the Ordinance

Code of Practice on RT & Embryo Research
3.5 The embryology laboratory should be in close proximity to the egg collection room.

3.6 RT centres should ensure a continuous supply of electricity.

3.7 Centres performing embryo transfer should have cryopreservation facilities. If cryopreservation is among the activities carried out by the RT centre, the appropriate equipment, including a controlled biological freezer and properly maintained liquid nitrogen facilities, will be required. In RT centres undertaking research as well as providing services, additional and more sophisticated equipment may be required.

Storage Facilities for Gametes and Embryos

3.8 A proper and safe storage facility must be provided to preserve the viability of gametes and embryos, to minimise chances of accident, loss or contamination.

Counselling Facilities

3.9 If counselling is carried out in the RT centre, there should be a designated place with privacy and comfort for counselling, where discussion can take place undisturbed.
CHAPTER IV — ASSESSMENT OF CLIENTS, DONORS AND WELFARE OF CHILDREN

4.1 Under the Ordinance, any RT procedure may be provided only to persons who are the parties to a marriage, except where the RT procedure is:

(a) provided to a surrogate mother pursuant to a surrogacy arrangement;
(b) continued to be provided to persons who were the parties to a marriage when gametes were, or an embryo was, placed in the body of a woman pursuant to the procedure; or
(c) for obtaining gametes.

Assessment of Clients

4.2 Clients should be offered fair and unprejudiced assessment. Clients’ medical conditions should be fully assessed to determine the most appropriate treatment option.

4.3 In assessing clients’ suitability for RT procedure, the welfare of the child is of paramount importance. The assessment should take into account the clients’ physical, mental and social well-being, including the following factors:

(a) their commitment to having and bringing up a child or children;
(b) their ability to provide a stable and supportive environment for any child born as a result of treatment;
(c) their medical histories and the medical histories of their families;
(d) their ages and likely future ability to look after or provide for a child’s needs;
(e) their ability to meet the needs of any child or children who may be born as a result of treatment, including the implications of any possible multiple births or disability;
(f) any risk of harm to the child or children who may be born, including the risk of inherited disorders, problems during pregnancy and of neglect or abuse;
(g) in cases where donated gametes are used, the possible attitudes of other members of the family towards the child.

Proper Counselling

4.4 Proper counselling should be provided to the commissioning couple and concerned parties before RT procedure is provided (please also see paras. 7.5 to 7.8).

Assessment of Donors of Gametes and Embryos

4.5 RT centres must ensure that all potential donors are carefully screened to prevent transmission of infectious diseases. Donors should also be assessed for any personal or family history of hereditary disorders.

4.6 The necessity and implications of the screening procedure must
be explained to potential donors so that they understand screening may reveal previously unknown diseases such as HIV infection.

4.7 Guidelines for screening are at Appendix I. Gamete or embryo donors must be tested free of HIV antibody six months after donation before their donated gametes or embryos could be considered safe for use.

4.8 As a matter of good clinical practice, RT centres must ensure that the most up-to-date guidelines for screening against infectious diseases and hereditary disorders are followed. Re-screening and the inclusion of any other appropriate tests as may be indicated for a particular case should be adopted in line with professional standards of the relevant specialties.

4.9 Female donors should be below the age of 35 and male donors should be under 55 (Note 1). These age limits may be exceeded in appropriate circumstances or where the gametes are to be used for their own or their spouse’s treatment. For female donors, the age limit of 35 might be exceeded in appropriate circumstances and only under exceptional circumstances it might exceed 40. The reasons for waiving the age limit should be explained in the treatment record.

4.10 Gametes should not be taken from anyone under the age of 18 unless in exceptional cases where the gametes are for their own or their spouse’s treatment (Note 2).

4.11 Gametes must not be taken from anyone incapable of giving a valid consent.

4.12 Proper counselling should also be provided to potential donors of gametes or embryos (please also see para. 7.9).

Persons Considered Unsuitable as Donors

4.13 If the RT centre decides that a person is unsuitable as a donor, the reasons for the decision should be recorded and explained to the person. Appropriate counselling and referral for treatment or assistance should be arranged where necessary.

Note 1: An upper age limit for gamete or embryo donation is set because the risk of chromosomal abnormalities in gametes increases with age. The age limits for the male and female donors from whom the gametes are obtained to form the donated embryos should follow the age limits set out in para. 4.9.

Note 2: The lower age limit of 18 aims to protect minors who may not be mature enough to fully understand the implications of gamete or embryo donation.
Payment to Donors

4.14 Under the Ordinance, donors should not be paid for the supply of gametes or embryos, except for reimbursing or defraying\(^\text{13}\):

(a) the cost of removing, transporting or storing gametes or an embryo to be supplied; and

(b) any expenses or loss of earnings incurred by the donor.

4.15 Guidelines for payment to donors are at Appendix II. RT centres shall follow the guidelines strictly such that gamete donors shall not be paid more than the maximum daily payment level.

\(^{13}\) s.2(1) of the Ordinance - interpretation of the term “payment” and s.16(1)(a)

Code of Practice on RT & Embryo Research
CHAPTER V — INFORMATION TO CLIENTS AND DONORS

General

5.1 RT centres should devise a mechanism to ensure that relevant information is given to persons seeking RT procedure and those who want to donate gametes or embryos. RT centres should provide clients and donors with information on the services offered.

Information to Clients

5.2 Persons seeking RT procedure should be informed of the following -

(a) explanation of the procedure;
(b) possible discomfort, side effects and complications of treatment to the woman and the resulting pregnancy including, where relevant, risk of ovarian hyperstimulation syndrome or multiple pregnancy and indications for embryonic reduction;
(c) limitations and possible outcomes of the treatment;
(d) any other options available; and
(e) charges for services.

5.3 RT centres should also advise their clients on any information disseminated by the Council on matters related to legal provisions under the Ordinance and the Parent and Child Ordinance (Cap. 429) such as -

(a) the legal status of the child and parents;\(^\text{14}\)
(b) the child's right to access to information about whether he/she was born in consequence of RT involving donated gametes or donated embryos and non-identifying information about the donor on reaching the age of 16;\(^\text{15}\) and
(c) the legal obligation of RT centres to report information to the Council in accordance with the Ordinance.\(^\text{16}\)

Information to Donors of Gametes or Embryos

5.4 Donors of gametes or embryos should be informed of the following -

(a) the procedures involved and the associated discomfort, pain and risks, including the risk of ovarian hyperstimulation syndrome for egg (oocyte) donors;
(b) the screening tests to be performed and the implications of having the HIV antibody test (also see para. 4.7 and Appendix I);
(c) the purpose(s) for which their gametes or embryos may be used;
(d) a child may be born disabled as a result of the donor's failure to disclose defects, about which he or she knows or should reasonably have known; and
(e) a donor's donated gametes or embryos may not be allowed to

\(^{14}\) s.9 - 12 of the Parent and Child Ordinance  
\(^{15}\) s.33(3)(a), s.33(4), s.33(5) and s.33(7) of the Ordinance  
\(^{16}\) s.33(1) and s.33(2), s.45(2)(c) and s.45(2)(d) of the Ordinance  

Code of Practice on RT & Embryo Research
bring about more than three live birth events to minimise risk of inadvertent incest in the offspring.

5.5 A “live birth event” for the purposes of this Code shall mean an event of the birth in Hong Kong of one or more than one live child from one single pregnancy. The birth of live twins, triplets and so on will therefore be considered as a single “live birth event”. A “live birth event” will be assumed after the use of a donor’s gametes or embryos for RT procedure has been reported to the Council, unless the Council is informed otherwise.

5.6 RT centres should also advise donors on any information disseminated by the Council such as -

(a) protection under the Ordinance regarding donor’s anonymity and confidentiality of patients seeking infertility treatment;  
(b) whether or not they will be regarded as the parents of any child born as a result under the Laws of Hong Kong;  
(c) RT centres are required to register information on the donors with the Council under the Ordinance; and  
(d) reimbursement may only be given in accordance with the provision in the Ordinance (please see para. 4.14, para. 4.15 and Appendix II for details).

---

17 s.34 of the Ordinance  
18 s.9 - 12 of the Parent and Child Ordinance  
19 s.33(1) and s.33(2), s.45(2)(c) and s.45(2)(d) of the Ordinance  
20 s.2(1) of the Ordinance - interpretation of the term “payment” and s.16(1)(a)

Code of Practice on RT & Embryo Research
CHAPTER VI — CONSENT

Informed Consent

6.1 Informed consent with respect to receiving RT procedure, and to donating gametes or embryos must be obtained in writing.

6.2 RT practitioners are advised to refer to the Professional Code and Conduct for the Guidance of Registered Medical Practitioners issued by the Medical Council of Hong Kong for consent to surgical procedures.

Consent of Husband in Cases of Donor Insemination

6.3 In accepting appropriate recipients of donor insemination, the person responsible should always consider the welfare of the child.

6.4 The legitimacy of children born by donor insemination is protected by law. Sections 9-11 of the Parent and Child Ordinance (Cap. 429) have provided for this. The parentage of children born by donor insemination is to be determined in accordance with the law.

6.5 RT centres should obtain the written consent of the commissioning woman's husband to avoid any disputes about the fatherhood of the child born of donor insemination.

Consent to Use of Gametes and Embryos

6.6 Clients / Donors must consent in writing and specify the purpose(s) for which the gametes or embryos may be used. Consent in writing may be given for one or more of the following purpose(s) -

(a) to provide treatment for themselves or their spouse;
(b) to donate to a pool kept by the RT centre for treating other infertile patients; or
(c) for research.

For (b) and (c) above, consent cannot be revoked once the gametes or embryos have been donated.

Consent to Storage of Gametes and Embryos
(This section is not applicable to anonymous donors and designated donors)

6.7 Clients who consent to the storage of their gametes or embryos must -

(a) specify the maximum period of storage if this is to be less than the maximum storage period recommended by the Code (details on maximum storage period are described in Chapter X); and
(b) state what is to be done with the gametes or embryos if he or she dies or becomes incapable of varying or revoking his or her consent (details on post-humous arrangement are described in Chapter X).
6.8 Clients should be informed that they are required to give a written notice of renewal of consent to the RT centre every two years. In the absence of a renewal notice, RT centres may dispose of the stored gametes or embryos, donate them for treatment of other infertile couple(s) or donate for research in accordance with the instruction given by the clients at the start of the storage.

6.9 Clients may vary or withdraw their consent at any time in writing provided that the gametes or embryos have not already been used in treatment.

Consent Forms

6.10 RT centres are required to make use of the appropriate sample consent forms at Annex II unless there are justifiable reasons why they should not be used or should be departed from or modified.
CHAPTER VII — COUNSELLING

General

7.1 Counselling service must be recommended and made available to all clients and donors. Counselling service may be provided by doctors, nurses, social workers, clinical psychologists or other persons with suitable experience and/ or qualifications. For RT procedures involving donation of gamete(s) or embryo(s) from person(s) other than the couple who seeks treatment, counselling service should be provided by an independent person who is not involved in the treatment or clinical decision-making process.

7.2 Counselling services provided pursuant to paragraph 7.1 above should be non-directional and should include discussions on the implications of the RT procedure intended to be undertaken as well as consideration of other options (including adoption). Couples seeking treatment should be given adequate time to consider the matter after counselling before they make a decision as to whether to undergo the RT procedure. If necessary, more than one session of counselling ought to be provided. Counselling service should also be recommended and provided to the patient after commencement or completion of the RT procedure (e.g. to address the consequences of treatment and to cope with the emotional stress and social adjustment) if the situation so warrants.

7.3 Information obtained during counselling must be kept in confidence.

7.4 Proper records should be kept of the counselling service offered.

Counselling for Potential Clients of RT Services

7.5 Counsellors should ask potential clients to consider carefully all possible implications before receiving RT services, such as -

(a) the implications of the RT procedure on themselves, their family and relatives, their social life, and any resulting or existing children;
(b) the financial implications of the RT procedure (e.g. there is the possibility of multiple pregnancy);
(c) their feelings about manipulation of their own gametes or embryos outside their bodies, and the possible storage and disposal of gametes or embryos;
(d) the chances that treatment may fail;
(e) the possibility of the need of embryonic/fetal reduction;
(f) the alternative of adoption of a child;
(g) the possibilities that the implications of and feelings about their RT procedure may change as personal circumstance changes;
(h) all the terms and conditions set out in the consent form;
(i) the submission of their particulars to the register(s) kept by the Council in accordance with the Ordinance and its subsidiary legislation(s).21 They should also be informed that a child born from RT procedure may apply to the Council when he/she reaches the age of 16 to check whether he/she was born in consequence of a RT procedure involving gametes or embryos.

21 s.33(1) and s.33(2), s.45(2)(c) and s.45(2)(d) of the Ordinance
not solely from his/her parents.  

Counselling for Clients where Donated Gametes or Embryos are to be Used

In cases where donated gametes or embryos are used, clients should be advised to consider -

(a) their own feelings about not being the genetic parent of the child;
(b) their spouse's feelings about not being the genetic parent of the child;
(c) the desirability of revealing the history of gamete/embryo donation to their future child and the possible reaction of the child;
(d) the desirability of informing their future child of the right to check information in Register A before marriage (please see para. 7.5(i) above) to avoid incest; and
(e) the importance of reporting to the RT centres any successful births so that donated gametes or embryos will not be used to bring about more than three live birth events to avoid the possibility of inadvertent incest in the offspring (please also see para. 9.6).

Counselling for Clients Undergoing Infertility Treatment

Counselling must be available to help clients to cope with consequences of infertility and RT services. Counselling should be offered to support infertile people who are not suitable for RT procedure or those whose treatment has failed to allow them to adjust their expectation and to accept the situation.

When indicated by the clients, they should be referred for specialist counselling or support group counselling as appropriate.

Counselling for Potential Donors of Gametes or Embryos

Counsellors should ask potential donors of gametes or embryos to consider all possible implications such as -

(a) their reasons for wanting to donate gametes or embryos;
(b) implications of the procedure for themselves, their spouse, their family and relatives, their social circle and any resulting child;
(c) their feelings about manipulation of their gametes or embryos outside the human body and the possible storage and disposal of gametes or embryos;
(d) their willingness to forego knowledge of and responsibility for the resulting children;
(e) their perception of the needs of any resulting children;
(f) the feelings of their spouse or sex partner;
(g) their attitudes to allowing embryos which have been produced from their gametes to be used for research;
(h) the submission of their particulars to the register(s) kept by the Council in accordance with the Ordinance and its subsidiary

22 s.33(3), s.33(4) and s.33(5) of the Ordinance
They should also be informed that a child born from RT procedure may apply to the Council when he/she reaches the age of 16 to check whether he/she was born in consequence of a RT procedure involving gametes or embryos not solely from his/her parents.
CHAPTER VIII — TREATMENT METHOD

General Standards

8.1 The attending clinician must ensure that the treatment method offered is the one which best suits the couple's particular medical indication.

8.2 Established laboratory standards and clinical practices accepted by the professional association of the relevant specialty should be adopted to safeguard the health and safety of clients and donors.

8.3 New reproductive technology and techniques must be scientifically validated and subject to ethical sanction by the Ethics Committee of the Council prior to introduction into clinical practice.

8.4 Indication for selecting a particular RT procedure must be stated in each case.

8.5 Side effects and complications arising from RT procedure must be recorded for each case.

Embryonic/Fetal Reduction

8.6 Whenever possible, RT practitioners must take measures to prevent high multiple pregnancies. This is to avoid the known risks of fetal mortality and retarded growth development in such cases, the health hazards to the mother and the possible psychological and practical consequences for both parents.

8.7 For IVF techniques, no more than three embryos should be placed at a time. For gamete intra-fallopian transfer (GIFT), the number of oocytes placed should not normally be more than three. However, as the fertilization/implantation rate is dependent on a woman's age and her medical condition, under special circumstances with medical justification, the limit of three oocytes or embryos may be relaxed for women above the age of 35 so that a maximum of four or five oocytes/embryos could be placed in the first and subsequent treatment cycles respectively. Such justifications must be recorded in the medical record and only the minimum number of embryo(s) should be placed. The Council will request additional information from clinics reporting high rates of multiple pregnancies.

8.8 If a pregnancy involving more than three fetuses should occur despite the above-mentioned precautions having been taken, and if the prognosis for the fetuses is so unfavourable, a procedure of fetal reduction may be necessary. The carrying out of fetal reduction procedure should comply with section 47A of the Offences Against the Person Ordinance (Cap. 212). The possibility of fetal reduction should be included in the pre-treatment counselling. Parents should be clearly informed of the reasons for embryonic/fetal reduction and the possible risks involved, and the procedure may not be carried out without their consent.
8.9 Embryonic/fetal reduction should not be carried out simply to comply with the request of the parents who prefer to have a fewer number of children from the pregnancy.

Pre-implantation Genetic Diagnosis

8.10 When pre-implantation genetic diagnosis (PGD) is used to combine IVF and genetic testing as a means of avoiding the transmission of a genetic abnormality or disease, the medical practitioners shall follow the principles of the Ethical Guidelines on PGD at Appendix III.
CHAPTER IX — USE OF GAMETES AND EMBRYOS

Collection of Gametes or Embryos

9.1 Collection of sperm for donation purpose and retrieval of eggs or embryos should only take place at a RT centre.

Screening and Selection of Gametes or Embryos

9.2 Only banked semen should be used for donor insemination (DI) to allow time for the screening process of donors and to reduce the possibility of incest. For artificial insemination by husband (AIH), both banked and fresh semen can be used.

9.3 Gametes and embryos which have been subject to procedures which carry an actual or unreasonable risk or harm to their developmental potential should not be used for treatment.

Local Transfer of Gametes or Embryos between Licensed Centres

9.4 In the case of local transfer of gametes or embryos between licensed centres, the guidelines at Appendix IV should be observed.

Importation of Gametes or Embryos

9.5 Gametes or embryos should not be imported for infertility treatment or embryo research unless the following conditions have been fulfilled -

(a) the use of imported embryos must follow the Ordinance and the laws of Hong Kong. No embryo that is created for research should be imported. Information as required in data collection forms (DC Form) 5 and 6 of Annex III has to be submitted to the Council (please see para. 14.5);

(b) the supplier has fulfilled all statutory health and export requirements of the exporting country;

(c) the supplier has not breached the code of practice in relation to RT or embryo research of the exporting country;

(d) the supplier is from a credible institution with good track records;

(e) the supplier certifies that the donated gametes or embryos have been screened against communicable diseases and hereditary disorders in compliance with international professional standards, taking into account the epidemiological pattern of diseases of the population from whom they are collected;

(f) the supplier and RT practitioner concerned ensure that the safety and quality of the gametes or embryos are protected during the transport process, in which -

(i) a reputable courier should be employed;

(ii) the container must be securely sealed to avoid contamination and prevent tampering;

(iii) suitable cold storage to preserve the gametes or embryos should be ensured; and

(iv) a specified person should be assigned to collect the

25 s.45(2)(g) of the Ordinance

Code of Practice on RT & Embryo Research
gametes or embryos upon arrival.

**Limitation on Number of Times Donated Gametes or Embryos may be Used**

9.6 Gametes or embryos from any single donor should not be used to produce more than three “live birth events”. The person responsible must try his/her best to ensure that this is observed through close liaison with the recipient couple(s), donor(s) and other RT centres to which the donor(s) has/have made donations. RT centres should obtain appropriate consent from donors to agree on proper checking and recording procedures to ensure that the limit is not exceeded.

9.7 RT centres are required to inform the Council within one week of the date when a donor’s gametes or embryos are used (DC Forms 5 and 6 at Annex III are relevant) and report on any successful pregnancy and birth resulting from donor’s gametes or embryos.

9.8 In case of imported gametes or embryos, only live birth events achieved in Hong Kong will be counted.26

9.9 If the donor has specified a limit lower than three live birth events, this must be observed if practicable.

**Limitation on Number and Source of Eggs or Embryos that may be Placed in a Woman**

9.10 Normally, no more than three oocytes or embryos should be placed in a woman in any one cycle. As the fertilization or implantation rate is dependent on a woman’s age and her medical condition, under special circumstances with medical justifications, the limit of three oocytes or embryos may be relaxed for patients above the age of 35 so that a maximum of four or five oocytes or embryos could be placed in the first and subsequent treatment cycles respectively. Such justifications must be recorded in the medical record.

9.11 Women should not be treated with gametes or with embryos derived from the gametes of more than one man or woman during any treatment cycle.

**Fresh Ovum Donation**

9.12 Fresh ova should only be used and embryo transfer should only be performed after full discussion with the concerned parties on the respective risks of HIV transmission involved in the use of fresh ova/embryos and thawed embryos. The donor must have been screened negative for HIV status before the donation.

---

26 s.45(2)(g) of the Ordinance

Code of Practice on RT & Embryo Research
Exportation of Gametes or Embryos

9.13 No embryo beyond 14 days old may be exported.

9.14 If the donated gametes or embryos are intended to be exported for use by persons overseas, this should be specified in the consent form for donation.

9.15 A donor’s gametes or embryos which have produced three live birth events in Hong Kong should not be exported for treatment of infertile patients overseas.

9.16 RT centres should report to the Council within three months after they have exported any gametes or embryos. Information should include the personal particulars of the client/couple exporting the gamete(s)/embryo(s), destinations, date of export and the reason for export, etc.

27 s.45(2)(g) of the Ordinance

Code of Practice on RT & Embryo Research
CHAPTER X — STORAGE AND DISPOSAL OF GAMETES AND EMBRYOS

Security

10.1 The storage facility must be properly designed and maintained at a secure location with controlled access and away from possible sources of contamination.

10.2 The person responsible should allow access only to designated individuals in the RT centre for whom such access is essential for their work.

10.3 The source of gametes and embryos should be accurately recorded and labelled in a manner which is not susceptible to unauthorised or undetectable alteration.

Ensuring Quality of Gametes and Embryos

10.4 RT centres are responsible for maintaining the gametes and embryos in good condition through periodic review of the status of the storage equipment and records.

Disposal of Gametes and Embryos

10.5 The ways by which surplus gametes and embryos will be disposed of should be discussed with the donors or clients and consent obtained in relation thereto vide the appropriate consent form(s). The guidelines on disposal of gametes or embryos at Appendix V should be observed.

Maximum Storage Period for Gametes or Embryos

10.6 The maximum storage period for anonymous donation involving gametes or embryos should be 10 years or when the donated gametes or embryos have brought about three live birth events, whichever is earlier.

10.7 Subject to para. 10.13, the maximum storage period for gametes or embryos stored for patients’ own use in a RT procedure should not exceed 10 years. RT centres may formulate their own policy for a maximum storage period less than 10 years.

10.8 Only under special circumstances may a designated recipient be permitted (please also see para. 14.9 for reporting information to the Council on such cases). The maximum storage period for donated gametes or embryos for a designated recipient should not exceed 2 years. Except under special circumstances (in which event reporting to the Council is required, please see para. 14.10), the maximum storage period for embryos produced from fertilizing donated gamete(s) with the gamete(s) from a designated recipient should also be 2 years.

Storage of Embryos for Married Persons Only

10.9 Embryos may be stored in licensed premises only for and on behalf of the parties to a marriage. A single person should not be allowed to store embryos created by using his/her own gametes including such embryos created outside Hong Kong since creation of embryos involves RT procedures which
should not be provided to a single person under the Ordinance.28

Storage of Gametes or Embryos for Cancer Patients or Other Patients

10.10 Cancer patients or other patients may be rendered infertile as a result of chemotherapy, radiotherapy, surgery or other medical treatment. Service may be provided for these patients, either single or married, who wish to store their gametes or embryos for their own or their spouse's future use. Only married patients are allowed to store embryos (please see para. 10.9 above).

10.11 In determining whether RT services should be provided to a patient, the clinician must take into account the welfare of the potential child born to this person and the patient's fitness for parenting. In order to protect the welfare of the child, gametes or embryos stored for cancer patients should only be used after the patient is "cured". The appropriate timing for insemination or gamete/embryo transfer is a matter for clinical judgement between the oncologists and gynaecologists. The arrangement for a post-humous child shall not be allowed.29 The same principles apply to other patients whose fertility is compromised as a result of other diseases or treatment process.

10.12 Stored gametes or embryos should not be used by "cured" patients unless the patients are married.30

10.13 Notwithstanding the provision in para. 10.7, the maximum storage period for gametes for cancer patients or other types of patients for medical reasons is until that patient is 55 years old or for 10 years, whichever is later. The maximum storage period for embryos for cancer patients or other types of patients for medical reasons is 10 years. The patient can specify an age limit lower than 55 or a maximum period shorter than 10 years.

10.14 The following should be observed when considering whether to provide gamete or embryo storage facilities for patients who may be rendered infertile as a result of disease or treatment -

(a) the welfare of the child is of paramount importance;
(b) fitness for parenting should be assessed;
(c) the gamete or embryo storage facilities are for patients who have not completed their families and whose fertility is compromised as a result of disease. The stored gametes or embryos are to be for the own use of the patient and his/her spouse;
(d) appropriate counselling on all the implications must be provided by service providers before patients make the decision to store their gametes or embryos;
(e) consent of the patient to store the gametes or embryos must be obtained in writing. The patient should specify the maximum storage period (if this is less than the period specified in para. 10.13) and state what is to be done with the gametes or embryos if they die or become incapable of revoking their consent (i.e. whether to donate them to other infertile couples or for research or to let them perish). The patient should also state in the

28 s.15(5) of the Ordinance
29 s.45(3) of the Ordinance
30 s.15(5) of the Ordinance

Code of Practice on RT & Embryo Research
consent form what is to be done with the stored embryos if the patient divorces or becomes legally separated. The patient’s consent for insemination or gamete/embryo transfer should also be obtained in writing;

(f) a couple should have joint authority to determine what is to be done to the embryos created from their gametes. Their conjoint decision in this regard should be obtained in writing before gametes collection and fertilization;

(g) upon death of the patient, gametes or embryos stored for the patient’s or spouse’s own use shall not be used by the surviving spouse to bring about a post-humous child.31

Post-humous Arrangement

10.15 Under the Parent and Child Ordinance (Cap. 429), where the sperm of a man was used after his death, or where an embryo was used after the death of the man with whose sperm the embryo was created, that man is not to be regarded as the father of the child for the purposes of the law of succession.32

10.16 Given the complexities and potential consequences of post-humous use of gametes or embryos, stored gametes or embryos should not be used to bring about a post-humous child. In cases where gametes or embryos are for the patient’s or the commissioning couple’s own use, upon the death of the patient/either one of the commissioning couple, the stored gametes or embryos should be disposed of, except that the gametes of the surviving spouse may still be retained for storage. However, if the patient has given written consent, or the commissioning couple has given conjoint written consent, the stored gametes or embryos can be donated for research or for treatment of other infertile couples.

General Principles for Storing Gametes and Embryos

10.17 In general, the following guiding principles for storing gametes and embryos should be observed -

(a) the welfare of the child is of paramount importance;

(b) all clients / donors must consent in writing and specify the purpose(s) for which their gametes or embryos may be used. Consent in writing may be given for one or more of the following purpose(s) -
   (i) to provide treatment for themselves or their spouse;
   (ii) to donate to a pool kept by the RT centre for the purpose of treating other infertile patients;
   (iii) for research;

(c) anyone consenting to store his/her gametes or embryos must specify the maximum storage period (if this is less than the periods specified in para. 10.6 - 10.8 and 10.13). In cases where gametes or embryos are stored for their own use, they must state what is to be done with the gametes or embryos (i.e. whether to donate them to other infertile couples or for research or to let them perish) if they die or become incapable of revoking their consent;

(d) a couple should have joint authority to determine what is to be
done to the embryos created from their gametes or donors' gametes. Their conjoint decision in this regard should be obtained in writing before gametes collection and fertilization;

gametes or embryos stored for the client's or commissioning couple's own use should not be stored beyond the death of the client or either one of the commissioning couple, except that the gametes of the surviving spouse may still be retained for storage.

If it is the wish of the client or commissioning couple and their written (conjoint) consent is obtained, the stored gametes or embryos may be donated for research or for treatment of other infertile couples. Such donated gametes or embryos for treatment of other infertile couples have to be properly screened before use to ensure that no genetic or infectious disease would be transmitted. (please see para. 4.5 to 4.8 on screening of donors);

(f) a client / patient may, by giving a written notice to the RT centre, collect his or her own gametes or embryos stored in the centre for the transfer of these gametes or embryos to –

(i) another local licensed centre; or

(ii) an overseas centre

for own use in RT procedure, donation to other couple(s) for use in RT procedure, or for donation for research.
CHAPTER XI — RESEARCH

Basic Principles

11.1 The Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects at Appendix VI should be observed.

11.2 No person shall bring about the creation of a human embryo for the purpose of research.

11.3 All researches which involve the development, storage, manipulation and usage of human embryos outside human body must be licensed by the Council.

11.4 Research protocols on human embryo research must be approved by the institution’s own research ethics committee before it is submitted to the Council for licence.

11.5 One of the factors that the Council will take into account in deciding whether to grant a licence for an embryo research project is the purpose for which the proposed project is carried out. Under normal circumstances, the Council will not grant a licence unless the project is considered necessary or desirable for the furtherance of one or more of the following purposes -

(a) to promote advances in the treatment of infertility;
(b) to increase knowledge about the causes or treatment of congenital disease;
(c) to increase knowledge about the causes or treatment of miscarriages;
(d) to develop more effective techniques of contraception;
(e) to develop methods for detecting the presence of gene or chromosome abnormalities in embryos before implantation;
(f) to increase knowledge about the development of embryos;
(g) to increase knowledge about serious disease; and
(h) to enable such knowledge to be applied in the development of treatments to combat serious disease.

Prohibitions in Connection with Embryos

11.6 The following activities in relation to human embryos are prohibited under the Ordinance -

(a) to bring about the creation of a human embryo for the purpose of embryo research;
(b) to combine human and non-human gametes or embryos or any part thereof such as to give rise to a two-cell zygote for the purpose of research (under such restriction, the Hamster Test may be performed under licence);
(c) to keep or use an embryo after the appearance of the primitive streak;
(d) to place any non-human gamete or embryo or any part thereof in

---

33 s.15(1)(a)(i) of the Ordinance
34 s.2(1) of the Ordinance - interpretation of the term "relevant activities" and s.13
35 s15(1)(a) to (f) of the Ordinance
any human;
(e) to place any human gamete or embryo or any part thereof in any animal;
(f) to replace the nucleus of a cell of an embryo with a nucleus taken from any other cell; and
(g) to clone any embryo.

Use of Embryos for Research

11.7 Where excess embryos are donated for research, written consent from the donors of the embryo must be obtained.

11.8 The standard of care provided to infertile couple should not be affected by their decision to donate or not to donate embryos for research.

11.9 No inducement or payment may be offered to potential donors to influence their decision.

11.10 No staff should be under any obligation to participate in embryo research if they have conscientious objection.36

11.11 Each institution involved in embryo research must maintain a multi-disciplinary institutional research ethics committee. Before permitting research, the institutional research ethics committee must satisfy itself -

(a) on the validity of the research;
(b) that the objectives of the proposed research cannot be achieved in any other way; and
(c) that the researchers have the necessary facilities and skills.

11.12 The institutional research ethics committee has the duty to monitor the progress of the research.

Use of Human Embryonic Stem Cell for Research

11.13 Researchers should note that extraction of embryonic stem cell would be regarded as use or manipulation of embryo and any research which involves the creation, use or manipulation of an embryo is an embryo research. Thus, the combination of human embryonic stem cells with non-human embryos, for the purpose of embryo research, is controlled under section 15(1)(a)(ii) of the Ordinance. Any person involving in the research relating to the use of human embryonic stem cell shall observe and follow the Ethical Guidelines for Human Embryonic Stem Cell Research at Appendix VII.

Use of Fetal Ovarian or Testicular Tissue

11.14 The use of fetal ovarian or testicular tissue for infertility treatment is prohibited under the Ordinance.37

11.15 In the case of research where no embryo is to be created, the use of fetal ovarian or testicular tissue is acceptable subject to the following controls -
(a) any activity prohibited under the Ordinance is strictly banned;  
(b) any embryo research activity not prohibited by law must be vetted by the applicant’s own institutional ethics committee before it is submitted to the Council for approval to carry on the relevant activity under licence;  
(c) written consent must be obtained from the mother of the fetus;  
(d) written consent should be obtained from the spouse or sex partner of the mother of the fetus where practicable; and  
(e) there should be no financial reward for donating fetal tissue.

11.16 The decision to carry out an abortion must be reached without consideration of the benefits of subsequent use of the aborted fetal tissue.

11.17 The management of the pregnancy of any mother should not be influenced by any potential use of the fetal tissue.

Genetic Manipulation

11.18 Any research which involves alteration of the genetic structure of gametes or embryos must be approved by the institutional research ethics committee before it is submitted to the Council for licence.

11.19 An intervention or research seeking to modify the human genome may only be undertaken for preventive, diagnostic or therapeutic purposes and only if its aim is not to introduce any modification in the genome of any descendants.

11.20 Germ-line gene therapy should not be performed.

11.21 As with all innovative therapies, somatic cell gene therapy should be subject to rigorous ethical appraisal and be used only when there is no alternative available or when it offers genuine advantages, such as safety or efficacy, over other types of treatment.

11.22 Somatic cell gene therapy may hold great potential benefit for some patients, but it may also carry risks. To ensure that the benefits are assessed and the risks are identified as expeditiously as possible, somatic cell gene therapy should be conducted in accordance with the principles for biomedical research involving human subjects of the Declaration of Helsinki.

11.23 The first candidates for somatic cell gene therapy should be patients who are suffering from a disorder which is life-threatening, or causes serious handicap, and for which treatment is unavailable or unsatisfactory, but which has not already progressed so far as to reduce significantly the potential for benefit.

Prohibition Against Commercial Dealings

11.24 Commercial dealings in gametes, embryos or fetal ovarian or testicular tissues are prohibited under the Ordinance.\(^{38}\)

\(^{38}\) s.16 of the Ordinance
11.25 The institutional research ethics committee should be responsible for scrutinizing research proposals involving human gametes or embryos before the proposals are submitted to the Council. In considering any such research proposal, guidelines relating to the use of human gametes, embryos or fetal tissues as provided in the Code should be followed.

11.26 An institution performing embryo research should have a research ethics committee, such committee should be formed and operated in accordance with the principles of the Declaration of Helsinki. As a general guideline, the following terms of reference could be considered -

(a) to advise the appointing institution on the ethics of the methodology involved in research involving human gametes or embryos;
(b) to keep under review such guidelines on the ethical requirements in research involving human gametes or embryos;
(c) to consider individual research protocols submitted to the committee, to advise the investigators and other bodies in the light of approved guidelines and where appropriate to certify that ethical requirements have been fulfilled, to enable researchers to state in their publications that ethical problems have received independent consideration; and
(d) to seek advice as appropriate from specialist advisers.

11.27 The membership of research ethics committees should allow for a sufficiently broad range of experience and expertise so that the committee can take account of the scientific and medical aspects as well as the ethical implications of a research proposal. Cooption of members should be allowed where appropriate. Members should be required to declare any interest for each proposal submitted.
CHAPTER XII — SURROGACY

12.1 Commercial surrogacy is prohibited under the Ordinance. Its arrangement or advertising is a criminal offence.\(^{39}\)

12.2 RT procedure may be provided pursuant to a surrogacy arrangement only if -

(a) the gametes used in the procedure are those of the parties to a marriage\(^{40}\), and

(b) the wife in that marriage is unable to carry a pregnancy to term and no other treatment option is practicable for her.

12.3 The suitability of a woman to be a surrogate mother should be assessed by a registered medical practitioner\(^{41}\), who is not responsible for the RT procedures regarding the surrogacy, by taking into account the following considerations -

(a) marital status;

(b) history of pregnancy; and

(c) physical and mental fitness to carry a baby of the woman. A woman who is at a higher risk of suffering from complications of pregnancy should not be allowed to be a surrogate mother.

12.4 A woman under the age of 21 shall not act as a surrogate mother.

12.5 Surrogacy should require the consent of both the surrogate mother and her husband if she is currently married.

12.6 The commissioning couple and surrogate mother should be informed that the surrogacy arrangement is unenforceable under law.\(^{42}\)

12.7 Counselling must be provided by a multi-disciplinary team of the RT centre for the commissioning couple and surrogate mother and her husband (if any) to ensure that all parties concerned understand the medical, social, legal, moral and ethical implications of surrogacy. The multi-disciplinary team for counselling in surrogacy should at least comprise -

(a) two non-attending registered medical practitioners who both recommended the arrangement to explain the medical implications and consequences;

(b) a legal advisor familiar with family matters to explain the legal implications to both the surrogate mother and the commissioning couple;

(c) a social worker familiar with medical related issues to explain the social and moral impacts;

(d) and/or a clinical psychologist when appropriate to make assessment.

\(^{39}\) s.17 of the Ordinance

\(^{40}\) s.14 of the Ordinance

\(^{41}\) a medical practitioner registered in accordance with s.14 of the Medical Registration Ordinance (Cap. 161)

\(^{42}\) s.18 of the Ordinance

Code of Practice on RT & Embryo Research
12.8 In assessing surrogate mother (and her husband if any), the welfare of the child is of paramount importance. The assessment should take into account her (their) physical, mental and social well-being, including the following factors -

(a) their commitment to having and bringing up a child or children;
(b) their ability to provide a stable and supportive environment for any child born as a result of surrogacy;
(c) their medical histories and the medical histories of their families;
(d) their ages and likely future ability to look after or provide for a child’s needs;
(e) their ability to meet the needs of any child or children who may be born as a result of surrogacy, including the implications of any possible multiple births or disability;
(f) any risk of harm to the child or children who may be born, including the risk of inherited disorders, problems during pregnancy and of neglect or abuse;
(g) the possible attitudes of other members of the family towards the child.

12.9 Recommendations of surrogacy with reasons and details of the counselling should be recorded properly.

12.10 RT centres should report to the Council on cases of surrogacy within three months after completion of the procedure for each treatment cycle. It is advisable to submit this report together with data collection form (DC Form) 1 at Annex III as required in para. 14.8. Information to be reported should include the personal particulars of the commissioning couple and surrogate mother (and her husband if any), their relationship and detailed justifications.
CHAPTER XIII — GENDER SELECTION

13.1 The use of RT procedures for the purpose of fetal sex selection for avoidance and prevention of the birth of a child with a severe sex-linked genetic disease should only be offered in cases where not less than 2 registered medical practitioners each state in writing that such selection is for the aforesaid purpose and that the disease sought to be avoided or prevented would be sufficiently severe to a person suffering it to justify such selection.\(^3\)

13.2 Sex selection for social reasons or for reasons other than the avoidance or prevention of the birth of a child with a severe sex-linked genetic disease is prohibited under the Ordinance.\(^4\)

13.3 Counselling should be provided to clients to facilitate their informed decision on sex selection or other available options.

13.4 Sex selection may be conducted only for the purpose of avoiding a sex-linked genetic disease specified in Schedule 2\(^5\) to the Ordinance which may prejudice the health of the embryo. Each disease in the schedule by itself is not an indication for sex selection. The Schedule is at Appendix VIII for reference.

13.5 Patients/clients should be advised to take into account the following factors when considering whether sex selection is an option to avoid the birth of a child with a severe sex-linked genetic disease -

(a) the probability of having an affected child;
(b) the chance of the child being physically or mentally handicapped;
(c) the natural history of the disease;
(d) the life expectancy of an affected child;
(e) whether the affected child needs to go through life long and/or invasive medical procedures/treatment;
(f) the perception of the parents of having an affected child;
(g) the ability of the parents to cope with an affected child; and
(h) the family and social support available for the parents.

13.6 Sperm treatment with sex-selective insemination has variable effectiveness. If this is recommended for cases which have a clear medical indication, the lack of reliability of any technique used should be disclosed to the patient.

13.7 PGD with sex-selective zygote transfer should only be carried out on medical grounds and in compliance with the requirement laid down in this part. PGD technique applied to determine normality of the embryo shall not be used for the purpose of sex selection.

13.8 Prenatal diagnosis with sex-selective abortion without medical grounds contravenes sections 46-47B of the Offences Against the Person Ordinance (Cap. 212) and renders the offender liable to criminal prosecution.

---

\(^3\) s.15(3)(b) of the Ordinance  
\(^4\) s.15(3)(b) of the Ordinance  
\(^5\) s.15(3)(a) and Schedule 2 of the Ordinance
13.9 RT centres should report to the Council on cases of sex selection achieved through RT (e.g. using sperm treatment with sex-selective insemination or PGD with sex-selective zygote transfer) within three months after the procedure has taken place. Information should include the personal particulars of the commissioning couple, the indication, the choice of technique and the outcome of sex selection procedure. The Council may make regulation specifying any other information to be submitted to the Council.\textsuperscript{46}

13.10 RT centres should also report to the Council on cases which resort to sex-selective abortion within three months after the abortion. Information should include the personal particulars of the couple, details of the indication as well as the sex of the abortus. Service providers are reminded to comply with section 47A of the Offences Against the Person Ordinance (Cap. 212) in relation to medical termination of pregnancy.

\textsuperscript{46} s.45(2)(d) of the Ordinance
CHAPTER XIV — RECORD KEEPING AND INFORMATION MANAGEMENT

Accuracy and Confidentiality of Information

14.1 RT centres must ensure personal records with identifying information are kept in confidence with controlled access and disclosed only in circumstances permitted by the Ordinance.\(^\text{47}\)

Keeping of Record

14.2 RT centres must keep medical records containing the names, correspondence addresses, identity card/passport numbers of all patients, donors and recipients of gametes and embryos. The record should include information on RT procedures performed, outcomes of RT procedures, the storage of gametes and embryos and the offspring produced as far as it is practicable. The registers and records required to be kept and maintained by RT centres are listed at Appendix IX.

14.3 General medical record kept and maintained under a treatment licence should be retained by the RT centres for at least 6 years. Record concerning the usage of donated gametes or embryos should be kept for at least 80 years. RT centres with research licence should keep record for at least 3 years after the report of the related research project was finalized and submitted to the Council.

Submission of Information to Council

14.4 RT centres are required to submit to the Council any information as required by it.

(A) Register A

14.5 Under section 33 of the Ordinance, the Council is required to keep and maintain a register, called Register A\(^\text{48}\), which shall contain any information obtained by the Council that:

(a) relates to the provision of a RT procedure where a child born or intended to be born in consequence of the procedure was not created from the gametes solely of the parents of the child; and

(b) the child, any of the parties to the marriage, or any individual whose gametes have been used, or any combination thereof, can be identified from the information.

14.6 The information required in para. 14.5 above should be submitted in the prescribed format using the data collection forms (DC Form) 2, 3, 4, 5 and 6 at Annex III.

(B) RT Procedures not Involving Use of Donated Gametes or Embryos

14.7 For RT procedures not involving use of donated gametes or donated embryos, RT centres are required to submit non-identifying information

---

\(^{47}\) s.34, s.35 and s.36 of the Ordinance

\(^{48}\) s.33(1) and s.33(2), s.45(2)(c) and s.45(2)(d) of the Ordinance

Code of Practice on RT & Embryo Research
on such cases to the Council.

14.8 The information required in para. 14.7 above should be submitted in the prescribed format using the data collection forms (DC Form) 1 and 4 at Annex III.

(C) Designated Donation

14.9 Designated donations of sperm/eggs/embryos should not be permitted unless under special circumstances. RT centres should report to the Council on such cases in writing within three months after completion of the procedure for each treatment cycle. It is advisable to submit this report together with the appropriate data collection forms (DC Forms) (as in Annex III), as required in para. 14.6 and 14.8. Information should include personal particulars of the donor(s) and the recipient couple, their relationship and detailed justifications as to why the donation has to be designated.

14.10 Embryos produced from fertilizing donated gamete(s) with the gamete(s) from a designated recipient should not be stored for more than two years except under special circumstances. In case embryo(s) produced from fertilizing donated gamete(s) with the gamete(s) from a designated recipient, and which has/have been stored for more than two years, is/are used, the RT centres concerned should submit a report to the Council within three months after completion of the procedure for each treatment cycle. It is advisable to submit this report together with the appropriate data collection forms (DC Forms). The period for which the embryo(s) has been stored before use, together with the reasons and justifications for the use of embryo(s) which exceed the maximum storage period of two years, should be clearly stated in the report.

(D) Others

14.11 Detailed information on the following should also be submitted to the Council on each case -

(a) exportation of gametes and embryos (para. 9.16);
(b) surrogacy (para. 12.10);
(c) sex selection (para. 13.9 and 13.10).

(E) Annual Statistics

14.12 Other non-identifying data in the prescribed format at Annex IV should be submitted on an annual basis to the Council. The use of uniform definitions should be adopted (please refer to the glossary of common terms used in RT in this Code).

Disclosure of Information in Register A

14.13 Under section 34 of the Ordinance, no person who is or has been an authorized person or a person to whom a licence applies or the holder of a licence shall disclose any information contained or required to be contained in Register A, except under one or more of the circumstances specified in Appendix X.49

49 s.33, s.34, s.35 and s.36 of the Ordinance

Code of Practice on RT & Embryo Research
Access to Information

14.14 Donors and recipients of gametes or embryos should be advised that a person who has attained the age of 16 may apply to the Council to ascertain whether or not that person was or may have been born in consequence of a RT procedure involving donated gametes or donated embryos.\(^{50}\)

Handling of Personal Data under the Personal Data (Privacy) Ordinance

14.15 The Personal Data (Privacy) Ordinance (Cap. 486) enables individuals to request access to and correction of personal data held by data users. RT service providers are advised that the rules and principles stipulated in the Personal Data (Privacy) Ordinance on the collection, retention, use, disposal, access to and correction of the personal data should be complied with.

Disclosure of Personal Information

14.16 RT centres should clearly explain to their clients (patient, donor, surrogate mother and their spouses) that the personal data they provide in connection with the provision of RT procedure(s) / donation may be disclosed for the purposes as stipulated by the Ordinance and the Code published from time to time by the Council (references should be made to Appendices X and XI). Consent from the party concerned on such disclosure should be obtained before the provision of the RT procedure(s) or the making of donation (consent form (15) is relevant).

\(^{50}\) s.33(3) of the Ordinance
CHAPTER XV — HANDLING OF COMPLAINTS

Complaints against RT Centres

15.1 RT centres should have in place an administrative arrangement with a designated staff at the appropriate level to acknowledge receipt of complaints and to take charge of investigations. The outcome of the investigation should be recorded and explained to the complainant.

15.2 If the complainant is dissatisfied with the outcome of investigation by the RT centre, he/she should be advised of other channels of airing their grievances including, if appropriate, the Investigation Committee of the Council or the Medical Council of Hong Kong (for matters relating to possible professional misconduct of medical practitioners).

Breach of Code of Practice

15.3 Any allegations of breach of the Code will be investigated by the Investigation Committee of the Council. Failure to co-operate with the Investigation Committee will be taken into account by the Council in assessing whether there is a ground for revocation, variation and/or suspension of the licence.

15.4 Professionals concerned are reminded that they are also bound by the codes of practice or ethics of their respective professional disciplines.

---

51 Schedule 1 s.6(c) of the Ordinance

Code of Practice on RT & Embryo Research
References

In drawing up this Code, references have been made to the following documents -


2. Code of Practice of the Human Fertilization & Embryology Authority, United Kingdom.


5. Professional Code and Conduct for the Guidance of Registered Medical Practitioners by the Medical Council of Hong Kong.


Glossary of Abbreviations in the Code and Common Terms Used in RT

Abbreviations in the Code

1. RT reproductive technology
2. the Ordinance the Human Reproductive Technology Ordinance
3. the Code the Code of Practice on Reproductive Technology and Embryo Research
4. the Council the Council on Human Reproductive Technology

Common terms used in RT

1. Artificial insemination (AI):
   This refers to the placing of sperm inside a woman’s vagina or uterus (i.e. womb) by means other than sexual intercourse. In artificial insemination by husband (AIH), the husband’s sperm is used. In artificial insemination by donor (AID or DI), sperm collected from a man who is not the woman’s husband is used.

2. Cell:
   The basic unit of all living organisms. Complex organisms such as humans are composed of somatic (body) cells and germ line (reproductive) cells.

3. Chromosome:
   A threadlike structure of DNA and associated proteins found coiled tightly together in the cell nucleus which carries genetic information in the form of genes. In humans each somatic cell contains 46 chromosomes (23 pairs); one of each chromosome in the pair is of maternal and one of paternal origin. Of these 22 are matching pairs and one pair determines sex (XX=female, XY=male).

4. Cloning:
   The production of two or more genetically identical individuals by nucleus substitution (“fusion cloning”) or by mechanical division of a cleaving zygote to yield identical cells each of which can form a new individual.

5. Cryopreservation:
   The freezing of gametes or embryos, usually in liquid nitrogen at -196°C, in order to store them for subsequent use.

6. Dispose of:
   The term “dispose of” used in this Code in relation to gametes or embryos refers to the process of thawing, being left to perish and disposal.

7. DNA:
   Deoxyribonucleic acid, the major constituent of the chromosomes, and the hereditary material of most living organisms.

8. Ectogenesis:
   The complete development of an embryo outside the body.
9. **Ectopic pregnancy:**
   A pregnancy in which implantation has taken place outside the uterine cavity.

10. **Egg donation:**
    Process where a fertile woman donates an egg to be fertilized in vitro with the semen of the partner of a woman who no longer produces eggs.

11. **Embryo:**
    The product of human conception, often understood to cover the period from fertilization to the end of the eighth week of pregnancy, during which time all the main organs are formed. “Pre-embryo” is sometimes used to cover the first fourteen days' development after fertilization. Around this point the “primitive streak” develops.

12. **Embryo (or ovum) transfer:**
    The process of transferring a fertilized egg in the course of IVF or GIFT procedures, where following development in vitro for two or three days, or after flushing from a woman’s uterus by lavage (at 5 days), an early embryo is placed in the uterus of an infertile woman in order to try to achieve implantation and pregnancy.

13. **Epididymal sperm aspiration (ESA):**
    A technique which aims to treat male infertility due to absence of sperm in the semen as a result of a blockage of the duct system. Such patients can have an operation to collect their sperm directly from the collection ducts behind the testicle (known as the epididymis).

14. **Fallopian tube:**
    The organ which carries an egg from the ovary to the womb.

15. **Fallopian replacement of eggs with delayed insemination (FREDI):**
    Eggs of any maturity are placed in the fallopian tube without spermatozoa, which are supplied later by high intrauterine insemination (IUI) at a time when the eggs are judged to be fully mature.

16. **Fertilization:**
    The fusing together of the maternal and paternal genetic material from the sperm and the egg.

17. **Foetus:**
    The product of conception from end of embryonic stage (eight weeks after fertilization) until birth.

18. **Gametes:**
    The reproductive cells, sperm and egg, which fuse to form a zygote. Each human gamete contains a basic set of 23 chromosomes - a haploid set; on fusion of egg and sperm a full (diploid) set of 46 chromosomes results. All other (somatic) cells in the body contain 46 chromosomes in their nuclei.
19. **Gamete micromanipulation**: These methods aim to enable those couples where the male partner has a low sperm count or poor quality sperm to use the partner’s sperm rather than donated sperm. The objective of many of these techniques is to bypass the zona pellucida (protein shell) which surrounds the egg, as this layer often prevents sperm which have poor motility or morphology from penetrating and fertilizing the egg. Examples of these micromanipulation techniques include Zona Drilling (ZD), Partial Zona Dissection (PZD), Sub Zonal Insemination (SUZI), Intra Cytoplasmic Sperm Injection (ICSI), and Epididymal Sperm Aspiration (ESA).

20. **Gamete intra-fallopian transfer (GIFT)**: A process by which an egg or eggs are transferred with sperm into the woman’s fallopian tube so that fertilization can take place in vivo.

21. **Germ-line gene therapy**: A kind of gene therapy which would entail “foreign” genes into fertilized eggs; the inserted genes would be distributed among somatic cells (cells that form the non-genetic component of an organism) and germ cells (cells that constitute the reproductive or genetic material of an organism) and would be transmitted into future generations.

22. **Implantation**: The process whereby the embryo becomes burrowed in the lining of the uterus.

23. **Intra cytoplasmic sperm injection (ICSI)**: A method of gamete micromanipulation by which a single sperm is injected into the inner cellular structure of the egg.

24. **In vitro**: Literally, in glass. More commonly to describe a biological event that occurs in a laboratory or in an artificial environment.

25. **In vivo**: Describing a biological event that occurs in an intact animal or in the natural environment.

26. **In vitro fertilization (IVF)**: This technique is used mainly where a woman has no fallopian tubes or they are blocked. It has also been used in dealing with some types of male infertility and where the cause of infertility is unknown. Eggs are taken from the woman’s ovaries when judged to be ripe and before they are released naturally. It is then mixed with sperms in a dish (in vitro) so that fertilization can occur. Once the fertilized egg has started to develop it is transferred back to the woman’s womb. The embryo must implant in the womb for a pregnancy to be established.

27. **Laparoscopy**: Examination of the pelvic or other abdominal organs with a fibreoptic telescope inserted surgically below the navel. During laparoscopy, suction applied to the
needle can be used in the recovery of eggs from follicles in the ovary.

28. **Microinjection intra-fallopian transfer (MIFT):**
The process of laparoscopic transfer of microinjected oocytes to the fallopian tube.

29. **Ovary:**
The female reproductive organ in which oocytes are produced from pre-existing germ cells.

30. **Ovulation:**
The release of an egg from a follicle in the ovary.

31. **Ovum:**
Egg; female gamete.

32. **Primitive streak:**
A groove which develops in the embryo about 14-15 days after fertilization. This is the rudimentary nervous tissue of the embryo.

33. **Pronuclear stage tubal transfer (PROST):**
A technique similar to ZIFT by which eggs fertilized in vitro are transferred to the fallopian tube before cell division occurs.

34. **Sperm:**
A mature male germ cell, produced in the testicles.

35. **Superovulation:**
The medical stimulation of the ovary with hormones so that a woman produces more eggs than usual in a monthly cycle.

36. **Uterus:**
The womb; the female organ in which the foetus grows during pregnancy.

37. **Zygote:**
The cell formed by the union of sperm and egg.

38. **Zygote intra-fallopian transfer (ZIFT):**
A technique by which eggs fertilized in vitro are transferred to the fallopian tubes at the pronuclear stage so as to implant the zygote in the uterus for it to develop into a foetus under the natural environment.
Appendix I

Guidelines for Screening of Potential Gamete/Embryo Donors Against Infectious Diseases

1. The following guidelines for screening potential gamete/embryo donors aim at decreasing the potential hazard of transmission of infectious diseases through gamete/embryo donation. They are modified from the “2002 Guidelines for Gamete and Embryo Donation” issued by the American Society for Reproductive Medicine. Modifications are required because local conditions differ.

Guidelines for Screening Potential Semen Donor

2. The main purposes of these guidelines are to decrease the potential hazard for transmitting infectious agents by the use of frozen semen samples that have been adequately quarantined.

Medical History

3. The donors should be generally healthy and in general give no history to suggest hereditary and familial diseases.

4. A complete sexual history should be obtained to exclude as donors individuals who might be at high risk for HIV and/or who have multiple sex partners.

Physical Examination

5. The donor should have a complete physical examination including evaluation for urethral discharge, genital warts and genital ulcers, as well as routine laboratory screening, including blood group and Rh factor testing, before enlisting him in the programme.

6. Donor should have follow-up examinations for urethral discharge, genital warts, and genital ulcers and not be utilised if any of these findings are present.

Laboratory Screening

7. There is no absolute method of completely ensuring that infectious agents will not be transmitted by donor insemination, but the following guidelines, in addition to adequate history-taking and exclusion of individuals at high risk for HIV, should minimise the risk. The following serological tests should be performed -

(a) serologic tests for syphilis should be obtained initially on blood serum and need not be repeated unless clinically indicated;
(b) serum hepatitis B antigen (HBsAg) and hepatitis C antibody should be obtained initially and at 6-month intervals;
(c) semen or urethral cultures should be obtained initially for Neisseria gonorrhoeae. Either urethral or urinary testing for Chlamydia trachomatis should be performed. These cultures should be repeated at 6-month intervals or more frequently if clinically indicated;
(d) serum antibody tests (immunoglobulin G) for CMV should be obtained -
(i) if the antibody tests are positive, it is suggested that the donor should only be used with recipients who are CMV-positive;
(ii) if the titers are negative, the donor should have CMV titers done at 6-month intervals; quarantined semen samples should not be released if the donor develops an antibody titer suggesting recent CMV infection;
(iii) the donor should also be monitored for any development of heterophil-negative mononucleosis-type illness;
(c) an initial serum screening for HIV antibodies should be performed -
(i) a positive assay should be verified with a Western Blot test before notifying the potential donor;
(ii) if the test is negative, semen samples may be collected and prepared for cryopreservation;
(iii) the donor should be tested again in 180 days for HIV, and the specimen should be released for use only if the results are negative;
(f) haematological tests on MCV screening for thalassaemia should be performed initially. Patients with low MCV should be subject to Haemoglobin pattern test.

Guidelines for Screening Potential Egg Donors

8. In general, the screening of egg donors should follow the guidelines for screening potential semen donors described above. The donor must have been screened negative for HIV status before the donation.

9. If the use of donor eggs creates the potential of an Rh incompatibility, couples should be informed about the obstetrical significance of this condition.

10. Freezing and quarantining of eggs or embryos -

(a) egg-freezing is not a standard technique. Fresh eggs should normally be used unless there are situations making the use of frozen eggs necessary;
(b) in case donated eggs are frozen, they should be quarantined for at least 180 days before being used for fertilization;
(c) couples entering an egg donation arrangement should be -
(i) informed that the use of fresh eggs for fertilization carries a risk, albeit a low risk, of acquiring HIV;
(ii) asked whether they are willing to assume such risk;
(iii) asked whether, alternative to (ii) above and in order to avoid the said risk, they would like to have the donated eggs fertilized, the resulting embryos frozen and quarantined, and the donor recalled and retested for HIV six months after donation before undergoing embryo transfer; and
(iv) asked whether they would like to use frozen eggs if there are situations making the use of frozen eggs necessary.

Guidelines for Screening Embryo Donors

11. The respective donors of the sperm and the egg in embryo donation should undergo screening according to the guidelines described in para. 2-10 above.
Appendix II

Guidelines for Payment to Donors

1. This appendix provides guidance to RT centres when paying gamete donors.

2. Under the Ordinance, donors should not be paid for the supply of gametes or embryos, except for reimbursing or defraying –
   
   (a) the cost of removing, transporting or storing an embryo or gamete to be supplied; and
   (b) any expenses or loss of earnings incurred by the donor.

3. Donors should only be reimbursed for all accountable expenses or loss of earning incurred by the donor as a result of donation.

4. There should be NO payment for supernumerary semen/egg donation.

5. The cost of removing, transporting or storing of gametes would not be borne by the donors.

6. The total expense for the donors is classified into three categories -
   
   (a) loss of earnings;
   (b) other accountable expenses; and
   (c) medical expenses (for egg donors only).

Loss of Earnings

7. Payment for loss of earnings should be made on daily basis. The total daily amount that can be claimed under this category cannot exceed HK$380. RT centres might at their discretion decide on the amount of payment for loss of earnings subject to detailed evidence provided by the donor.

Other Accountable Expenses

Travelling Expenses

8. Semen/egg donors can be reimbursed a fixed sum of HK$300 to cover the travelling expenses incurred in getting to the RT center including the return trip.

9. For egg donation, the travelling expenses of the person accompanying the donor on the day of egg collection can also be reimbursed at the same rate i.e. HK$300.

Minding Services

10. The donor may claim for expenses incurred for employing minding services for persons to be taken care by the donor like children, parents or grandparents etc. However, the donor is not eligible to claim for minding services if such services are not employed solely for the purpose of donation.
11. A certifying receipt or letter on the expenses signed by the provider of minding service should be provided to the RT centre.

12. To prevent the abuse of the claim for minding services, the daily amount that can be reimbursed for employing minding services cannot exceed HK$240. A donor who claims for defrayal or reimbursement for loss of earnings and/or expenses for substitute worker is not allowed to claim reimbursement for minding services.

Miscellaneous Expenses

13. The donor can be reimbursed for other expenses incurred by the donor for the purpose of donation, which may include payment by the donor to someone to cover his/her temporary absence from his/her work for the purpose of donation. The claim should be supported by receipt signed by the substitute worker.

14. The total daily amount that can be claimed by the donor under this section cannot exceed HK$380.

Medical Expenses (For Egg Donor Only)

15. The egg donor is eligible to claim for medical expenses for treatment of medical implications arising from egg donation; no matter they are incurred during or after the donation procedure.

16. The donor should not be required to bear any medical expenses incurred as a result of donation. All medical expenses should be borne by the RT centre so long as the medical expense is incurred as a result of the donation.

17. The egg donor should be advised to return to the original RT centre where donation process is carried out for follow-up medical treatment. The egg donor should not be charged for the medical expenses related to donation regardless of the duration.

18. Where the egg donor receives medical treatment from other clinics, she should provide the original RT centre with the attending doctor’s supporting letter and receipt certifying the type of medical treatment and medical expenses for reimbursement.

19. There is NO maximum payment set for medical expenses incurred by the egg donor.

20. The egg donor is also eligible to claim for the loss of earnings and other accountable expenses incurred (same as sperm donor).

Maximum Daily Payment for Donation

21. Subject to the limit for each item of expenses as specified above, the maximum daily amount that may be paid to each donor for expenses or loss incurred is HK$1,060. Such amount may be increased to HK$1,360 for expenses or loss incurred by an egg donor on the day of egg collection (to cover additional travelling expenses if the egg donor is accompanied to the donation centre by other person(s)), excluding medical expenses for which there is no upper limit.

Code of Practice on RT & Embryo Research
Ethical Guidelines on Pre-implantation Genetic Diagnosis (PGD)

General Principles

1. Pre-implantation genetics diagnosis (PGD) is a technique that may be used to combine IVF and genetic testing as a means of avoiding the transmission of a genetic abnormality or a disease. PGD must be conducted in accordance with the following basic ethical principles -

   (a) human life in all its forms warrants respect and special moral consideration;
   (b) the welfare of the child is of paramount importance;
   (c) personal autonomy, individual liberty and human integrity must be duly safeguarded;
   (d) basic community values such as responsible parenthood, parental love and the family should be recognized;
   (e) use of resources must be based on the principles of care, equality, justice and accountability and a reasonable balance must be sought between individual and collective interests to protect vulnerable parties from harm or exploitation.

Application of PGD

2. PGD should only be used for the detection of serious genetic conditions or abnormalities that significantly affect the health of an individual who might be born. Due attention should be given to the differing views in society about seriousness of genetic conditions or abnormalities, and the potential development in medicine that may shift the boundaries defining seriousness of genetic conditions or abnormalities.

3. PGD should not be used with the intention to enable parents to select a baby with abnormality or with some desired social, physical or psychological characteristics.

Preparation for PGD procedures

4. The use of PGD should be a matter of discussion between those seeking PGD (i.e. the parents and their experience and perception of abnormality) and the clinical team on the seriousness of the genetic condition or abnormality.

5. The clinical team should consist of 2 doctors, one of whom should have proper training in genetics.

6. The clinical team, having discussed with the persons seeking PGD and determined the condition to be sufficiently serious to warrant PGD, need to provide the Council with a report detailing -

   (a) the nature of the genetic condition/abnormality;
   (b) the likely effect of the genetic condition;
(c) the anticipated risk of transmission; and
(d) the effectiveness of the testing.

7. The clinical team should follow the detailed reporting requirements as specified under the Human Reproductive Technology Ordinance, its regulations, and the legal notices and government notices issued from time to time by the Council on Human Reproductive Technology.

8. It is also necessary for the clinical team to provide the person seeking PGD with appropriate counselling and adequate information on the other genetic testing options.

**Tissue typing in conjunction with PGD**

9. In addition to using PGD for genetic diagnosis to avoid serious genetic diseases, PGD can be used together with histocompatibility leukocyte antigen (HLA) tissue typing to identify matched embryo where the embryos are matched with a living sibling who has a genetic condition, and where blood is harvested from the umbilical cord to provide stem cells for transplantation to the affected sibling. The practitioners who intend to undertake PGD and HLA have to seek prior approval from the Council, where applications would be considered on a case by case basis. Only application for the harvest of cord blood or bone marrow would be considered and the harvesting of non-regenerative organs is not acceptable. Tissue typing in conjunction with PGD should be reviewed case by case with regard to compliance with the following basic ethical principles -

(a) all other possibilities of treatment and existing sources of tissue for the affected child should have been explored;
(b) the condition of the affected child should be severe or life-threatening;
(c) the parents cannot be the intended tissue recipient and the primary intended tissue recipient should be a sibling;
(d) embryos should not be genetically modified to provide a tissue match;
(e) appropriate pre-treatment and follow-up counselling should be provided to the couples undergoing the treatment (If the child was wanted for his/her own worth, it might be justifiable. If PGD was solely applied for the purpose of creating a child as a donor of stem cells for an existing sibling, the child’s dignity might be violated).

10. Implications counselling should be provided by the centres offering pre-implantation tissue typing and the following factors should be considered -

(a) the motivation and level of understanding of the parents (in particular the woman undertaking the IVF treatment) seeking to have additional child;
(b) the condition of the existing child such as the degree of suffering associated with the condition of the affected child, the prognosis for the affected child in relation to all treatment options available;
(c) the possible consequences of the child to be born (such as the risks associated with embryo biopsy for the child to be born, the likely long term emotional and psychological implications for the child to be born, whether the treatment of the affected child is likely to require intrusive surgery for the child to be born);
(d) the family circumstances of the people seeking treatment such as the perception of the family on the consequences of the unsuccessful outcome,
the issue which might arise when the birth of a child does not resolve the genetic condition of the existing child; and

(c) the extent of social support available.

11. A clinical report in addition to that mentioned in paragraph 7 should be submitted to the Council with the application for the tissue typing procedure which should include the details of the condition of the existing child, prognosis for the affected child in relation to all treatment options available and evidences showing that the guiding principles of the above are strictly followed.
Appendix IV

Guidelines for Local Transfer of
Gametes or Embryos between Licensed Centres

1. Gametes or embryos which have been stored in a licensed centre (the Original Centre) must only be transferred to another licensed centre (the Receiving Centre) for the purposes of carrying out relevant activities subject to the licence approved by the Council on Human Reproductive Technology (the Council).

2. If gametes or embryos are to be transferred between licensed centres, adequate arrangements should be made to protect their quality and security. Both the Original Centre and the Receiving Centre must make every endeavour to ensure that the correct gametes or embryos are being transferred.

3. Licensed centres must ensure that the gametes or embryos, which are to be transferred, are kept in such manner that their condition would not deteriorate. The containers shall be labelled in such a way as to make them easily identifiable according to the information provided by the Original Centre below. Above all, access to them should be restricted to the authorized persons and persons to whom the licence applies.

4. The Original Centre should keep a record of the centre to which the gametes or embryos were supplied and the date on which they were supplied. The Receiving Centre should keep a record of the centre from which the gametes or embryos were received and the date on which they were received.

Information to be provided by Original Centre to Receiving Centre

5. The Original Centre should keep the original and provide a copy of the following documents to the Receiving Centre -

   (a) a copy of the consent form(s) that relate to the gametes or embryos being supplied or transferred;
   (b) if donated gametes or embryos are being supplied, a copy of the donor’s record; and
   (c) if patient’s gametes or embryos are being transferred, a copy of the treatment records.

6. It is the responsibility of the Receiving Centre to ensure that effective consents have been given to the use and storage of any gametes or embryos that are being transferred to the centre. If the patient’s own gametes or embryos are being transferred, the Receiving Centre must obtain consents from the patient for providing storage and treatment services.

7. The Original Centre should also provide a document certifying that the gametes or embryos have been collected and screened in accordance with the Code of Practice published by the Council.
Information to be provided to the Council

8. If the transfer involves donor gametes or embryos, the **Original Centre** should report to the Council within 2 weeks after the completion of the transfer. Information to be provided to the Council should include -

(a) the name and licence number of the Original Centre;
(b) the name and licence number of the Receiving Centre;
(c) the purpose of transfer;
(d) the donor's clinical record number;
(e) the date of transfer and receipt;
(f) the type and quantity of material being transferred (the Original Centre should state whether there is a partial or complete transfer of the gametes or embryos of a particular donor stored in the centre).

9. The **Receiving Centre** should also report to the Council by completing the data collection forms (DC Form) 5 or 6, and returning it/them to the Council upon the use of the gametes or embryos.

Payment for Transfer or Supply of Gametes or Embryos

10. The Original Centre could charge the Receiving Centre on the reasonable expenses incurred for the transfer or supply of the gametes or embryos. These may include defraying or reimbursing for:

(a) the cost of removing, transporting or storing an embryo or gamete to be supplied; and
(b) any expenses or loss of earnings incurred by a person and attributable to the person supplying an embryo or gamete from the person's body.

---

52 Human Reproductive Technology Ordinance (Cap. 561) s.2(1) interpretation of the term "payment"
Appendix V

Guidelines on Disposal of Gametes or Embryos

1. Gametes or embryos may be disposed of in accordance with this appendix with the consent of the person / couple entitled to them.

2. Gametes or embryos may be disposed of by allowing the gametes or embryos in its container to stand at room temperature, in a secure area, for a period of not less than 24 hours.

3. The centre should follow the relevant Ordinances in the Laws of Hong Kong and any practice notes issued by the Government concerning the method of disposal.
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI

Ethical Principles
for
Medical Research Involving Human Subjects

Adopted by the 18th WMA General Assembly
Helsinki, Finland, June 1964
and amended by the
29th WMA General Assembly, Tokyo, Japan, October 1975
35th WMA General Assembly, Venice, Italy, October 1983
41st WMA General Assembly, Hong Kong, September 1989
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996
and the
52nd WMA General Assembly, Edinburgh, Scotland, October 2000
Note of Clarification on Paragraph 29 added by the WMA General Assembly, Washington
2002 and the
Note of Clarification on Paragraph 30 added by the WMA General Assembly, Tokyo 2004

A. INTRODUCTION

1. The World Medical Association has developed the Declaration of Helsinki as a statement of ethical principles to provide guidance to physicians and other participants in medical research involving human subjects. Medical research involving human subjects includes research on identifiable human material or identifiable data.

2. It is the duty of the physician to promote and safeguard the health of the people. The physician’s knowledge and conscience are dedicated to the fulfillment of this duty.

3. The Declaration of Geneva of the World Medical Association binds the physician with the words, “The health of my patient will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician shall act only in the patient’s interest when providing medical care which might have the effect of weakening the physical and mental condition of the patient.”

4. Medical progress is based on research which ultimately must rest in part on experimentation involving human subjects.

5. In medical research on human subjects, considerations related to the well-being of the human subject should take precedence over the interests of science and society.

6. The primary purpose of medical research involving human subjects is to improve prophylactic, diagnostic and therapeutic procedures and the understanding of the aetiology and pathogenesis of disease. Even the best proven prophylactic, diagnostic, and therapeutic methods must continuously...
be challenged through research for their effectiveness, efficiency, accessibility and quality.

7. In current medical practice and in medical research, most prophylactic, diagnostic and therapeutic procedures involve risks and burdens.

8. Medical research is subject to ethical standards that promote respect for all human beings and protect their health and rights. Some research populations are vulnerable and need special protection. The particular needs of the economically and medically disadvantaged must be recognized. Special attention is also required for those who cannot give or refuse consent for themselves, for those who may be subject to giving consent under duress, for those who will not benefit personally from the research and for those for whom the research is combined with care.

9. Research Investigators should be aware of the ethical, legal and regulatory requirements for research on human subjects in their own countries as well as applicable international requirements. No national, ethical, legal or regulatory requirement should be allowed to reduce or eliminate any of the protections for human subjects set forth in this Declaration.

B. BASIC PRINCIPLES FOR ALL MEDICAL RESEARCH

10. It is the duty of the physician in medical research to protect the life, health, privacy, and dignity of the human subject.

11. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and on adequate laboratory and, where appropriate, animal experimentation.

12. Appropriate caution must be exercised in the conduct of research which may affect the environment, and the welfare of animals used for research must be respected.

13. The design and performance of each experimental procedure involving human subjects should be clearly formulated in an experimental protocol. This protocol should be submitted for consideration, comment, guidance, and where appropriate, approval to a specially appointed ethical review committee, which must be independent of the investigator, the sponsor or any other kind of undue influence. This independent committee should be in conformity with the laws and regulations of the country in which the research experiment is performed. The committee has the right to monitor ongoing trials. The researcher has the obligation to provide monitoring information to the committee, especially any serious adverse events. The researcher should also submit to the committee, for review, information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest and incentives for subjects.

14. The research protocol should always contain a statement of the ethical considerations involved and should indicate that there is compliance with the principles enunciated in this Declaration.

Code of Practice on RT & Embryo Research
15. Medical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research, even though the subject has given consent.

16. Every medical research project involving human subjects should be preceded by careful assessment of predictable risks and burdens in comparison with foreseeable benefits to the subject or to others. This does not preclude the participation of healthy volunteers in medical research. The design of all studies should be publicly available.

17. Physicians should abstain from engaging in research projects involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians should cease any investigation if the risks are found to outweigh the potential benefits or if there is conclusive proof of positive and beneficial results.

18. Medical research involving human subjects should only be conducted if the importance of the objective outweighs the inherent risks and burdens to the subject. This is especially important when the human subjects are healthy volunteers.

19. Medical research is only justified if there is a reasonable likelihood that the populations in which the research is carried out stand to benefit from the results of the research.

20. The subjects must be volunteers and informed participants in the research project.

21. The right of research subjects to safeguard their integrity must always be respected. Every precaution should be taken to respect the privacy of the subject, the confidentiality of the patient's information and to minimize the impact of the study on the subject's physical and mental integrity and on the personality of the subject.

22. In any research on human beings, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail. The subject should be informed of the right to abstain from participation in the study or to withdraw consent to participate at any time without reprisal. After ensuring that the subject has understood the information, the physician should then obtain the subject's freely-given informed consent, preferably in writing. If the consent cannot be obtained in writing, the non-written consent must be formally documented and witnessed.

23. When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship with the physician or may consent under duress. In that case the informed consent should be obtained by a well-informed physician who is not engaged in the investigation and who is completely independent of this relationship.
24. For a research subject who is legally incompetent, physically or mentally incapable of giving consent or is a legally incompetent minor, the investigator must obtain informed consent from the legally authorized representative in accordance with applicable law. These groups should not be included in research unless the research is necessary to promote the health of the population represented and this research cannot instead be performed on legally competent persons.

25. When a subject deemed legally incompetent, such as a minor child, is able to give assent to decisions about participation in research, the investigator must obtain that assent in addition to the consent of the legally authorized representative.

26. Research on individuals from whom it is not possible to obtain consent, including proxy or advance consent, should be done only if the physical/mental condition that prevents obtaining informed consent is a necessary characteristic of the research population. The specific reasons for involving research subjects with a condition that renders them unable to give informed consent should be stated in the experimental protocol for consideration and approval of the review committee. The protocol should state that consent to remain in the research should be obtained as soon as possible from the individual or a legally authorized surrogate.

27. Both authors and publishers have ethical obligations. In publication of the results of research, the investigators are obliged to preserve the accuracy of the results. Negative as well as positive results should be published or otherwise publicly available. Sources of funding, institutional affiliations and any possible conflicts of interest should be declared in the publication. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.

C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE

28. The physician may combine medical research with medical care, only to the extent that the research is justified by its potential prophylactic, diagnostic or therapeutic value. When medical research is combined with medical care, additional standards apply to protect the patients who are research subjects.

29. The benefits, risks, burdens and effectiveness of a new method should be tested against those of the best current prophylactic, diagnostic, and therapeutic methods. This does not exclude the use of placebo, or no treatment, in studies where no proven prophylactic, diagnostic or therapeutic method exists.¹

30. At the conclusion of the study, every patient entered into the study should be assured of access to the best proven prophylactic, diagnostic and therapeutic methods identified by the study.²

31. The physician should fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study must never interfere with the patient-physician relationship.

Code of Practice on RT & Embryo Research
32. In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic methods do not exist or have been ineffective, the physician, with informed consent from the patient, must be free to use unproven or new prophylactic, diagnostic and therapeutic measures, if in the physician’s judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, these measures should be made the object of research, designed to evaluate their safety and efficacy. In all cases, new information should be recorded and, where appropriate, published. The other relevant guidelines of this Declaration should be followed.

1 Note of Clarification on Paragraph 29 of the WMA Declaration of Helsinki

The WMA hereby reaffirms its position that extreme care must be taken in making use of a placebo-controlled trial and that in general this methodology should only be used in the absence of existing proven therapy. However, a placebo-controlled trial may be ethically acceptable, even if proven therapy is available, under the following circumstances:

- Where for compelling and scientifically sound methodological reasons its use is necessary to determine the efficacy or safety of a prophylactic, diagnostic or therapeutic method; or

- Where a prophylactic, diagnostic or therapeutic method is being investigated for a minor condition and the patients who receive placebo will not be subject to any additional risk of serious or irreversible harm.

All other provisions of the Declaration of Helsinki must be adhered to, especially the need for appropriate ethical and scientific review.

2 Note of clarification on paragraph 30 of the WMA Declaration of Helsinki

The WMA hereby reaffirms its position that it is necessary during the study planning process to identify post-trial access by study participants to prophylactic, diagnostic and therapeutic procedures identified as beneficial in the study or access to other appropriate care. Post-trial access arrangements or other care must be described in the study protocol so the ethical review committee may consider such arrangements during its review.

9.10.2004
Appendix VII

Ethical Guidelines for Human Embryonic Stem Cell Research

Preamble

1. Research on the early human embryo has long been recognized as essential to progress in a host of biomedical areas, from reproductive medicine to the treatment of paediatric cancers. Nowadays, with the possibility of stem cell research and cell replacement therapies, embryo research holds out the promise of cures for many serious disease conditions, such as diabetes and Alzheimer’s disease. Stem cell has been the focus of discussion in the science circle. It also raises a lot of ethical issues, such as reproductive cloning.

2. In Hong Kong, the Human Reproductive Technology Ordinance (Cap. 561) (the Ordinance), which was enacted in June 2000, is the only piece of legislation governing the use of technologies on assisted reproduction and the use of embryo for research. The Council on Human Reproductive Technology (the Council), a statutory body formed under this ordinance, has recognized the importance of the science and application of stem cell technologies. A Working Group on New Developments in Reproductive Technology, which was formed under the Council to look into the development of advances in reproductive technology, has discussed the issues on human embryonic stem cells research. The Ethics Committee of the Council has also looked into the ethical issues of human embryonic stem cell research.

3. On the basis of the recommendations from the Ethics Committee, the Council adopted the following ethical guidelines for compliance by embryo researchers.

Human Embryonic Stem Cell Research

4. An underlying intermediate position with regard to the moral status of the human embryo is adopted. The intermediate position neither accords the embryo full moral status from the moment of its conception nor considers it void of any moral status. Instead, it accords the embryo moral respect, which increases relative to its biological development.

5. The potential benefits of embryonic stem cell research are sufficient justification of such research. Based on the intermediate position, the use of embryos or fetal tissues as sources for generating stem cells is ethically justified subject to the options as stated in paragraphs 6 to 11 below.

Options for deriving human embryonic stem cells

6. As the embryo represents human life in its early form, its potential use for research must be commensurate with its moral status. In accordance with the intermediate position, it is ethically permissible to use “excess RT embryos”* for the derivation of stem cell lines and research.

7. Before “excess RT embryos” are used for deriving embryonic stem cells, it is necessary to first find out, in so far as is practicable, whether at present any stem cell lines exist in Hong Kong and to what extent they would meet present research needs.
8. Alternatively, the possibility of importing stem cell lines should be examined. If human embryonic stem cells are to be imported into Hong Kong, it will be necessary to ensure that the Ordinance, its regulations and other relevant Ordinances are followed and that those stem cells are not derived from cloned embryos or embryos created for research purposes.

9. It is also worthy to consider whether adult stem cells could first be used before resorting to embryonic stem cells, given the fact that greater potential is increasingly being discovered with adult stem cells. Nevertheless, the apparent greater plasticity of embryonic stem cells compared to adult stem cells in developing into various types of cells needs to be taken into account as well as the fact that, at present, the yield of adult stem cells is insufficient.

10. Should none of these options meet research needs, it is ethically justified to generate stem cells from “excess RT embryos” in Hong Kong subject to certain restrictions.

11. Only the minimum number of excess RT embryos may be used for research.

**Conditions for human embryonic stem cell research**

12. The purposes and the therapeutic benefits of human embryonic stem cell research must be sufficiently significant, non-trivial and well-founded. They must be commensurate with the respect due to the human embryo. Non-medical research with human embryonic stem cells (including eugenic enhancement and cosmetic research) is considered ethically unjustified.

13. There should be no commercial transactions or benefits with regard to embryo donation.

14. The morality of the process of donation must be ensured. This implies that the roles of persons conducting embryonic stem cell research and the persons providing IVF treatment should be separated and that documented, free and informed consent must be obtained. Due to the specific nature of embryonic stem cells and their virtual “immortality”, such consent should be obtained before donation for embryonic stem cell research. Donors should be protected against inducement, coercion or undue influence. Measures should be taken to provide for the protection and safeguarding of donor identity without necessarily precluding the possibility to trace donor and/or recipient in case of adverse side effects of treatment.

15. Fair access to and sharing of research results among researchers should be possible so as not to unduly restrict further research and adversely affect the development of therapeutic benefits.

**Somatic cell nuclear replacement**

16. From both the scientific and ethical point of view, the Council considers that the “embryo” created by somatic cell nuclear replacement (SCNR) should be regarded as an embryo since it has the full potential to develop into a human being, regardless of the means of its creation (i.e. whether it has been formed by fertilization or not).
17. As section 15(1)(a) of the Ordinance prohibits the creation of an embryo for the purposes of embryo research, the creation of an embryo by SCNR for embryo research is therefore prohibited.

**Research involving mixing of human embryonic stem cells with non-human embryos or vice versa**

18. Regarding research involving the mixing of human embryonic stem cells with non-human embryos or vice versa, the relevant provision is section 15(1)(a)(ii) of the Ordinance.

19. For the purpose of embryo research, combining human and non-human gametes or embryos or any part thereof such as to give rise to a 2 cell zygote is prohibited in section 15(1)(a)(ii) of the Ordinance. Since any embryonic stem cell forms part of the embryo, the mixing of human embryonic stem cells with non-human embryo or vice versa for the purpose of embryo research is not allowed.

**Patenting of embryonic stem cell lines**

20. The patenting of inventions involving elements of human origin leads to the question of morality as it tends to devaluate human dignity. The bottom line drawn in the Hong Kong Patents Ordinance is that “patenting must not be contrary to public order and morality”. The following principles for patenting of human embryonic stem cell lines should be observed -

(a) in accordance with the ethical principle of the non-commercialization of the human body, embryos should not be used for commercial or industrial purposes;
(b) no remuneration should be paid to the persons who donate embryos for research purposes except for the reimbursement of necessary expenses;
(c) based on the general distinction between discovery (not patentable) and invention (patentable), neither the human body itself, nor knowledge related to the human body or its elements (e.g. unmodified stem cells) are patentable. Embryonic stem cell lines with identified functions may, however, be patentable;
(d) a just balance should be sought between the interests of the inventors and the interests of society so that access to health care will not be adversely affected;
(e) embryo donors should be provided with complete and specific information on how the donated embryo will be used, in particular the potential patenting of the embryonic stem cells extracted from the donated embryos and that they will not participate in the profit made from it. Informed and free consent needs to be obtained when embryos are donated and when the embryos are actually used for research to cultivate stem cell lines.
Use of human embryonic stem cell lines

21. In order to minimize the destructive use of human embryos for the generation of embryonic stem cells and avoid unnecessary duplication of research, researchers should obtain information on existing stem cell lines and make best use of the resources available, both locally and from overseas.

*The term “excess RT embryos” is defined as human embryos that-
(a) were produced, by reproductive technology (RT) procedures, for use in treatment of a woman; and
(b) are excess to the needs of-
   (i) the woman for whom they were produced for RT treatment; and
   (ii) her spouse at the time the embryos were produced by RT procedures.*
### Appendix VIII

#### Sex-linked Genetic Diseases

<table>
<thead>
<tr>
<th>No.</th>
<th>Condition Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Addison's disease with cerebral sclerosis</td>
</tr>
<tr>
<td>2.</td>
<td>Adrenoleuadystrophy</td>
</tr>
<tr>
<td>3.</td>
<td>Adrenal hypoplasia</td>
</tr>
<tr>
<td>4.</td>
<td>Agammaglobulinaemia, Bruton type</td>
</tr>
<tr>
<td>5.</td>
<td>Agammaglobulinaemia, Swiss type</td>
</tr>
<tr>
<td>6.</td>
<td>Albinism, ocular</td>
</tr>
<tr>
<td>7.</td>
<td>Albinism-deafness syndrome</td>
</tr>
<tr>
<td>8.</td>
<td>Aldrich syndrome</td>
</tr>
<tr>
<td>9.</td>
<td>Alport syndrome</td>
</tr>
<tr>
<td>10.</td>
<td>Amelogenesis imperfecta, hypomaturation type</td>
</tr>
<tr>
<td>11.</td>
<td>Amelogenesis imperfecta, hypoplastic type</td>
</tr>
<tr>
<td>12.</td>
<td>Anaemia, hereditary hypochromic</td>
</tr>
<tr>
<td>13.</td>
<td>Angiokeratoma (Fabry's disease)</td>
</tr>
<tr>
<td>14.</td>
<td>Cataract, congenital</td>
</tr>
<tr>
<td>15.</td>
<td>Cerebellar ataxia</td>
</tr>
<tr>
<td>16.</td>
<td>Cerebral sclerosis, diffuse</td>
</tr>
<tr>
<td>17.</td>
<td>Charcot-Marie-Tooth peroneal muscular atrophy</td>
</tr>
<tr>
<td>18.</td>
<td>Choroideraemia</td>
</tr>
<tr>
<td>19.</td>
<td>Choroidoretinal degeneration</td>
</tr>
<tr>
<td>20.</td>
<td>Coffin-Lowry syndrome</td>
</tr>
<tr>
<td>21.</td>
<td>Colour blindness, Deutan type</td>
</tr>
<tr>
<td>22.</td>
<td>Colour blindness, Protan type</td>
</tr>
<tr>
<td>23.</td>
<td>Diabetes insipidus, nephrogenic</td>
</tr>
<tr>
<td>24.</td>
<td>Diabetes insipidus, neurohypophyseal</td>
</tr>
<tr>
<td>25.</td>
<td>Dyskeratosis congenita</td>
</tr>
<tr>
<td>26.</td>
<td>Ectodermal dysplasia, anhidrotic</td>
</tr>
<tr>
<td>27.</td>
<td>Ehlers-Danlos syndrome, type V</td>
</tr>
<tr>
<td>28.</td>
<td>Faciogenital dysplasia, (Aarskog syndrome)</td>
</tr>
<tr>
<td>29.</td>
<td>Focal dermal hypoplasia (x-linked dominant, male lethal)</td>
</tr>
<tr>
<td>30.</td>
<td>Glucose 6-phosphate dehydrogenase deficiency</td>
</tr>
<tr>
<td>31.</td>
<td>Glycogen storage disease, type VIII</td>
</tr>
<tr>
<td>32.</td>
<td>Gonadal dysgenesis (XY female type)</td>
</tr>
<tr>
<td>33.</td>
<td>Granulomatous disease (chronic)</td>
</tr>
<tr>
<td>34.</td>
<td>Haemophilia A</td>
</tr>
<tr>
<td>35.</td>
<td>Haemophilia B</td>
</tr>
<tr>
<td>36.</td>
<td>Hydrocephalus (aqueduct stenosis)</td>
</tr>
<tr>
<td>37.</td>
<td>Hypophosphataemic rickets</td>
</tr>
<tr>
<td>38.</td>
<td>Ichthyosis (steroid sulphatase deficiency)</td>
</tr>
<tr>
<td>39.</td>
<td>Incontinentia pigmerti (x-linked dominant, male lethal)</td>
</tr>
<tr>
<td>40.</td>
<td>Kallmann syndrome</td>
</tr>
<tr>
<td>41.</td>
<td>Keratosis follicularis spinulosa</td>
</tr>
<tr>
<td>42.</td>
<td>Lesch-Nyhan syndrome (hypoxanthine-guanine-phosphoribosyl transferase deficiency)</td>
</tr>
<tr>
<td>43.</td>
<td>Lowe (oculocerebrorenal) syndrome</td>
</tr>
<tr>
<td>44.</td>
<td>Macular dystrophy of the retina</td>
</tr>
<tr>
<td>45.</td>
<td>Menkes syndrome</td>
</tr>
<tr>
<td>46.</td>
<td>Mental retardation, FMRI type</td>
</tr>
<tr>
<td>47.</td>
<td>Mental retardation, FRAXE type</td>
</tr>
<tr>
<td>48.</td>
<td>Mental retardation, MRXI type</td>
</tr>
<tr>
<td>49.</td>
<td>Microphthalmia with multiple anomalies (Lenz syndrome)</td>
</tr>
<tr>
<td>50.</td>
<td>Mucopolysaccharidosis II (Hunter syndrome)</td>
</tr>
<tr>
<td>51.</td>
<td>Muscular dystrophy, Becker type</td>
</tr>
<tr>
<td>52.</td>
<td>Muscular dystrophy, Duchenne type</td>
</tr>
<tr>
<td>53.</td>
<td>Muscular dystrophy, Emery-Dreifuss type</td>
</tr>
<tr>
<td>54.</td>
<td>Myotubular myopathy</td>
</tr>
<tr>
<td>55.</td>
<td>Night blindness, congenital stationary</td>
</tr>
<tr>
<td>56.</td>
<td>Norrie's disease (pseudogioma)</td>
</tr>
<tr>
<td>57.</td>
<td>Nystagmus, ocularmotor or 'jerky'</td>
</tr>
<tr>
<td>58.</td>
<td>Ornithine transcarbamylase deficiency (type I hyperammonaemia)</td>
</tr>
<tr>
<td>59.</td>
<td>Orofaciodigital syndrome (type I, x-linked dominant, male lethal)</td>
</tr>
<tr>
<td>60.</td>
<td>Perceptive deafness, with ataxia and loss of vision</td>
</tr>
<tr>
<td>61.</td>
<td>Perceptive deafness, DNFZ type</td>
</tr>
<tr>
<td>62.</td>
<td>Phosphoglycerate kinase deficiency</td>
</tr>
<tr>
<td>63.</td>
<td>Phosphoribosylpyrophosphate (PRPP) synthetase deficiency</td>
</tr>
<tr>
<td>64.</td>
<td>Reifenstein syndrome</td>
</tr>
<tr>
<td>65.</td>
<td>Retinitis pigmentosa</td>
</tr>
<tr>
<td>66.</td>
<td>Retinoschisis</td>
</tr>
<tr>
<td>67.</td>
<td>Spastic paraplegia</td>
</tr>
<tr>
<td>68.</td>
<td>Spinal muscular atrophy</td>
</tr>
<tr>
<td>69.</td>
<td>Spondyloepiphyseal dysplasia tarda</td>
</tr>
<tr>
<td>70.</td>
<td>Testicular feminization syndrome</td>
</tr>
<tr>
<td>71.</td>
<td>Thrombocytopenia, hereditary</td>
</tr>
<tr>
<td>72.</td>
<td>Thyroxine-binding globulin, absence or variants of</td>
</tr>
<tr>
<td>73.</td>
<td>Xg blood group system</td>
</tr>
</tbody>
</table>

---

53 Schedule 2 to the Ordinance
Appendix IX

Records to be Kept and Maintained by Licensed Centres

1. Under section 45(2) of the Human Reproductive Technology Ordinance (Cap. 561) (the Ordinance), the Council may make regulation to specify the registers and other records to be kept and maintained by licensed centres.

Registers to be kept and maintained by licensed centres

2. Licensed centres are required to keep and maintain the following -

   (a) a Donors Register which contains information on every donor of gametes or embryos stored in the licensed premises at any time on or after the commencement of the Human Reproductive Technology (Licensing) Regulation (the Regulation);

   (b) a Patients Register which contains -

      (i) information on every person who undergoes a RT procedure in the licensed premises at any time on or after the commencement of the Regulation;

      (ii) where the person is a woman, information on the person who was her husband when gametes were, or an embryo was, placed in her body pursuant to that procedure; and

      (iii) where the person is a man, information on the person who was his wife when gametes were obtained from him;

   (c) a Children Register which contains information, if available, on every child born in consequence of a RT procedure provided in the licensed premises at any time on or after the commencement of the Regulation.

Records to be kept and maintained by licensed centres

3. Licensed centres are required to keep and maintain the following records -

   (a) assessment of donors and patients on suitability for RT procedure;

   (b) counselling services provided to donors and patients;

   (c) consents and withdrawals of consent to the storage and removal from storage of gametes or embryos at the centre;

   (d) collection and storage of gametes or embryos at the centre;

   (e) diagnosis of collected and stored gametes or embryos at the centre;

   (f) any amounts paid to donors in respect of donations made at the centre;

   (g) creation or attempted creation of embryos in vitro at the centre;

   (h) destruction or disposal at the centre of any stored gametes or embryos created in vitro;

   (i) RT procedures carried out on a woman at the centre;

   (j) use of gametes or embryos in a RT procedure or research at the centre;

   (k) outcome of a RT procedure, such as clinical pregnancy, miscarriage or death of an embryo or foetus, if this information is available at the centre;

   (l) transfer of gametes or embryos to/from another licensed centre;

   (m) importation and exportation of any gametes or embryos from/to overseas...
licensed centres;
(n) surrogacy arrangement carried out at the centre;
(o) fetal reduction carried out at the centre;
(p) gender selection carried out at the centre;
(q) any complaints received by the centre; and
(r) any other records as determined by the Council in accordance with the Ordinance and its regulations.
Fact Sheet on Disclosure of Information
Related to Provision of Reproductive Technology Procedure

Keeping of Register A

1. Under section 33 of the Human Reproductive Technology Ordinance (Cap. 561) (the Ordinance), the Council on Human Reproductive Technology (the Council) shall keep and maintain a register, namely Register A.

2. Information contained in Register A shall be kept for 80 years.

Information contained in Register A

3. The register shall contain -

   (a) information related to the provision of a RT procedure where a child born or intended to be born in consequence of the procedure involving donated gametes or donated embryos; and

   (b) identifying information of the child born, the parties to a marriage who will be the parents of the child and any individual whose gametes have been used.

Disclosure of Information

4. Under section 34(2) & (3) of the Ordinance, disclosure of any information contained or required to be contained in Register A is allowed in the following circumstances -

   (a) disclosure to a member of the Council, a member of its Committees or a designated public officer designated by the Secretary for Food and Health (the Secretary) is allowed;

   (b) disclosure to the following persons for the purposes of performing their functions in such capacities is allowed -

      (i) the licensee who is holder of a licence, which permits the licensee to carry out activities which consist of or involve provision of a RT procedure, conducting of embryo research or handling, storing or disposing of a gamete or embryo used or intended to be used in the RT procedure or embryo research;

      (ii) the person responsible under a licence;

      (iii) any person designated in a licence or in a notice duly given to the Council by the persons in (i) and (ii) above; and

      (iv) any person acting under the direction of the person responsible or of any person so designated;

   (c) disclosure may be allowed where no individual to whom the information relates can be identified;

   (d) any adult (age 16 or above) may request the Council to state whether or not the information contained in Register A shows that -

      (i) a person other than his/her parents, would or might be his/her parent; and if yes then

      (ii) a person whom the adult proposes to marry, would or might be related;

Code of Practice on RT & Embryo Research
any information that the Council is required to give pursuant to regulations made by the Secretary. However, no information that identifies the donors of gametes or embryos shall be given if such information was provided at a time when the Council could not have been required to give such information;

disclosure is allowed when it is made pursuant to a court order made in the interests of justice, in any proceeding where the court has to determine whether a person is or is not the parent of a child by virtue of sections 9, 10 and 11 of the Parent and Child Ordinance (Cap. 429). However, such an order may not require the Council to disclose any information which may identify the donor(s) whose gamete(s) was/were used in the RT procedure;

the Council shall disclose to the Registrar of Births and Deaths or any deputy registrar of births and deaths upon their notice requesting the Council to disclose whether any information in Register A tends to show that a man may be the father of a child by virtue of section 10 of the Parent and Child Ordinance and, if so, disclose that information;

disclosure concerning an individual who undergoes a RT procedure may be made pursuant to consent in writing given by him/her before the provision of the procedure;

disclosure concerning an individual who undergoes a RT procedure may be made if -

(i) he/she gives a permission in writing before the provision of the procedure that he/ she may be contacted after the provision of the procedure to ascertain whether he/ she will consent to a disclosure of information relating to the provision of the procedure to him/ her, either generally or in circumstances specified in the permission; and

(ii) consent in writing is obtained from the individual in accordance with the said permission in writing;

disclosure is allowed in any proceedings relating to application for a parental order under section 12(1) of the Parent and Child Ordinance for establishing whether -

(i) the child has been carried by a surrogate mother; or

(ii) the gametes of either or both the parties to the marriage were used to bring about the creation of the embryo.
Appendix XI

Information Sheet on Personal Data Collected in Connection with Provision of Reproductive Technology Procedure/Donation

Purposes for which Personal Data may be used

1. The personal data that the RT centre collected in connection with the provision of RT procedure / donation may be used for the following purposes -

(a) all procedures (including administrative and treatment procedures) appertaining to the provision of the relevant RT procedure / donation;
(b) the keeping and maintaining of register(s) and/or record(s) as may be required under the Human Reproductive Technology Ordinance (Cap. 561) (the Ordinance) or its regulations, other laws of Hong Kong, and/or the code of practice published from time to time by the Council on Human Reproductive Technology (the Council);
(c) the communication between the RT centre and its clients;
(d) the provision of information to the Council for the keeping and maintaining of a register under section 33 of the Ordinance, and for the use provided for under the said section;
(e) disclosures permitted or required under section 34 of the Ordinance (such as disclosure pursuant to Court order and disclosure to the Registrar within the meaning of the Births and Deaths Registration Ordinance (Cap. 174)); and
(f) other modes of disclosure or use in respect of which the client(s) has/have given permission in writing before the provision of the procedure.

Classes of Persons to whom Personal Data may be transferred

2. The personal data provided to the RT centre may be transferred to the Council and/or other parties who become necessary recipient(s) thereof for the purposes mentioned in the first paragraph above.

Whether the Supply of Personal Data Obligatory

3. The supply of such personal data to the RT centre as it may require is obligatory. If the client fails or refuse to supply the data, the RT centre may refuse to carry out the RT procedure requested.
Access to Personal Data

4. The provider(s) of the data has/ have the right of access and correction with respect to the personal data provided, as provided for under sections 18 and 22 and Principle 6 of Schedule 1 to the Personal Data (Privacy) Ordinance (Cap. 486). Such right of access may include the right to obtain a copy of such data.

Enquiries

5. Reference of enquiries (name, address and telephone no. of contact person) concerning the personal data collected by the RT centre, including access thereto and correction thereof, should be provided to the parties providing the data.
Supplementary Code of Practice on Reproductive Technology - Artificial Insemination by Husband (AIH)

Council on Human Reproductive Technology
# SUPPLEMENTARY CODE OF PRACTICE ON REPRODUCTIVE TECHNOLOGY - ARTIFICIAL INSEMINATION BY HUSBAND (AIH)

## Contents

<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Introduction</td>
<td>i</td>
</tr>
<tr>
<td>- Preamble</td>
<td></td>
</tr>
<tr>
<td>- Application of the Supplementary Code</td>
<td></td>
</tr>
<tr>
<td>- Interpretation of the Human Reproductive Technology Ordinance and Promulgation of the Supplementary Code</td>
<td></td>
</tr>
<tr>
<td>II. Procedure of Artificial Insemination by Husband (AIH)</td>
<td>ii</td>
</tr>
<tr>
<td>- Classification of AIH</td>
<td></td>
</tr>
<tr>
<td>III. Staff</td>
<td>ii</td>
</tr>
<tr>
<td>- General</td>
<td></td>
</tr>
<tr>
<td>- Person Responsible</td>
<td></td>
</tr>
<tr>
<td>- Licensee</td>
<td></td>
</tr>
<tr>
<td>- Medical Practitioners</td>
<td></td>
</tr>
<tr>
<td>- Nursing Staff</td>
<td></td>
</tr>
<tr>
<td>- Counsellors</td>
<td></td>
</tr>
<tr>
<td>- Fitness to Practise</td>
<td></td>
</tr>
<tr>
<td>IV. Facilities and Equipment</td>
<td>iv</td>
</tr>
<tr>
<td>V. Assessment of Clients</td>
<td>iv</td>
</tr>
<tr>
<td>VI. Information to Clients</td>
<td>iv</td>
</tr>
<tr>
<td>VII. Consent</td>
<td>v</td>
</tr>
<tr>
<td>VIII. Counselling</td>
<td>v</td>
</tr>
<tr>
<td>- General</td>
<td></td>
</tr>
<tr>
<td>- Counselling for Potential Clients of AIH Service</td>
<td></td>
</tr>
<tr>
<td>IX. Treatment Method</td>
<td>v</td>
</tr>
<tr>
<td>X. Screening and Selection of Sperm</td>
<td>vi</td>
</tr>
</tbody>
</table>

Supplementary Code of Practice on RT- AIH
XI. Record Keeping and Information Management
  • Accuracy and Confidentiality of Information
  • Keeping of Record
  • Submission of Information to Council
  • Handling of Personal Data under the Personal Data (Privacy) Ordinance
  • Disclosure of Personal Information

XII. Handling of Complaints
  • Complaints against RT Centres
  • Breach of the Supplementary Code

XIII. References
I. Introduction

Preamble

1.1 Since artificial insemination by husband (AIH) is regarded as a relatively simple RT procedure, the Council considers that a simpler code is sufficient for AIH procedures. This Supplementary Code of Practice on Reproductive Technology - Artificial Insemination by Husband (AIH) (the Supplementary Code) is prepared for compliance when AIH is performed by a RT service provider (whether or not other RT procedures are provided by the same service provider). However, when RT procedures other than AIH are performed by the RT service provider, he should also comply with the provisions of the Code of Practice on Reproductive Technology and Embryo Research (the Code) in relation to the other RT procedures.

1.2 This Supplementary Code provides guidance for good practice, as described in subsequent paragraphs, which aim to support proper clinical and scientific procedures, to safeguard the health and interests of service users and to protect the welfare of children born through AIH. Professionals concerned should still follow the codes of practice and professional ethics of their individual disciplines. This Supplementary Code is not meant to supersede these.

Application of the Supplementary Code

1.3 The Supplementary Code is annexed to the Code and forms part and parcel thereof. The Code came into effect on 1st August 2007. It will be reviewed and updated as necessary to keep up with developments in RT. The Council, which is the licensing authority for RT services and embryo research, shall take into account any observance of or failure to observe the provisions of the Supplementary Code when considering granting, renewal, variation, revocation or suspension of licences relating to the practice of AIH.

Interpretation of the Human Reproductive Technology Ordinance and Promulgation of the Supplementary Code

1.4 All personnel involved in the provision of AIH procedure are advised to familiarize themselves with the Human Reproductive Technology Ordinance (the Ordinance). Reference should be made to the Ordinance for definitions of specific terms.

1.5 The Supplementary Code must be construed in a manner consistent with the provisions of the Ordinance.
II. **Procedure of Artificial Insemination by Husband (AIH)**

2.1 In this Supplementary Code, AIH refers to the placement of the husband’s sperm into the vagina or uterus of his wife otherwise than by sexual intercourse. Sperm washing may be performed before the husband’s sperm is used for this purpose. Ovarian stimulation may be used with appropriate monitoring. Every care should be made to minimize the risk of multiple pregnancies and reference should be made to the Hong Kong College of Obstetricians and Gynaecologists Guidelines Number 1.

**Classification of AIH**

2.2 The Council considers it appropriate to broadly categorize AIH into three types, namely intravaginal, intracervical and intrauterine insemination. Intravaginal insemination refers to the placement of sperm into the vagina. Intracervical insemination refers to the placement of sperm at the cervical os. Intrauterine insemination refers to the placement of sperm (usually after processing) into the uterine cavity. Respective guidelines for the three types of AIH are shown in the ensuing paragraphs.

III. **Staff**

**General**

3.1 As required by the Ordinance, no person shall carry on RT activities except pursuant to a licence.

**Person Responsible**

3.2 The “person responsible”, in relation to a licence, refers to the individual specified in the licence as the individual under whose supervision the activities authorized by the licence shall be carried on.

3.3 It shall be the duty of the person responsible to ensure that:

(a) the other persons to whom the licence applies are of such character, and are so qualified by training and experience, as to be suitable persons to participate in the relevant activity authorized by the licence;

(b) proper equipment is used;

(c) proper arrangements are made for the keeping of semen/sperm and for the disposal of semen/sperm that have been allowed to perish;

(d) proper practices are used in the course of that activity; and

---

4 s.13 of the Ordinance  
5 s.2(l) of the Ordinance - interpretation of the term “person responsible”  
6 s.24(1) of the Ordinance  
7 s.24(3) of the Ordinance
(e) the conditions of the licence are complied with.

3.4 The person responsible should ensure that this Supplementary Code is made known to all staff involved.

Licensee

3.5 The "licensee", in relation to a licence, is the holder of the licence as defined in the Ordinance. 8

3.6 It is the duty of the licensee to ensure that the person responsible discharges his/her duty. The discharge of the duty by the person responsible should not be prejudiced if the licensee and the person responsible are the same person. 9

Medical Practitioners

3.7 Intravaginal or intracervical insemination should be administered or supervised by a registered medical practitioner. Intruterine insemination should be performed by a registered medical practitioner recognised as an accredited specialist in Obstetrics & Gynaecology or Reproductive Medicine under the Specialist Register of the Medical Council of Hong Kong, with the assistance of a laboratory if necessary. Medical staff in training may carry out the insemination procedures under supervision. Registered medical practitioners under training should perform the intrauterine insemination under supervision of a specialist as mentioned above.

3.8 When ovarian stimulation with gonadotrophin is used for any of the three insemination procedures, it should be done or supervised by a specialist in Obstetrics & Gynaecology or Reproductive Medicine.

Nursing Staff

3.9 Nursing staff employed by RT centres 10 should be registered nurses or enrolled nurses under the Nurses Registration Ordinance (Cap. 164) and be appropriately trained for the duties they carry out.

Counsellors

3.10 Counselling may be provided by doctors, nurses, social workers, clinical psychologists or other persons with suitable experience and / or qualifications as appropriate.

Fitness to Practise

3.11 In the case of medical practitioners, reference should also be made to the Professional Code and Conduct for the Guidance of Registered Medical Practitioners laid down by the Medical Council of Hong Kong on fitness to practise.

---

8 s.2(1) of the Ordinance - interpretation of the term "licensee"

9 s.23(3) and s.24(2) of the Ordinance

10 RT centres refer to the hospitals or centres or clinics providing AIH services

Supplementary Code of Practice on Reproductive Technology - AIH
IV. Facilities and Equipment

4.1 The person responsible must ensure that proper facilities and equipment are used and maintained. Hormonal assay facilities should be available if needed.

4.2 The minimum facilities and equipment required for RT centres offering intrauterine insemination service should include-

   (a) ultrasound equipment, which should be readily available in the RT centre for monitoring ovarian function;
   (b) sperm washing facilities, which should either be available at the RT centre or provided if required by another laboratory closely linked to it.

4.3 If counselling is carried out in the RT centre, it should be provided in a place with privacy and comfort where discussion can take place undisturbed.

V. Assessment of Clients

5.1 In accordance with the Ordinance, AIH procedures should only be provided to legally married couples.

5.2 The clients concerned should be offered fair and unprejudiced assessment. Clients' medical conditions should be fully assessed to determine the most appropriate treatment option.

VI. Information to Clients

6.1 RT centres should devise a mechanism to ensure that relevant information is given to persons seeking AIH treatment. RT centres should provide clients with information on the services offered.

6.2 Persons seeking AIH treatment should be informed of the following -

   (a) explanation of the procedure;
   (b) possible discomfort, side effects and complications of treatment to the woman and the resulting pregnancy including, where relevant, risk of ovarian hyperstimulation syndrome or multiple pregnancies and indications for embryonic/fetal reduction;
   (c) limitations and possible outcomes of the treatment;
   (d) any other options available; and
   (e) charges for services.

11 s.24(1)(b) of the Ordinance
VII. Consent

7.1 Informed consent with respect to receiving AIH treatment must be obtained in writing.

7.2 RT centres are required to make use of the sample consent form (14) at Annex II of the Code unless there are justifiable reasons why they should not be used or should be departed from or modified.

VIII. Counselling

General

8.1 The clients concerned should be provided with counselling by doctors, nurses, social workers, clinical psychologists or other persons with suitable experience and / or qualifications as appropriate.

8.2 Non-directional counselling on the implications of the AIH procedure and consideration of other options must be offered to clients before they consent to AIH procedure. Couples seeking treatment should be given adequate time to consider the issue.

8.3 Information obtained during counselling must be kept in confidence.

8.4 Proper records should be kept of the counselling service offered.

Counselling for Potential Clients of AIH Service

8.5 Counsellors should ask potential clients to consider carefully all possible implications before receiving AIH service especially when ovarian stimulation has to be done, such as:

(a) the financial implications of the AIH treatment (e.g. there is the possibility of multiple pregnancies);
(b) their feelings about manipulation of the husband's sperm outside his body, and the possible storage and disposal of the sperm;
(c) the chances that treatment may fail;
(d) the possibility of the need of embryonic/fetal reduction;
(e) the alternative of adoption of a child;
(f) the possibilities that the implications of and feelings about their AIH treatment may change as personal circumstance changes;
(g) all the terms and conditions set out in the consent form.

IX. Treatment Method

9.1 The attending clinician must ensure that the treatment method offered is the one which best suits the couple's particular medical indication.
9.2 Established clinical practices and laboratory standards should be adopted to safeguard the health and safety of clients.

9.3 The indication for selecting the AIH procedure must be stated in each case.

9.4 Side effects and complications arising from the AIH procedure must be recorded for each case.

9.5 When ovarian stimulation has to be carried out, RT practitioners must take measures to prevent high multiple pregnancies whenever possible. This is to avoid the known risks of fetal mortality and morbidity in such cases, the health hazards to the mother and the possible psychological and practical consequences for both parents.

9.6 If multiple pregnancy should occur despite the above-mentioned precautions having been taken, and if the prognosis for the fetuses is so unfavourable, a procedure of fetal reduction may be necessary. The carrying out of fetal reduction procedure should comply with section 47A of the Offences Against The Person Ordinance (Cap. 212). The possibility of embryonic/fetal reduction should be included in the pre-treatment counselling. Parents should be clearly informed of the reasons for embryonic/fetal reduction and the possible risks involved, and the procedure may not be carried out without their consent.

9.7 Embryonic/fetal reduction should not be carried out simply to comply with the request of the parents who prefer to have a fewer number of children from the pregnancy.

X. Screening and Selection of Sperm

10.1 For AIH, both banked and fresh semen/ sperm of the husband can be used. If RT centres store semen/ sperm for their clients, a proper and safe storage facility must be provided to preserve the viability of semen/ sperm and to minimize the chance of accident, loss or contamination. In the case that the semen/ sperm is stored at a RT centre and is transferred to another RT centre where AIH is to be performed, the guidelines as contained in Appendix IV regarding the local transfer of gametes between RT centres should be observed.

10.2 Semen/ sperm which has been subject to procedures carrying an actual or unreasonable risk or harm to its developmental potential should not be used for treatment.

10.3 For intrauterine insemination, sperm washing should be performed. The insemination should be carried out by an obstetrician or gynaecologist or a specialist in reproductive medicine. Sperm washing should be carried out by a doctor or laboratory staff who has undergone the appropriate training with the assistance of a suitable laboratory.

10.4 If the semen is cryopreserved for storage, appropriate measures should be
taken to minimize the risk of contamination of the semen stored.

XI. Record Keeping and Information Management

Accuracy and Confidentiality of Information

11.1 RT centres must ensure that personal records with identifying information are kept in confidence with controlled access and disclosure of such should be in circumstances permitted by the Ordinance.\(^{12}\)

Keeping of Record

11.2 RT centres must keep medical records containing the names, correspondence addresses, identity card/passport numbers of all patients. The record should include information on the AIH procedure performed and outcomes of the procedure as far as it is practicable.

11.3 General medical record kept and maintained under an AIH licence should be retained by the RT centres for at least 6 years.

Submission of Information to Council

11.4 RT centres are required to submit non-identifying information on AIH cases to the Council. The information required should be submitted in the prescribed format using the data collection form (DC Form 7) at Annex III.

11.5 Other non-identifying data in the prescribed format, i.e. AS Form 9 at Annex IV, should be submitted on an annual basis to the Council. The use of uniform definitions should be adopted (please refer to the glossary of abbreviations and common terms used in RT and the explanatory notes for completing the forms on annual statistics on RT treatment in the Code).

Handling of Personal Data under the Personal Data (Privacy) Ordinance

11.6 The Personal Data (Privacy) Ordinance (Cap. 486) enables individuals to request access to and correction of personal data held by data users. RT service providers are advised that the rules and principles stipulated in the Personal Data (Privacy) Ordinance on the collection, retention, use, disposal, access to and correction of the personal data should be complied with.

Disclosure of Personal Information

11.7 RT centre should clearly explain to the patients and their spouses that the personal data they provide in connection with the provision of RT procedure(s) may be disclosed for the purposes as stipulated by the Ordinance and the Code published from time to time by the Council (references should be made to Appendix XI). Consent

---

\(^{12}\) s.34, s.35 and s.36 of the Ordinance
from the party concerned on such disclosure should be obtained before the provision of the RT procedure(s) (consent form (15) is relevant).

XII. **Handling of Complaints**

**Complaints against RT Centres**

12.1 RT centres should have in place an administrative arrangement with a designated staff at the appropriate level to acknowledge receipt of complaints and to take charge of investigations. The outcome of the investigation should be recorded and explained to the complainant.

12.2 If the complainant is dissatisfied with the outcome of investigation by the RT centre, he/she should be advised about other avenues of complaint including, if appropriate, the Investigation Committee of the Council or the Medical Council of Hong Kong (for matters relating to possible professional misconduct of medical practitioners).

**Breach of the Supplementary Code**

12.3 Any allegations of breach of the Supplementary Code will be investigated by the Investigation Committee of the Council. Failure to co-operate with the Investigation Committee will be taken into account by the Council in assessing whether there is a ground for revocation, variation and/or suspension of licence.

12.4 Professionals concerned are reminded that they are also under codes of practice or ethics of their respective professional disciplines.

XIII. **References**

13.1 In interpreting the terms used in the Supplementary Code, reference should be made to the glossary of abbreviations and common terms used in RT and the explanatory notes for completing the forms on annual statistics on RT treatment in the Code.

---

13 Schedule 1 s.6(c) of the Ordinance
Annex II

Consent Form (1)

Consent to Freezing and Storage of Gametes
(for own subsequent use)

1. I ____________________________________________________________________________
   (Surname, Given Names) (ID No.)
   (Single/Married*) of ____________________________________________________________________________
   (address) DO HEREBY AUTHORISE ____________________________________________________________________________
   (name of the reproductive technology centre) (hereinafter called “the Centre”) to freeze and store the sperm / eggs (oocytes)* produced from me and provided by me to the Centre, in a manner which accords with the practice and procedure adopted from time to time by the Centre (“the Programme”).

2. I acknowledge that the nature, procedures and possible complications of the Programme have been clearly explained to me by ____________________________________________________________________________ and I have been given the opportunity to ask any question I wish. I have also been offered a suitable opportunity to take part in counselling with ____________________________________________________________________________ about the implications of the Programme.

3. I consent that my sperm / eggs (oocytes)* will be stored for an initial period of two years from the date of freezing of the sperm / eggs (oocytes)* and that, subject to paragraph 5 below, the storage period will be extended thereafter two years at a time only if I give a written notice of extension. I understand that the said notice of extension must reach the Centre at least one month before the expiry of the current period of storage * (please delete this clause if the storage period indicated in paragraph 5 below is shorter than two years).

4. I consent that in the absence of a written notice of extension, the Centre may handle my sperm / eggs (oocytes)* in accordance with my instructions set out in paragraph 5 below.

5. I understand that, subject to the giving of proper notice(s) of extension as mentioned in paragraph 3 above, my sperm / eggs (oocytes)* will be frozen and stored for (complete either (a) or (b) –

   (a)* a maximum of _______ years@(a) from the date of freezing of the sperm / eggs (oocytes)*; or

   (b)* until I am _______ years old@(b), i.e. up to ________ (dd/mm/yr),

   and upon expiry of the maximum storage period specified above, or upon my death, whichever occurs sooner, I consent that the sperm / eggs (oocytes)* stored may be (please tick one) -

   [ ] disposed of in accordance with the “Guidelines on disposal of gametes or embryos” (“the Guidelines”) in the Code of Practice published from time to time by the Council on Human Reproductive Technology.
6. I understand that my stored sperm / eggs (oocytes)* will be used for insemination or other reproductive technology procedures only if I am a married person at the time of use of the sperm / eggs (oocytes)*, except in circumstances specified otherwise by the law or by the Code of Practice. Furthermore, upon my death, my stored sperm / eggs (oocytes)* cannot be used by my spouse to bring about any posthumous child(ren).

7. I understand that I can withdraw from and terminate the Programme at any time by giving a written notice to the Centre stating my intention to withdraw and terminate, and indicating to the Centre whether I would like the sperm / eggs (oocytes)* then stored with the Centre to be -

(a) transferred to another local licensed reproductive technology centre;
(b) exported to an overseas centre; or
(c) handled in accordance with my instructions set out in paragraph 5 above.

In the event that I withdraw from or terminate the Programme without giving any indication as aforesaid, the Centre will handle the stored sperm / eggs (oocytes)* in accordance with my instructions as set out in paragraph 5 above.

8. I understand that I am required to immediately inform the Centre of any change of my address.

9. I fully understand and accept that -

(a) my stored sperm / eggs (oocytes)* may not produce any successful pregnancy;
(b) the procedures of freezing, thawing and storage of my sperm / eggs (oocytes)* do not produce a higher incidence of carrying abnormal children as compared with a normal pregnancy. Any child conceived or born from the use of such sperm / eggs (oocytes)* may however suffer from defect(s) of health or mental or physical impairment(s) as a result of congenital, hereditary or other reasons;
(c) the quality of the sperm / eggs (oocytes)* stored depends to a large extent on the quality of the specimen submitted for storage;
(d) the quality of the sperm / eggs (oocytes)* may deteriorate following the freezing and thawing procedures and may not be found to be suitable for subsequent use; and
(e) the Centre will not be responsible for damage to or deterioration of the sperm/ eggs (oocytes)* due to whatever cause which is beyond its control or because of unforeseen circumstances.
[p.3 of Form (1)]

Dated the __________________ Day of __________________ (Month) (Year)

Signed __________________
(Patient’s Signature)

Name __________________ Spouse’s Name #
(in Block Letters) (in Block Letters)

____________________ (in Chinese) __________________
(in Chinese)

Marriage Certificate No. # ________________________________

Signed __________________
(Signature of Attending Doctor)

Signed __________________
(Signature of Witness)

Name __________________
(in Block Letters)

Name __________________
(in Block Letters)

Position __________________

Notes : * Delete whichever is inapplicable

@ (a) A maximum storage period for sperm / eggs (oocytes) of up to 10 years may be specified by the patient for own treatment.
(b) The maximum storage period for sperm / eggs (oocytes) stored for medical reasons is 10 years, or until the patient reaches the age of 55, whichever is the later.

# To be completed if the patient is married.
Consent to Freezing and Storage of Embryos
(for married couples' own use)

1. We ________________________________ (Surname, Given Names) (ID No.)
   (hereinafter called “the Husband”) and ________________________________ (Surname, Given Names) (ID No.)
   (wife's name) (hereinafter called “the Wife”), of ________________________________ (address),
   DO HEREBY AUTHORISE ________________________________ (name of the reproductive technology centre)
   (hereinafter called “the Centre”) to freeze and store the embryos produced from our gametes, in a manner which
   accords with the practice and procedure adopted from time to time by the Centre (“the Programme”).

2. We acknowledge that the nature, procedures and possible complications of the Programme
   have been clearly explained to us by ________________________________ and we have been
   given the opportunity to ask any question we wish. We have also been offered a suitable
   opportunity to take part in counselling with ________________________________ about the implications of the Programme.

3. We understand that, where a written notice from us is required under the Programme, the
   notice is only valid if it bears both our signatures.

4. We consent that our embryos will be stored for an initial period of two years from the date
   of freezing of the embryos and that, subject to paragraph 6 below, the storage period will be
   extended thereafter two years at a time only if we give a written notice of extension. We
   understand that the said notice of extension must reach the Centre at least one month before
   the expiry of the current period of storage * (please delete this clause if the storage period
   indicated in paragraph 6 below is shorter than two years).

5. We consent that in the absence of a written notice of extension, the Centre may handle our
   embryos in accordance with our instructions set out in paragraph 6 below.

6. We understand that, subject to the giving of proper notice(s) of extension as mentioned in
   paragraph 4 above, our embryos will be frozen and stored for a maximum of
   ________________ years@ from the date of freezing of the embryos and, upon expiry of the
   maximum storage period specified above, or upon the death of either of us, or in the event
   of divorce or legal separation, or upon one of us becoming incapable of revoking his or her
   consent, whichever occurs earlier in time, our stored embryos may be (please tick one) -

   [ ] disposed of in accordance with the “Guidelines on disposal of gametes or embryos”
   (“the Guidelines”) in the Code of Practice published from time to time by the Council
   on Human Reproductive Technology.
[ ] donated for the treatment of other infertile couples, in which event our embryos
would not be used to produce more than a total of one/ two/ three * live birth events
(failing which the Centre may dispose of the stored embryos in accordance with the
Guidelines).

[ ] donated for research (failing which the Centre may dispose of the stored embryos in
accordance with the Guidelines).

7. We understand that our stored embryos will only be used for reproductive technology
procedures when we are the parties to a marriage, except in circumstances specified
otherwise by the law or by the Code of Practice. Furthermore, upon the death of either of
us, our stored embryos cannot be used by the surviving spouse to bring about any
posthumous child(ren).

8. We understand that we can withdraw from and terminate the Programme at any time by
giving a written notice to the Centre stating our intention to withdraw and terminate, and
indicating to the Centre whether we would like the embryos then stored with the Centre to
be -

(a) transferred to another local licensed reproductive technology centre;
(b) exported to an overseas centre; or
(c) handled in accordance with our instructions set out in paragraph 6 above.

In the event that we withdraw from or terminate the Programme without giving any
indication as aforesaid, the Centre will handle the stored embryos in accordance with our
instructions as set out in paragraph 6 above.

9. We understand that we are required to inform the Centre of any change of our address or our
marital relationship.

10. We fully understand and accept that -

(a) the stored embryos may not produce any successful pregnancy;
(b) the procedures of freezing, thawing and storage of our embryos do not produce a
higher incidence of carrying abnormal children as compared with a normal pregnancy.
Any child conceived or born from the use of such embryos may however suffer from
defect(s) of health or mental or physical impairment(s) as a result of congenital,
hereditary or other reasons;
(c) the quality of the embryos stored depends to a large extent on their quality prior to
freezing;
(d) the quality of the embryos may deteriorate following the freezing and thawing
procedures and may not be found to be suitable for subsequent use; and
(e) the Centre will not be responsible for damage to or deterioration of the embryos due to
whatever cause which is beyond its control or because of unforeseen circumstances.
Dated the __________________ day of __________________ (Month) __________________ (Year)

Signed __________________
(Husband’s Signature)

Signed __________________
(Wife’s Signature)

Name __________________
(in Block Letters)

Name __________________
(in Block Letters)

_____________________
(in Chinese)

_____________________
(in Chinese)

Marriage Certificate No. __________________

Signed __________________
(Signature of Attending Doctor)

Signed __________________
(Signature of Witness)

Name __________________
(in Block Letters)

Name __________________
(in Block Letters)

Position __________________

Note: @ A maximum period of storage for embryos of up to 10 years may be specified by the patients.
Consent to Anonymous Donation of Sperm

1. I ________________________________ (Surname, Given Names) ________________________________ (ID No.) (Single/Married*), DO HEREBY CONSENT to donating my sperm anonymously to ________________________________ (name of reproductive technology centre) (hereinafter called “the Centre”) with the understanding that my sperm will be used for the treatment of infertile couples* or for research project * and that this consent cannot be revoked or varied once my sperm has been donated.

2. I consent that my sperm may be stored and/or disposed of by the Centre in such way(s) as the Centre may at its discretion deem appropriate.

3. I consent that my sperm should only be used to produce one / two / three* live birth events.

4. I have/ have not *, prior to my donation to the Centre on this occasion, donated my sperm on ________________ previous occasions. Details of my previous donations are as follows -

__________________________________________________________________________

(please state name(s) of the centre(s) to which donation was made, date of donation(s) and other relevant information.)

5. I acknowledge that the nature and implications of my donation have been explained to me by ________________________________ and I have been given the opportunity to ask any question I wish. I have also been offered a suitable opportunity to take part in counselling with ________________________________ about the implications of the donation.

6. I understand that under the Parent & Child Ordinance (Cap. 429), I shall not be the legal father of the child(ren) born from my donated sperm. I also agree never to seek to make any claim over such child(ren) in any circumstance whatsoever.

7. I understand that the identity of any recipient of my donation and of any child(ren) born from my donated sperm will not be disclosed to me. I shall also remain anonymous.

8. To the best of my knowledge and belief -

(a) I am in good health and have no communicable disease or hereditary disorder, except as follows -

__________________________________________________________________________
(b) None of my relatives has ever suffered from any inheritable disease, except as follows -

________________________________________________________________________

________________________________________________________________________

9. For the purpose of determining whether I am suitable as a donor of sperm, I consent to undergoing such blood tests (including HIV test) and medical examinations as shall be prescribed by the Centre.

Dated the ________________ day of ________________ (Month) ________________ (Year)

Signed ____________________________
(Donor’s Signature)

Name ____________________________ (in Block Letters) ____________________________ (in Chinese)

Date of Birth ____________________________ (dd/mm/yr)

Signed ____________________________
(Signature of the one who explained the nature & implications)

Signed ____________________________
(Signature of Witness)

Name ____________________________ (in Block Letters) ____________________________ (in Block Letters)

Position ____________________________ Position ____________________________

Note: * Delete whichever is inapplicable.
Consent Form (4)

Consent to Anonymous Donation of Eggs (Oocytes)

1. I ____________________________ (Surname, Given Names) ____________________________ (ID No.) (Single/Married*), DO HEREBY CONSENT to donating my eggs (oocytes) anonymously to ____________________________ (name of reproductive technology centre) (hereinafter called “the Centre”), with the understanding that my eggs (oocytes) will be used for the treatment of infertile couples* or for research project* and that this consent cannot be revoked or varied once my eggs (oocytes) have been donated.

2. I consent to -

(a) be prepared for egg (oocytes) retrieval including the use of drugs for hyperstimulation;
(b) the removal of eggs (oocytes) from my ovaries with the aid of laparoscopy/ultrasound; and
(c) the administration of appropriate drugs and/or anaesthetics to me if necessary for the procedure(s).

3. I consent that my eggs (oocytes) may be stored and/or disposed of by the Centre in such way(s) as the Centre may at its discretion deem appropriate.

4. I consent that my eggs (oocytes) should only be used to produce one / two / three* live birth events.

5. I have/ have not *, prior to my donation to the Centre on this occasion, donated my eggs (oocytes) on ____________ previous occasions. Details of my previous donations are as follows -

______________________________________________________________
(please state name(s) of the centre(s) to which donation was made, date of donation(s) and other relevant information.)

6. I acknowledge that the nature, procedures and possible complications associated with my donation have been explained to me by ____________________________ and I have been given the opportunity to ask any question I wish. I have also been offered a suitable opportunity to take part in counselling with ____________________________ about the implications of the donation and associated procedures.

7. I understand that under the Parent & Child Ordinance (Cap. 429), I shall not be the legal mother of the child(ren) born from my donated eggs (oocytes). I also agree never to seek to make any claim over any such child(ren) under any circumstance whatsoever.

8. I understand and agree that the identity of any recipient of my donation and of any child(ren) born from my donated egg(s) [oocyte(s)] will not be disclosed to me. I shall
also remain anonymous.

9. To the best of my knowledge and belief -

(a) I am in good health and have no communicable disease or hereditary disorder, except as follows -

(b) None of my relatives has ever suffered from any inheritable disease, except as follows -

10. For the purpose of determining whether I am suitable as a donor of eggs (oocytes), I consent to undergoing such blood tests (including HIV test) and medical examinations as shall be prescribed by the Centre.

Dated the __________________ day of ______________________ (Month) ______________________ (Year)

Signed ______________________
(Donor’s Signature)

Name ______________________ ______________________
(in Block Letters) (in Chinese)

Date of Birth ______________________
(dd/mm/yr)

Signed ______________________
(Signature of Attending Doctor)

Signed ______________________
(Signature of Witness)

Name ______________________
(in Block Letters)

Name ______________________
(in Block Letters)

Position ______________________

Note: *Delete whichever is inapplicable.
Consent to Anonymous Donation of Embryos

1. We ____________________________ (Surname, Given Names) ____________________________ (ID No.)
   (husband’s name) (hereinafter called “the Husband”), and ____________________________ (Surname, Given Names)
   ____________________________ (wife’s name) (hereinafter called “the Wife”),
   of ____________________________ (address), DO HEREBY CONSENT to donating our embryo(s) anonymously to
   ____________________________ (name of reproductive technology centre) (hereinafter called “the Centre”), with the
   understanding that our embryos will be used for the treatment of other infertile couples* or for research projects* and that this consent cannot be revoked or varied.

2. We consent that our embryos may be stored and/or disposed of by the Centre in such way(s) as the Centre may at its discretion deem appropriate.

3. We consent that our embryos should only be used to produce one / two / three* live birth events.

4. We have/ have not *, prior to our donation to the Centre on this occasion, donated our embryo(s) on _____________ previous occasions. Details of our previous donations are as follows -

   (please state name(s) of the centre(s) to which donation was made, date of donation(s) and other relevant information.)

5. We acknowledge that the nature and implications of our donation have been explained to us by ____________________________ and we have been given the opportunity to ask any question we wish. We have also been offered a suitable opportunity to take part in counselling with ____________________________ about the implications of the treatment.

6. We understand that under the Parent & Child Ordinance (Cap. 429), we shall not be the legal parents of the child(ren) born from our donated embryo(s). We also agree never to seek to make any claim over any such child(ren) under any circumstance whatsoever.

7. We understand and agree that the identity of any recipient of our donation and of any child(ren) born from our donated embryos will not be disclosed to us. We shall also remain anonymous.
8. To the best of our knowledge and belief -

(a) We are in good health and have no communicable disease or hereditary disorder, except as follows -

(b) None of our relatives has ever suffered from any inheritable disease, except as follows -

9. For the purpose of determining whether we are suitable as donors of embryos, we consent to undergoing such blood tests (including HIV test) and medical examinations as shall be prescribed by the Centre.

Dated the ______________ day of ______________
(Month) (Year)

Signed ______________
(Husband’s Signature)

Signed ______________
(Wife’s Signature)

Name ______________
(in Block Letters)

Name ______________
(in Block Letters)

(in Chinese)

(in Chinese)

Marriage Certificate No. ______________

Signed ______________
(Signature of Attending Doctor)

Signed ______________
(Signature of Witness)

Name ______________
(in Block Letters)

Name ______________
(in Block Letters)

Position ______________

Note: *Delete whichever is inapplicable.
Consent Form (6)

Consent to Donor Insemination

PART I  PATIENT'S CONSENT

1. I ________________________________, of 
   (Surname, Given Names) (ID No.) ________________________________, (address), 
   being lawfully married and desirous of having a child, DO HEREBY AUTHORISE 
   ________________________________, (name of reproductive technology centre) (hereinafter called “the Centre”), to perform the treatment of donor insemination for me.

2. I understand that appropriate drugs will be administered to me if necessary for the treatment.

3. I understand that the donor shall remain anonymous * (please delete this sentence if the donation is designated). Under the Parent & Child Ordinance (Cap. 429), the donor shall not be the legal father of any child(ren) born from the aforesaid treatment procedure.

4. I acknowledge that the nature, procedures and possible complications of the aforesaid treatment procedure have been explained to me by ________________________________, and I have been given the opportunity to ask any question I wish. I have also been offered counselling with ________________________________ about the implications of the treatment procedure.

5. I fully understand and accept that -
   (a) the aforesaid treatment procedure may not result in a successful pregnancy;
   (b) I may not be able to carry the pregnancy to term;
   (c) any child conceived or born as a result of the procedures, may suffer from defect(s) of health or mental or physical impairment(s) as a result of congenital, hereditary or other reasons, similar to the situation of a normal pregnancy.

6. I understand that -
   (a) this consent cannot be revoked or varied once insemination has been performed;
   (b) the procedure of donor insemination will not be performed if my husband revokes or varies his consent prior to insemination.
Dated the __________________ day of __________________

(Month) __________________ (Year) __________________

Signed __________________

(Patient’s Signature)

Name __________________

(in Block Letters)

 ____________________________

(in Chinese)

Signed __________________

(Signature of Attending Doctor)

Signed __________________

(Signature of Witness)

Name __________________

(in Block Letters)

Name __________________

(in Block Letters)

Position __________________

Name __________________

(in Block Letters)
PART II  HUSBAND’S CONSENT

7. I ___________________________ am
(Surname, Given Names) (ID No.)
the husband of ___________________________ and I consent to the
course of treatment outlined above. I understand that I will be the legal father of any
child(ren) born from the treatment.

8. I understand that this consent cannot be revoked or varied once the insemination has
been performed. Any revocation or variation of this consent will not be effective until
actual receipt by the Centre in writing.

Dated the ________________ day of ____________________
(Month) (Year)

Signed ___________________________
(Husband’s Signature)

Name ___________________________
(in Block Letters) ____________________
(in Chinese)

Marriage Certificate No. ___________________________

Note: *Delete whichever is inapplicable.
Consent to In Vitro Fertilization/Gamete Intra-Fallopian Transfer/Embryo Transfer (including frozen/thawed embryo) (IVF/GIFT/ET)

PART I PATIENT'S CONSENT

1. I, (Surname, Given Names) (ID No.), (address), being lawfully married and desirous of having a child, DO HEREBY AUTHORISE (name of reproductive technology centre) (hereinafter called “the Centre”), to perform the treatment of in-vitro fertilization/gamete intra-fallopian transfer/embryo transfer for me.

2. I also hereby consent that the Centre may proceed with the following reproductive technology procedures for me (please tick as appropriate) -

   ( ) in vitro fertilization & embryo transfer;
   ( ) gamete intra-fallopian transfer;
   ( ) pronuclear stage tubal transfer;
   ( ) others (please specify)

3. I consent to -

   (a) be prepared for egg (oocytes) retrieval including the use of drugs for hyperstimulation;
   (b) the removal of eggs (oocytes) from my ovaries with the aid of laparoscopy/ultrasound;
   (c) the administration of appropriate drugs and/or anaesthetics to me if necessary for the said procedure(s); and
   (d) the transfer of gametes/embryos to my body.

4. I consent to the mixing of the gametes of ____________________________ with those of ____________________________.

   (please specify the reference no. of man who provides the sperm and woman who provides the eggs (oocytes))

5. I understand that the donor(s) of the gamete(s)/embryo(s) shall remain anonymous * (please delete this sentence if the donation is designated). Under the Parent & Child Ordinance (Cap. 429), the donor(s) shall not be the legal parent(s) of any child(ren) born from the aforesaid treatment procedure. * (please delete the entire paragraph if no donated gamete(s)/embryo(s) are involved)
6. I acknowledge that the nature, procedures and possible complications of the treatment procedure have been explained to me by __________________________ and I have been given the opportunity to ask any question I wish. I have also been offered a suitable opportunity to take part in counselling with __________________________ about the implications of the treatment procedure.

7. I fully understand and accept that -

(a) the aforesaid treatment procedures may not result in a successful pregnancy;
(b) I may not be able to carry the pregnancy to term;
(c) I may suffer from illness(es) or complications arising out of or consequent upon a pregnancy resulting from in-vitro fertilization/gamete intra-fallopian transfer/embryo transfer;
(d) any child conceived or born as a result of the procedures, may suffer from defect(s) of health or mental or physical impairment(s) as a result of congenital, hereditary or other reasons, similar to the situation of a normal pregnancy.

8. I understand that the procedures as listed in paragraph 2 will not be performed if my husband revokes or varies his consent before the transfer of gamete(s) or embryo(s) to me.

9. I consent that unfertilised eggs (oocytes) obtained from me and/or excess embryos produced in the course of the procedures listed in paragraph 2 above may be (please tick one) -

[ ] disposed of in accordance with the “Guidelines on disposal of gametes or embryos” (“the Guidelines”) in the Code of Practice published from time to time by the Council on Human Reproductive Technology.

[ ] donated anonymously for the treatment of other infertile couples, in which event my gametes or embryos would not be used to produce more than a total of one/ two/ three * live birth events (failing which the Centre may dispose of the stored gametes or embryos in accordance with the Guidelines).

[ ] donated for research (failing which the Centre may dispose of the stored gametes or embryos in accordance with the Guidelines).
<table>
<thead>
<tr>
<th>Dated the</th>
<th>day of</th>
<th>(Month)</th>
<th>(Year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Patient’s Signature)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(in Block Letters)</td>
<td></td>
<td>(in Chinese)</td>
<td></td>
</tr>
<tr>
<td>Signed</td>
<td>Signed</td>
<td>(Signature of Witness)</td>
<td></td>
</tr>
<tr>
<td>(Signature of Attending Doctor)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td></td>
<td>(in Block Letters)</td>
<td></td>
</tr>
<tr>
<td>(in Block Letters)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Position</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PART II  HUSBAND’S CONSENT

10. I ____________________________ ___________________ am

    (Surname, Given Names)  (ID No.)

    the husband of ____________________________ and I consent to the
    course of treatment outlined above. I understand that I will be the legal father of any
    child(ren) born from the treatment.

11. I understand that this consent cannot be revoked or varied once the gamete(s) or
    embryo(s) has/have been transferred to my wife. Any revocation or variation of this
    consent will not be effective until actual receipt by the Centre in writing.

12. I consent that excess embryos produced in the course of the procedures listed in the
    paragraph 2 above may be handled in accordance with my wife’s instructions, as set out
    in paragraph 9 hereof.

Dated the  ______________ day of  __________________   __________________

    (Month)   (Year)

Signed  ________________________________

    (Husband’s Signature)

Name  ________________________________ ________________________________

    (in Block Letters)   (in Chinese)

Marriage Certificate No.  ________________________________

Notes:  *  Delete whichever is inapplicable.

    #  Under normal circumstances, gametes from the husband and wife should be
    used. The use of donated gamete(s) would be subject to proof of difficulties in
    obtaining normal gametes from either the husband or the wife.
Consent to Designated Donation of Sperm

Part I

DONOR’S CONSENT

1. I ____________________________ (name of donor) (hereinafter called “the Donor”), DO HEREBY CONSENT to donating my sperm to the following couple (hereinafter called “the Recipients”), ____________________________ (Surname, Given Names) (ID No.) (husband’s name), and ____________________________ (Surname, Given Names) (ID No.) (wife’s name), with the understanding that my sperm will be used for the treatment of the Recipients and that this consent cannot be revoked or varied once my sperm has been donated, subject to any written agreement to the contrary between the Donor and the Recipients.

2. I acknowledge that the nature and implications of my donation have been explained to me by ____________________________ and I have been given the opportunity to ask any question I wish. I have also been offered a suitable opportunity to take part in counselling with ____________________________ about the implications of the donation.

3. I understand that my sperm will be stored for a maximum period of two years from the date of freezing the sperm. If the aforesaid treatment of the Recipients cannot be successfully carried out within that period, or if before the expiry of the said maximum storage period, it becomes impossible for any reason whatsoever for the aforesaid treatment to be successfully carried out, or if excess sperm remains after the completion of the aforesaid treatment, I consent that the sperm obtained from me may be (please tick one) -

[ ] disposed of in accordance with the “Guidelines on disposal of gametes or embryos” (“the Guidelines”) in the Code of Practice published from time to time by the Council on Human Reproductive Technology.

[ ] donated anonymously for the treatment of other infertile couples, in which event my sperm would not be used to produce more than a total of one / two / three* live birth events, including the event of the designated donation, if successful (failing which the Centre may dispose of the stored sperm in accordance with the Guidelines).

[ ] donated for research (failing which the Centre may dispose of the stored sperm in accordance with the Guidelines).

4. I understand that the embryo(s) produced from the fertilization of my sperm will be used for the infertility treatment of the Recipients. If the aforesaid treatment cannot be successfully carried out, or if it becomes impossible for any reason whatsoever for the
aforesaid treatment to be successfully carried out, or if excess embryo(s) remain after the completion of the aforesaid treatment, I consent that the embryo(s) produced from the aforesaid fertilization may be handled in accordance with the Recipients’ instructions, as set out in paragraph 11 hereof.

5. I understand that under the Parent & Child Ordinance (Cap. 429), I shall not be the legal father of the child(ren) born from my donated sperm. I also agree never to seek to make any claim over such child(ren) under any circumstance whatsoever.

6. To the best of my knowledge and belief -

(a) I am in good health and have no communicable disease or hereditary disorder, except as follows -

(b) None of my relatives has ever suffered from any inheritable disease, except as follows -

7. For the purpose of determining whether I am suitable as a donor of sperm, I consent to undergoing such blood tests (including HIV test) and medical examinations as shall be prescribed by the Centre.
Dated the __________ day of __________ (Month) __________ (Year)

Signed __________________________
(Donor’s Signature)

Name __________________________
(in Block Letters) __________________________ (in Chinese)

Date of Birth __________________________
(dd/mm/yr)

Signed __________________________
(Signature of Attending Doctor)

Signed __________________________
(Signature of Witness)

Name __________________________
(in Block Letters) __________________________ (in Block Letters)

Position __________________________
Part II RECIPIENTS’ CONSENT

8. We (the Recipients), (Surname, Given Names) (ID No.) and (Surname, Given Names) (ID No.) of (address), being lawfully married and desirous of having a child, DO HEREBY CONSENT to receiving the sperm donated by (Surname, Given Names) (ID No.) (the Donor) for infertility treatment.

9. We acknowledge that the nature and implications of the aforesaid treatment have been explained to us by and we have been given the opportunity to ask any question we wish. We have also been offered a suitable opportunity to take part in counselling with about the implications of the donation.

10. We fully understand and accept that -

   (a) the aforesaid treatment procedure may not result in a successful pregnancy;
   (b) the wife may not be able to carry the pregnancy to term;
   (c) any child conceived or born as a result of the procedures may suffer from defect(s) of health or mental or physical impairment(s) as a result of congenital, hereditary or other reasons, similar to the situation of a normal pregnancy.

11. We understand that the embryo(s) produced from the fertilization of the gametes of (please specify names of persons who are the origins of the gametes)

will be used for the aforesaid infertility treatment and stored for such purpose for a maximum period of two years from the date of freezing the embryos, unless there are special circumstances justifying a longer storage period. If the aforesaid treatment cannot be successfully carried out within that period, or if, before the expiry of the said maximum storage period, it becomes impossible for any reason whatsoever for the aforesaid treatment to be successfully carried out, or if excess embryo(s) remain after completion of the aforesaid treatment, we consent that the embryo(s) produced from the aforesaid fertilization may be (please tick one) -

[ ] disposed of in accordance with the “Guidelines on disposal of gametes or embryos” (“the Guidelines”) in the Code of Practice published from time to time by the Council on Human Reproductive Technology.
[ ] donated anonymously for the treatment of other infertile couples, in which event
the embryo(s) would not be used to produce more than a total of one/two/three *
live birth events@, including the event of the designated donation, if successful
(failing which the Centre may dispose of the embryo(s) in accordance with the
Guidelines).

[ ] donated for research (failing which the Centre may dispose of the embryo(s) in
accordance with the Guidelines).

12. We understand that under the Parent & Child Ordinance (Cap. 429), we shall be the legal
parents of the child(ren) born from the aforesaid treatment procedure.
Dated the __________ day of __________ (Month) (Year)

Signed ____________________________ Signed ____________________________
(Husband’s Signature) (Wife’s Signature)

Name ____________________________ Name ____________________________
(in Block Letters) (in Block Letters)

______________________________ ______________________________

Marriage Certificate No. ______________________________

Signed ____________________________ Signed ____________________________
(Signature of Attending Doctor) (Signature of Witness)

Name ____________________________ Name ____________________________
(in Block Letters) (in Block Letters)

Position ______________________________

Notes:  * Delete whichever is inapplicable.
   # To be completed only if the embryo(s) were produced from the wife’s egg(s) (oocytes).
   @ If the Donor has indicated to donate surplus or unused sperm to other infertile couple, the limit of “live birth event” specified by the donor in paragraph 3 should also be considered for the case which the Recipients indicate to donate the surplus or unused embryos to other infertile couple. The total no. of live birth events produced by the excess sperm and embryos subsequently created should not be more than three.
Consent to Designated Donation of Eggs (Oocytes)

Part I DONOR’S CONSENT

1. I ________________________________ (name of donor) (hereinafter called
(Surname, Given Names) (ID No.)
"the Donor"), DO HEREBY CONSENT to donating my eggs (oocytes) to the following
couple (hereinafter called "the Recipients"),
(Surname, Given Names) (ID No.)
(husband’s name), and
(Surname, Given Names) (ID No.)
(wife’s name), with
the understanding that my eggs (oocytes) will be used for the treatment of the Recipients
and that this consent cannot be revoked or varied once my eggs (oocytes) have been
donated, subject to any written agreement to the contrary between the Donor and the
Recipients.

2. I consent to -

   (a) be prepared for egg (oocytes) retrieval including the use of drugs for
       hyperstimulation;
   (b) the removal of eggs (oocytes) from my ovaries with the aid of
       laparoscopy/ultrasound;
   (c) the administration of appropriate drugs and/or anaesthetics to me if necessary for
       the procedure(s).

3. I acknowledge that the nature and implications of my donation have been explained to
   me by ________________________________ and I have been given the opportunity to
   ask any question I wish. I have also been offered a suitable opportunity to take part in
   counselling with ________________________________ about the implications of the
   donation.

4. I understand that my eggs (oocytes) will be stored for a maximum period of two years
   from the date of freezing the eggs (oocytes). If the aforesaid treatment of the Recipients
   cannot be successfully carried out within that period, or if, before the expiry of the said
   maximum storage period, it becomes impossible for any reason whatsoever for the
   aforesaid treatment to be successfully carried out, or if excess eggs (oocytes) remain after
   completion of the aforesaid treatment, I consent that the eggs (oocytes) obtained from me
   may be (please tick one) -

[ ] disposed of in accordance with the “Guidelines on disposal of gametes or
   embryos” ("the Guidelines") in the Code of Practice published from time to
time by the Council on Human Reproductive Technology.
[ ] donated anonymously for the treatment of other infertile couples, in which event my eggs (oocytes) would not be used to produce more than a total of one / two / three* live birth events, including the event of the designated donation, if successful (failing which the Centre may dispose of the stored eggs (oocytes) in accordance with the Guidelines).

[ ] donated for research (failing which the Centre may dispose of the stored eggs (oocytes) in accordance with the Guidelines).

5. I understand that the embryo(s) produced from fertilization of my egg(s) [oocyte(s)] will be used for the infertility treatment of the Recipients. If the aforesaid treatment cannot be successfully carried out, or if it becomes impossible for any reason whatsoever for the aforesaid treatment to be successfully carried out, or if excess embryo(s) remain after completion of the aforesaid treatment, I consent that the embryo(s) produced from the aforesaid fertilization may be handled in accordance with the Recipients’ instructions, as set out in paragraph 12 hereof.

6. I understand that under the Parent & Child Ordinance (Cap. 429), I shall not be the legal mother of the child(ren) born from my donated egg(s) [oocyte(s)]. I also agree never to seek to make any claim over such child(ren) under any circumstance whatsoever.

7. To the best of my knowledge and belief -

(a) I am in good health and have no communicable disease or hereditary disorder, except as follows -

(b) None of my relatives has ever suffered from any inheritable disease, except as follows -

8. For the purpose of determining whether I am suitable as a donor of eggs (oocytes), I consent to undergoing such blood tests (including HIV test) and medical examinations as shall be prescribed by the centre.
Dated the ________________ day of ____________________
(Month) (Year)

Signed ________________________________
(Donor’s Signature)

Name ________________________________
(in Block Letters) ______________________
(in Chinese)

Date of Birth __________________________
(dd/mm/yr)

Signed ________________________________
(Signature of Attending Doctor)

Name ________________________________
(in Block Letters) ______________________

Signed ________________________________
(Signature of Witness)

Name ________________________________
(in Block Letters) ______________________

Position ______________________________
Part II  RECIPIENTS’ CONSENT

9. We (the Recipients), ___________________________ (husband’s name),
   ___________________________ (Surname, Given Names) (ID No.),
   and ___________________________ (wife’s name),
   ___________________________ (Surname, Given Names) (ID No.),
   of ___________________________,
   being lawfully married and desirous of having a child, DO HEREBY CONSENT to
   receiving the eggs (oocytes) donated by ___________________________,
   ___________________________ (Surname, Given Names) (ID No.)
   (the Donor) for infertility treatment.

10. We acknowledge that the nature and implications of the aforesaid treatment have been
    explained to us by ___________________________ and we have been given the
    opportunity to ask any question we wish. We have also been offered a suitable
    opportunity to take part in counselling with ___________________________,
    about the implications of the donation.

11. We fully understand and accept that-

   (a) the aforesaid treatment procedure may not result in a successful pregnancy;
   (b) the wife may not be able to carry the pregnancy to term;
   (c) any child conceived or born as a result of the procedures may suffer from
       defect(s) of health or mental or physical impairment(s) as a result of congenital,
       hereditary or other reasons, similar to the situation of a normal pregnancy.

12. We understand that the embryo(s) produced from the fertilization of the gametes of
    ___________________________ (please specify names of persons who are the origins of the gametes)
    will be used for
    the aforesaid infertility treatment and stored for such purpose for a maximum period of
    two years from the date of freezing the embryos, unless there are special circumstances
    justifying a longer storage period. If the aforesaid treatment cannot be successfully
    carried out within that period, or if, before the expiry of the said maximum storage
    period, it becomes impossible for any reason whatsoever for the aforesaid treatment to be
    successfully carried out, or if excess embryo(s) remain after completion of the aforesaid
    treatment, we consent that the embryo(s) produced from the aforesaid fertilization may
    be (please tick one) -

   [ ] disposed of in accordance with the “Guidelines on disposal of gametes or
      embryos” (“the Guidelines”) in the Code of Practice published from time to time
      by the Council on Human Reproductive Technology.

   [ ] donated anonymously for the treatment of other infertile couples, in which event
      the embryo(s) would not be used to produce more than a total of one/two/three *
      live birth events @, including the event of the designated donation, if successful
      (failing which the Centre may dispose of the embryo(s) in accordance with the
      Guidelines).
[ ] donated for research (failing which the Centre may dispose of the embryo(s) in accordance with the Guidelines).

13. We understand that under the Parent & Child Ordinance (Cap. 429), we shall be the legal parents of the child(ren) born from the aforesaid treatment procedure.

Dated the ______________ day of ________________  ________________
(Month) (Year)

Signed _____________________________
(Husband’s Signature)

Signed _____________________________
(Wife’s Signature)

Name ______________________________
(in Block Letters)

Name ______________________________
(in Block Letters)

_______________________________
(in Chinese)

_______________________________
(in Chinese)

Marriage Certificate No. __________________________

Signed _____________________________
(Signature of Attending Doctor)

Signed _____________________________
(Signature of Witness)

Name ______________________________
(in Block Letters)

Name ______________________________
(in Block Letters)

Position __________________________

Notes: * Delete whichever is inapplicable.
# To be completed only if the embryo(s) were produced from the husband’s sperm.
@if the Donor has indicated to donate surplus or unused eggs (oocytes) to other infertile couple, the limit of “live birth event” specified by the donor in paragraph 4 should also be considered for the case which the Recipients indicate to donate the surplus or unused embryos to other infertile couple. The total no. of live birth events produced by the excess eggs (oocytes) and embryos subsequently created should not be more than three.
Consent to Designated Donation of Embryos

PART I DONORS’ CONSENT

1. We ______________________ (Surname, Given Names) (ID No.) (husband’s name),
    and ______________________ (Surname, Given Names) (ID No.) (wife’s name)
    (name of the donors) (hereinafter jointly called “the Donors”), DO HEREBY CONSENT
to donating the embryo(s) produced from our gametes to the following couple
(hereinafter called “the Recipients”),
__________________________ (Surname, Given Names) (ID No.)
    (husband’s name),
    and ______________________ (Surname, Given Names) (ID No.)
    (wife’s name), with
the understanding that our embryos will be used for the treatment of the Recipients and that
this consent cannot be revoked or varied.

2. We acknowledge that the nature and implications of our donation have been explained to
us by ______________________ and we have been given the opportunity to
ask any question we wish. We have also been offered a suitable opportunity to take part in
counselling with ______________________ about the implications of the
donation.

3. We understand that our embryo(s) will be stored for a maximum period of two years from
the date of freezing the embryo(s). If the aforesaid treatment of the Recipients cannot be
successfully carried out within that period, or if, before the expiry of the said maximum
storage period, it becomes impossible for any reason whatsoever for the aforesaid treatment
to be successfully carried out, or if excess embryo(s) remain after completion of the
aforesaid treatment, we consent that the embryo(s) obtained from us may be (please tick
one)

[ ] disposed of in accordance with the “Guidelines on disposal of gametes or embryos”
(“the Guidelines”) in the Code of Practice published from time to time by the
Council on Human Reproductive Technology.

[ ] donated anonymously for the treatment of other infertile couples, in which event
our embryos will not be used to produce more than a total of one / two / three* live
birth events, including the event of the designated donation, if successful (failing
which the Centre may dispose of the stored embryos in accordance with the
Guidelines).

[ ] donated for research (failing which the Centre may dispose of the stored embryos in
accordance with the Guidelines).
4. We understand that under the Parent & Child Ordinance (Cap. 429), we shall not be the legal parents of the child(ren) born from our donated embryo(s). We also agree never to seek to make any claim over such child(ren) under any circumstance whatsoever.

5. To the best of our knowledge and belief -

   (a) We are in good health and have no communicable disease or hereditary disorder, except as follows -

   (b) None of our relatives has ever suffered from any inheritable disease, except as follows

6. For the purpose of determining whether we are suitable as donors of embryos, we consent to undergoing such blood tests (including HIV test) and medical examinations as shall be prescribed by the Centre.
Dated the ________________ day of ________________

  (Month)  (Year)

Signed ____________________________
  (Husband’s Signature)

Name ______________________________
  (in Block Letters)

  (in Chinese)

Marriage Certificate No. ____________________________

Signed ____________________________
  (Signature of Attending Doctor)

Name ______________________________
  (in Block Letters)

Signed ____________________________
  (Signature of Witness)

Name ______________________________
  (in Block Letters)

Position ____________________________
PART II  RECIPIENTS' CONSENT

7. We (the Recipients), ___________________________ (Surname, Given Names) (ID No.) (husband’s name),
and ___________________________ (Surname, Given Names) (ID No.) (wife’s name),
of ___________________________ (address), being lawfully married and desirous of having a child, DO HEREBY CONSENT to receive the embryo(s) donated by the Donors, ___________________________ (Surname, Given Names) (ID No.) (husband’s name),
and ___________________________ (Surname, Given Names) (ID No.) (wife’s name), for infertility treatment.

8. We acknowledge that the nature and implications of the aforesaid treatment have been explained to us by ___________________________ and we have been given the opportunity to ask any question we wish. We have also been offered a suitable opportunity to take part in counselling with ___________________________ about the implications of the treatment.

9. We fully understand and accept that-
   (a) the aforesaid treatment procedure may not result in a successful pregnancy;
   (b) the wife may not be able to carry the pregnancy to term;
   (c) any child conceived or born as a result of the procedures may suffer from defect(s) of health or mental or physical impairment(s) as a result of congenital, hereditary or other reasons, similar to the situation of a normal pregnancy.

10. We understand that the embryo(s) donated to us will be stored for a maximum period of two years from the date of freezing of the embryo(s). If the aforesaid infertility treatment cannot be successfully carried out within that period, or if, before the expiry of the said maximum storage period, it becomes impossible for any reason whatsoever for the aforesaid treatment to be successfully carried out, or if excess embryo(s) remain after completion of the aforesaid treatment, we consent that the embryo(s) donated to us may be handled in accordance with the donor’s instructions, as set out in paragraph 3 hereof.

11. We understand that under the Parent & Child Ordinance (Cap. 429), we shall be the legal parents of the child(ren) born from the aforesaid treatment procedure.
Dated the ______________ day of ______________

Signed ____________________________  Signed ____________________________
(Husband's Signature)     (Wife's Signature)

Name ____________________________  Name ____________________________
(in Block Letters)     (in Block Letters)

____________________________     ____________________________

Marriage Certificate No. ____________________________

Signed ____________________________  Signed ____________________________
(Signature of Attending Doctor)     (Signature of Witness)

Name ____________________________  Name ____________________________
(in Block Letters)     (in Block Letters)

Position ____________________________
Consent to Disposal of Stored Embryos

1. We ____________________________________________(husband’s name) (hereinafter called “the Husband”), and _________________________________________(Surname, Given Names) (ID No.) (wife’s name), (hereinafter called “the Wife”), of ___________________________________________(address), DO HEREBY CONSENT AND AUTHORISE ______________________________________________ (name of the reproductive technology centre) (hereinafter called “the Centre”), to dispose of the stored embryos produced with our gametes for which a consent form on embryo storage was previously signed by us on ________________ (dd/mm/yr).

2. We acknowledge that the nature and the implications of the disposal have been explained to us by ________________________________ and we have been given the opportunity to ask any question we wish. We have also been offered a suitable opportunity to take part in counselling with ________________________________ about the implications of the disposal.

Note: If no conjoint consent is obtained, the Centre will keep the stored embryos until the maximum storage period expires.

Dated the __________________________ day of __________________________ (Month) __________________________ (Year)

Signed __________________________ (Husband’s Signature) Signed __________________________ (Wife’s Signature)

Name __________________________ (in Block Letters) Name __________________________ (in Block Letters)


Marriage Certificate No. ________________________________

Signed __________________________ (Signature of Attending Doctor) Signed __________________________ (Signature of Witness)

Name __________________________ (in Block Letters) Name __________________________ (in Block Letters)

Position ________________________________
Consent Form (12)

Consent to Surrogacy Arrangement

PART I COMMISSIONING COUPLE’S CONSENT

1. We (hereinafter called “the Commissioning Couple”) (husband’s name), (Surname, Given Names) (ID No.) and (wife’s name), (Surname, Given Names) (ID No.) DO HEREBY CONSENT (ID No.) to commissioning (Surname, Given Names) (ID No.) (surrogate mother’s name) (hereinafter called “the Surrogate Mother”) to act as the surrogate mother in the surrogacy arrangement herein, with the understanding that only our own gametes and embryo(s) will be used for the surrogacy arrangement.

2. We acknowledge that the nature and implication of the arrangement and the procedures involved have been explained to us by ____________ and we have been given the opportunity to ask any question we wish. We have also been offered a suitable opportunity to take part in counselling with a multi-disciplinary team about the implications of the surrogacy arrangement.

3. We acknowledge that our attending physician, ____________, has explained to us that surrogacy arrangement is the only approach that may assist us in having a baby of our own, after discussing with us our clinical condition and confirming with us that other methods of assisted reproduction are not applicable.

4. We understand that under the Parent & Child Ordinance (Cap. 429), we shall not be the legal parents of the child(ren) born from the surrogacy arrangement unless the court makes a parental order in favour of us upon our application within 6 months of the birth of the said child(ren).

5. We understand that under the Human Reproductive Technology Ordinance (Cap. 561) -

   (a) no surrogacy arrangement involving the making or receiving of any payment is allowed; and
   (b) no surrogacy arrangement is enforceable by or against any of the persons making it.

6. For the purpose of determining whether we are medically suitable for the surrogacy arrangement, we consent to undergoing such blood tests (including HIV test) and medical examinations as shall be prescribed by ________________ (the Centre).
7. We fully understand and accept that -

(a) the medical procedure carried out pursuant to the surrogacy arrangement may not result in a successful pregnancy;
(b) the Surrogate Mother may not be able to carry the pregnancy to term;
(c) any child conceived or born as a result of the procedures, may suffer from defect(s) of health or mental or physical impairment(s) as a result of congenital, hereditary or other reasons, similar to the situation of a normal pregnancy.

8. I ________________________________ (the wife’s name), consent to -

(Surname, Given Names) (ID No.)

(a) be prepared for egg (oocytes) retrieval including the use of drugs for hyperstimulation;
(b) the removal of eggs (oocytes) from my ovaries with the aid of laparoscopy/ultrasound;
(c) the administration of appropriate drugs and/or anaesthetics to me if necessary for the procedure(s);

and acknowledge that the nature, procedures and possible complications of the egg (oocyte) collection procedures mentioned above have been explained to me by ___________________________ and I have been given the opportunity to ask any question I wish. I have also been offered a suitable opportunity to take part in counselling with ___________________________ about the implications of the procedures.

9. We consent that unfertilized gamete(s) and/or excess embryo(s) obtained from us in the course of procedures carried out pursuant to the surrogacy arrangement may be (please tick one) -

[ ] disposed of in accordance with the “Guidelines on disposal of gametes or embryos” (“the Guidelines”) in the Code of Practice published from time to time by the Council on Human Reproductive Technology.

[ ] donated anonymously for the treatment of other infertile couples, in which event our gametes or embryos would not be used to produce more than a total of one/two/three* live birth events, including the event of the aforesaid surrogacy arrangement, if successful (failing which the Centre may dispose of the stored embryos in accordance with the Guidelines).

[ ] donated for research (failing which the Centre may dispose of the stored embryos in accordance with the Guidelines).
<table>
<thead>
<tr>
<th>Dated the</th>
<th>day of</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(Month)</th>
<th>(Year)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Signed</th>
<th>Signed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(Husband’s Signature)</th>
<th>(Wife’s Signature)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(in Block Letters)</th>
<th>(in Block Letters)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Marriage Certificate No.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Signed</th>
<th>Signed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(Signature of Attending Doctor)</th>
<th>(Signature of Witness)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(in Block Letters)</th>
<th>(in Block Letters)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Position</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PART II   SURROGATE MOTHER’S CONSENT

10. I, ________________________________ (Surname, Given Names) (ID No.)
(name of the surrogate mother) (hereinafter called “the Surrogate Mother”) DO HEREBY
CONSENT to act as the surrogate mother for the Commissioning Couple,
______________________________ (Surname, Given Names) (ID No.)
(husband’s name), and
______________________________ (Surname, Given Names) (ID No.)
(wife’s name),
with the understanding that gametes/embryos* of the Commissioning Couple would be
used for the surrogacy arrangement.

11. I acknowledge that the nature and implications of the surrogacy arrangement have been
explained to me by ________________________________ and I have been given the
opportunity to ask any question I wish. I have also been offered a suitable opportunity to
take part in counselling with a multi-disciplinary team about the implications of the
surrogacy arrangement.

12. I understand that under the Parent & Child Ordinance (Cap. 429), I shall be the legal
mother of the child(ren) born from the surrogacy arrangement unless the court makes a
parental order in favour of the Commissioning Couple upon their application within 6
months of the birth of the said child(ren).

13. I consent that the Centre may transfer gametes/embryos* of the Commissioning Couple to
me by any one or more than one of the following reproductive technology procedures
(please tick as appropriate) -

( ) embryo transfer;
( ) gamete intra-fallopian transfer;
( ) pronuclear stage tubal transfer;
( ) others (please specify) ________________________________

14. I acknowledge that the nature, procedures and possible complications of the above
reproductive technology procedures have been explained to me by
______________________________ and I have been given the opportunity to ask any
question I wish. I have also been offered a suitable opportunity to take part in counselling
with ________________________________ about the implications of the procedures.

15. I fully understand and accept that -

(a) the aforesaid procedures may not result in successful pregnancy;
(b) I may not be able to carry the pregnancy to term;
(c) I may suffer from illness(es) or complications arising out of or consequent upon a
pregnancy resulting from the embryo transfer/gamete intra-fallopian
transfer/pronuclear stage tubal transfer or other reproductive technology procedures;
(d) any child conceived or born as a result of the procedures, may suffer from defect(s) of health or mental or physical impairment(s) as a result of congenital, hereditary or other reasons, similar to the situation of a normal pregnancy.

16. For the purpose of determining whether I am medically suitable to act as a surrogate mother, I consent to undergoing such blood tests (including HIV test) and medical examinations as shall be prescribed by the Centre.

Dated the ______________ day of ______________ (Month) ______________ (Year)

Signed __________________________
(Surrogate Mother’s Signature)

Name __________________________
(in Block Letters) __________________________
(in Chinese)

Signed __________________________
(Signature of Attending Doctor)

Signed __________________________
(Signature of Witness)

Name __________________________
(in Block Letters) __________________________
(in Block Letters)

Position __________________________
PART III# HUSBAND OF THE SURROGATE MOTHER’S CONSENT

17. I, ________________________________, am the husband of ________________________________ and I consent to the surrogacy arrangement outlined above. I understand that under the Parent & Child Ordinance (Cap. 429), I shall be the legal father of any child(ren) born from the said arrangement unless the court makes a parental order in favour of the Commissioning Couple upon their application within 6 months of the birth of the said child(ren).

18. I understand that this consent cannot be revoked or varied once the procedures as listed in paragraph 13 above have been performed.

19. I acknowledge that the nature and implications of the surrogacy arrangement have been explained to me by ________________________________ and I have been given the opportunity to ask any question I wish. I have also been offered a suitable opportunity to take part in counselling with a multi-disciplinary team about the implications of the surrogacy arrangement.
Dated the __________________ day of __________________ (Month) (Year)

Signed ____________________________
(Husband of the Surrogate Mother’s Signature)

Name ____________________________
(in Block Letters) (in Chinese)

Marriage Certificate No. # ____________________________

Signed ____________________________  Signed ____________________________
(Signature of Attending Doctor) (Signature of Witness)

Name ____________________________  Name ____________________________
(in Block Letters) (in Block Letters)

Position ____________________________

Notes:  * Delete whichever is inapplicable
# To be completed if the surrogate mother is a party to a marriage when making the surrogacy arrangement.
Consent Form (13)

Consent to Use of Reproductive Technology Procedures for Purposes of Gender Selection on Medical Ground

1. We ________________________________ (husband’s name), (hereinafter called “the Husband”), and ________________________________ (wife’s name), (hereinafter called “the Wife”), of __________________________ (address), DO HEREBY CONSENT AND AUTHORISE ________________________________ (name of the reproductive technology centre), (hereinafter called “the Centre”), to apply gender selection technique on our gametes/embryos* for fetal gender selection, with the understanding that only our own gametes will be used.

2. We also hereby consent that the Centre may proceed with the following RT procedures (please tick as appropriate) -

( ) sperm treatment with sex-selective insemination
( ) sperm treatment with gamete intra-fallopian transfer
( ) sperm treatment with pronuclear stage tubal transfer
( ) in-vitro fertilization
( ) preimplantation genetic diagnosis with sex-selective zygote transfer
( ) prenatal diagnosis with sex-selective abortion
( ) others (please specify) ________________________________

3. We understand that the reproductive technology procedures mentioned in para. 2 can result in the gender of our foetus being selected and that the procedure is necessary to avoid a sex-linked genetic disease, called ________________________________, which is specified in Schedule 2 to the Human Reproductive Technology Ordinance (Cap.561), and which may prejudice the health of the embryo. The nature and implication of the sex-linked genetic disease has been explained to us by ________________________________.

4. We acknowledge that the nature and implications of fetal gender selection have been explained to us by ________________________________ and we have been given the opportunity to ask any question we wish. We have also been offered a suitable opportunity to take part in counselling with ________________________________ about the implications of the treatment.

5. We fully understand and accept that -

(a) the wife may not become pregnant;
(b) the wife may not be able to carry the pregnancy to term;
(c) the wife may suffer from illness(es) or complications arising out of or consequent upon a pregnancy resulting from the in-vitro fertilization/gamete intra-fallopian transfer/embryo transfer*;
(d) any child conceived or born as a result of the procedures may suffer from defect(s) of health or any mental or physical impairment(s) as a result of congenital, hereditary or other reasons similar to the situation of a normal pregnancy; and
(e) any RT technique in fetal gender selection has variable effectiveness and the resulting child(ren) born may not possess the correct gender as we chosen.
6. I ____________________________ (the Wife’s name), consent to -
(Surname, Given Names) (ID No.)
(a) be prepared for egg (oocyte) retrieval including the use of drugs for hyperstimulation;
(b) the removal of eggs (oocytes) from my ovaries with the aid of laparoscopy/ultrasound;
and
(c) the administration of appropriate drugs and/or anaesthetics to me if necessary for the
procedure(s),
and acknowledge that the nature, procedures and possible complications for egg (oocyte)
collection procedures as mentioned above have been explained to me by
_____________________________ and I have been given the opportunity to ask any
question I wish. I have also been offered a suitable opportunity to take part in counselling
with ___________________________ about the implications of the procedures.

Dated the ____________________ day of ____________________ (Month) (Year)

Signed ________________________ Signed ________________________
(Husband’s Signature) (Wife’s Signature)

Name ________________________ Name ________________________
(in Block Letters) (in Block Letters)

____________________________ (in Chinese) ________________________
                (in Chinese)

Marriage Certificate No. ________________________

Signed ________________________ Signed ________________________
(Signature of Attending Doctor) (Signature of Witness)

Name ________________________ Name ________________________
(in Block Letters) (in Block Letters)

Position ________________________

Note: * Delete whichever is inapplicable
Consent to Artificial Insemination by Husband (AIH)

PART I  WIFE’S CONSENT

1. I _____________________________, of _____________________________ (Surname, Given Names) (ID No.) _____________________________ (address), being lawfully married and desirous of having a child, DO HEREBY AUTHORISE _____________________________ (name of reproductive technology centre) (hereinafter called “the Centre”) to perform the treatment of intravaginal/ intracervical/ intrauterine * insemination on me, using the sperm from my husband #.

2. I acknowledge that the nature, procedures and possible complications of the said treatment have been explained to me by _____________________________ and I have been given the opportunity to ask any question I wish. I have also been offered a suitable opportunity to take part in counselling with _____________________________ about the implications of the treatment.

3. I fully understand and accept that -
   
   (a) the said treatment procedure may not result in a successful pregnancy;
   (b) I may not be able to carry the pregnancy to term;
   (c) any child conceived or born as a result of the procedure, may suffer from defect(s) of health or mental or physical impairment(s) as a result of congenital, hereditary or other reasons, similar to the situation of a normal pregnancy.

4. I understand that -
   
   (a) this consent cannot be revoked or varied once the insemination has been performed;
   (b) the insemination will not be performed if my husband revokes or varies his consent prior to insemination.

Dated the ___________________________ day of ___________________________ (Month) ___________________________ (Year)

Signed _____________________________
( Wife’s Signature)

Name _____________________________ (in Block Letters) _____________________________ (in Chinese)

Signed _____________________________
(Signature of Attending Doctor)

Signed _____________________________
(Signature of Witness)

Name _____________________________ (in Block Letters)

Name _____________________________ (in Block Letters)

Position _____________________________
PART II  HUSBAND’S CONSENT

5. I ________________________________ am the (Surname, Given Names) (ID No.) husband of ________________________________ and I consent to the course of treatment outlined above. I understand that I will be the legal father of any child(ren) born from the treatment.

6. I understand that this consent cannot be revoked or varied once the insemination has been performed. Any revocation or variation of this consent will not be effective until actual receipt by the Centre in writing.

Dated the ____________________ day of ____________________ (Month) (Year)

Signed __________________________
   (Husband’s Signature)

Name ____________________________  __________________________
   (in Block Letters)   (in Chinese)

Marriage Certificate No. ____________________________

Notes:

* Delete whichever is inapplicable.

# Intravaginal insemination refers to the placement of sperm into the vagina. Intracervical insemination refers to the placement of sperm at the cervical os. Intrauterine insemination refers to the placement of sperm (usually after processing) into the uterine cavity.
Consent Form (15)

Consent to Disclosure of Personal Data in Connection with Reproductive Technology Procedure/ Donation

Introduction

The Reproductive Technology Centre (the “Centre”) is subject to the Code of Practice published by the Council on Human Reproductive Technology (the “Council”) from time to time and to all laws which are or will be in force including the Human Reproductive Technology Ordinance (Cap. 561) (the “Ordinance”) which requires or will require, amongst other things, the supply of information on the particulars of the patients / donors to the Council.

This form documents your consent to disclosure of your personal data / information in connection with the reproductive technology procedure / donation under circumstances as specified below.

Consent

To be filled by Patients (and Spouses)/ Donors / Surrogate Mothers (and Spouses)*

1. I/we * ____________________________
   (Surname, given names of client) (ID No.)
   (Surname, given names of client’s spouse) (ID No.)

   consent that -

   (a) all data and information relating to me/ us* may be provided by the Centre to the Council or other governmental or statutory bodies in accordance with the requirements of -
   (i) the Ordinance;
   (ii) the Code of Practice published and amended from time to time by the Council;
   and
   (iii) other statutory provisions in Hong Kong;

   (b) all data and information relating to me/ us* may be provided by the Centre to the Council for the purpose of compiling, keeping and/or maintaining of register(s) established by regulation(s) made by the Secretary for Food and Health under section 45(1)(a) of the Ordinance;

   (c) all documents, records, data and information relating to me/ us* may be shown, provided and revealed by the Centre to persons duly authorized by the Council in inspection(s) conducted by the Council for the purpose of determining whether to
grant or renew licence(s) to the Centre;

(d) all documents, records, data and information relating to me/us* may be shown, provided and revealed by the Centre to persons duly authorised by the Council for the purpose of investigation or inquiry into complaints or information with which the Centre is involved, in accordance with regulations made by the Council pursuant to section 45(2)(h), (i), (j) and/or (k) of the Ordinance.

(e) in the event that the licence of the Centre is revoked or suspended, or in the event that the Centre for any reason whatsoever becomes unable or unsuitable to continue to provide treatment to me/us* or to store my/our gametes or embryos, all documents, records, data and information relating to me/us* (together with my gametes or embryos) may be transferred to and/or taken over by a backing up centre appointed by the Centre and/or the Council. I/we* also consent that in such event, the backing up centre may contact me for follow-up arrangements concerning the treatment and the storage of my/our* gametes or embryos;  

(please delete this paragraph for anonymous donors)

(f) I/we* may be contacted at any time by the Centre and/or the Council for the purpose of ascertaining whether or not I/we* will consent to the disclosure or use of data or information relating to me/us*, in addition to the disclosure or use set out above. 

(please delete part or whole of this paragraph if the patient(s) / donor(s) / their spouses donot want to be contacted by the Centre and/or the Council)
Dated the ___________ day of __________ (Month) _______ (Year)

Signed ____________________________
(Client’s Signature)

Name ______________________________
(in Block Letters)

_______________________________
(in Chinese)

Signed ____________________________
(Signature of Attending Doctor*
or the one who explained the
nature & implications of the RT
procedure / donation*)

Name ______________________________
(in Block Letters)

Name ______________________________
(in Block Letters)

Position __________________________

Note: * Delete whichever is inapplicable
Consent to Checking on Previous Record of Donation of Gametes

1. I (donor of sperm/ eggs (oocytes)*),

________________________________________________________________________

(Surname, Given Names) (ID No.)

of ________________________________________________________________________ (address),

DO HEREBY CONSENT that -

________________________________________________________________________

(name of reproductive technology centre to which donation is presently made) (hereinafter called "the Centre"), may contact -

(a) _____________________________________________________________________

(b) _____________________________________________________________________

(c) _____________________________________________________________________

(names of reproductive technology centres to which donations were previously made) (hereinafter collectively called "the Previous Centres") or any of them to enquire about the number of live birth events that have been produced from the sperm / eggs (oocytes)* that I previously donated to the Previous Centres.

2. I consent that the Previous Centres, any one of them, may disclose to the Centre the number of live birth events that have been produced from the sperm/ eggs (oocytes)* that I previously donated to them. Also, the Centre and the Previous Centres may at any time make mutual enquiries of and mutual disclosures to each other as to the number of live birth events that have been produced from the sperm/ eggs (oocytes)* that I previously donated to them.
Dated the _________________ day of ____________  (Month)   ____________  (Year) 

Signed  ____________________________  (Donor’s Signature)  

Name  ____________________________  (in Block Letters)  

_____________________________  (in Chinese)  

Signed  ____________________________  (Signature of Attending Doctor*  
or the one who explained the nature & implications of the donation*) 

Name  ____________________________  (in Block Letters)  

Name  ____________________________  (in Block Letters)  

Position  ____________________________  

Note: * Delete whichever is inapplicable.
Consent to Checking on Previous Record of Donation of Embryo(s)

1. We, __________________________________ (husband's name)
   (Surname, Given Names) (ID No.)
   and __________________________________ (wife's name)
   (Surname, Given Names) (ID No.)

   of __________________________________ (address),

   DO HEREBY CONSENT that: __________________________________
   (name of reproductive technology centre to which donation is presently made)
   (hereinafter called "the Centre"), may contact -

   (a) __________________________________
   (b) __________________________________
   (c) __________________________________

   (names of reproductive technology centres to which donations were previously
   made) (hereinafter collectively called "the Previous Centres") or any of them to
   enquire about the number of live birth events that have been produced from the
   embryo(s) that we previously donated to the Previous Centres.

2. We consent that the Previous Centres, or any one of them, may disclose to the
   Centre the number of live birth events that have been produced from the
   embryo(s) that we previously donated to them. Also, the Centre and the
   Previous Centres may at any time make mutual enquiries of and mutual
   disclosures to each other as to the number of live birth events that have been
   produced from the embryo(s) that we previously donated to them.
### Marriage Certificate

Dated the __________________ day of __________________

(Month) (Year)

Signed ____________________________

(Husband’s Signature)

Name ____________________________

(in Block Letters)

(in Chinese)

Signed ____________________________

(Wife’s Signature)

Name ____________________________

(in Block Letters)

(in Chinese)

Marriage Certificate No. ____________________________

Signed ____________________________

(Signature of Attending Doctor* or the one who explained the nature & implications of the donation*)

Name ____________________________

(in Block Letters)

Position ____________________________

Signed ____________________________

(Signature of Witness)

Name ____________________________

(in Block Letters)

Note: * Delete whichever is inapplicable.
REPRODUCTIVE TECHNOLOGY TREATMENT FORM
(For treatment NOT involving donor gametes/embryos) Note 1

Please complete the form in block letters

| 1. Name of centre: |  |
| 2. Licence number: | [ ] [ ] [ ] [ ] [ ] [ ] |
| 3. Patient’s clinic record number: | [ ] [ ] [ ] [ ] [ ] [ ] [ ] |
| 4. Age of wife: | [ ] [ ] |
| 5. Age of husband: | [ ] [ ] |

6. Infertility Diagnosis (please tick the appropriate option(s)):
   - [ ] Male
   - [ ] Tubal
   - [ ] Endometriosis
   - [ ] Immunologic
   - [ ] Tubo-peritoneal
   - [ ] Ovulatory
   - [ ] Unexplained
   - [ ] Others (please specify):

| Treatment cycle: | ……… (e.g. 1st/2nd/3rd cycle for this couple) |
| Type of treatment: | IVF | ICSI with IVF | |
|                   | GIFT | ICSI with PROST | |
|                   | ZIFT/PROST | ICSI with MIFT | |
| Other Micromanipulation (please specify): | Surrogacy Note 3 | Frozen-thawed ET | |
| Others (please specify): | |

8. Ovarian stimulation
   - [ ] Yes
   - [ ] No

9. Number of embryos developed in this cycle:
   - [ ] [ ] [ ]
   - Developed from:
     - Fresh eggs (oocytes)
     - Frozen eggs (oocytes)

10. Date of *gamete transfer/embryo replacement or *Date when cycle was abandoned:
    - Day [ ] [ ] [ ]
    - Month [ ] [ ] [ ]
    - Year [ ] [ ] [ ]

11. Embryos transferred:
    - Number of embryos transferred: [ ]
    - Developed from:
      - Fresh embryos
      - Frozen/thawed embryos

12. Number of eggs (oocytes) transferred:
    - [ ]
    - Fresh eggs (oocytes)
    - Frozen eggs (oocytes)

13. Excess RT embryos after replacement:
    - Cumulative total number of excess RT embryos since first treatment cycle:
      - [ ] [ ] [ ]
      - Number stored for treatment of patient
      - Number stored for treatment of others Note 4
      - Number used for research Note 4
      - Number stored for research
      - Number discarded

14. Outcome of treatment:
    - No pregnancy
    - Miscarriage
    - Ectopic pregnancy
    - Heterotopic pregnancy Note 5
    - Pregnancy terminated
    - Ongoing pregnancy
    - Hydatidiform mole
    - Lost to follow up

Note 1: For Official Use
No.
Form received on
[ ]/ [ ]/ [ ]
Day Month Year
Notes: (1) Please complete one form for each couple for each treatment cycle and submit the form to HRT Council within three months after the treatment. Please also complete DC Form 4 within 12 months after treatment to report on details concerning outcome of pregnancy.

(2) “Patient’s clinic record number” should be a record number used by the centre for identification of the patient. Same patient who has undergone several treatment cycles at a centre should have the same record number.

(3) For surrogacy cases, please refer to para. 12.10 of the Code of Practice and report on the case with detailed information including detailed justifications to the HRT Council within three months after the treatment.

(4) When stored embryos are used or stored for research, please report the usage in AS Form 10 and return to the HRT Council as required.

(5) Heterotopic pregnancy refers to simultaneous existence of intrauterine and ectopic pregnancy. For such a case, please only tick against “heterotopic pregnancy” and need not tick against “ectopic pregnancy”.
Please complete the form in block letters

1. Name of centre: .................................................................
2. Licence number: ............................................................... 3. Patient’s clinic record number, Note 2: ................................
4. Name of centre where treatment started, if different: ......................
5. FULL NAME of patient: ...................................................... (Surname first)
   Day Month Year
6. Date of birth: ................................................................. 7. HKID Card / Passport / Other Entry Permit Number, Note 3:
   ...................................................................................
7. Day Month Year
8. FULL NAME of husband: ..................................................... (Surname first)
9. Date of birth: ................................................................. 10. HKID Card / Passport / Other Entry Permit Number, Note 3:
    ...................................................................................
8. Day Month Year
11. Infertility Diagnosis (please tick the appropriate option(s)):
    □ Male □ Tubal □ Endometriosis □ Immunologic
    □ Tubo-peritoneal □ Ovulatory □ Unexplained
    □ Others (please specify): ..............................................................

12. Does the treatment involve donated sperm: YES □ NO □ donor’s clinic record no.: ..............................................
13. Does the treatment involve donated eggs: YES □ NO □ donor’s clinic record no.: ..............................................
14. Does the treatment involve donated embryos: YES □ NO □ donor’s clinic record no.: ..............................................
15. Donor(s) centre licence number(s) (if gamete/embryo is obtained from another licensed centre):
    sperm donor .................................................................... egg donor ............................................................
    embryo donor ................................................................

16. The donation is *anonymous/designated. (If the donation is designated, please refer to para. 14.9 of the Code of Practice and report the case with detailed information including detailed justifications to the HRT Council within three months after the treatment.)
   (*please delete where in appropriate.)

17. Type of treatment:
    IVF □ ICSI with IVF □
    GIFT □ ICSI with PROST □
    ZIFT/PROST □ ICSI with MIFT □
    Other Micromanipulation (please specify) ...................................................
    Frozen-thawed ET □
    Others (please specify) ................................................................

18. Ovarian stimulation:
    Yes □ No □

19. Number of embryos developed in this cycle:
    □□□□ Developed from:
    Fresh eggs (oocytes) □
    Frozen eggs (oocytes) □
<table>
<thead>
<tr>
<th>20. Date of <em>gamete transfer/</em> embryo replacement or *Date when cycle was abandoned :</th>
<th>Day</th>
<th>Month</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*please delete where inappropriate.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>21 Embryos transferred :</th>
<th>Number of embryos transferred :</th>
<th>Developed from :</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Fresh embryos</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Frozen/thawed embryos</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>22. Number of eggs (oocytes) transferred :</th>
<th>Fresh eggs (oocytes)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>23. Excess RT embryos after replacement :</th>
<th>Cumulative total number of excess RT embryos since first treatment cycle :</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>24. Outcome of treatment :</th>
<th>No pregnancy</th>
<th>Miscarriage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Heterotopic pregnancy</td>
</tr>
<tr>
<td>Ectopic pregnancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy terminated</td>
<td></td>
<td>Ongoing pregnancy</td>
</tr>
<tr>
<td>Hydatidiform mole</td>
<td></td>
<td>Lost to follow up</td>
</tr>
</tbody>
</table>

**Notes**:

1. Please complete one form for each couple for each treatment cycle and submit the form to HRT Council within three months after the treatment. Please also complete DC Form 4 within 12 months after treatment to report on details concerning outcome of pregnancy.

2. “Patient’s clinic record number” should be a record number used by the centre for identification of the patient. Same patient who has undergone several treatment cycles at a centre should have the same record number.

3. Please fill in the HKID Card number of patient/husband, or Passport / Other Entry Permit number for non-HKID Card holder. “Other Entry Permit” refers to official document which the donor is holding in entering Hong Kong.

4. When stored embryos are used or stored for research, please report the usage in AS Form 10 and return to the HRT Council as required.

5. Heterotopic pregnancy refers to simultaneous existence of intrauterine and ectopic pregnancy. For such a case, please only tick against “heterotopic pregnancy” and need not tick against “ectopic pregnancy”.

- Fresh embryos
- Frozen/thawed embryos
- Developed from:
- Fresh eggs (oocytes)
- Frozen eggs (oocytes)
- Excess RT embryos after replacement:
- Cumulative total number of excess RT embryos since first treatment cycle:
- Number stored for treatment of patient
- Number stored for treatment of others
- Number used for research
- Number stored for research
- Number discarded
- Notes: (1) Please complete one form for each couple for each treatment cycle and submit the form to HRT Council within three months after the treatment. Please also complete DC Form 4 within 12 months after treatment to report on details concerning outcome of pregnancy.
- (2) “Patient’s clinic record number” should be a record number used by the centre for identification of the patient. Same patient who has undergone several treatment cycles at a centre should have the same record number.
- (3) Please fill in the HKID Card number of patient/husband, or Passport / Other Entry Permit number for non-HKID Card holder. “Other Entry Permit” refers to official document which the donor is holding in entering Hong Kong.
- (4) When stored embryos are used or stored for research, please report the usage in AS Form 10 and return to the HRT Council as required.
- (5) Heterotopic pregnancy refers to simultaneous existence of intrauterine and ectopic pregnancy. For such a case, please only tick against “heterotopic pregnancy” and need not tick against “ectopic pregnancy”.

<table>
<thead>
<tr>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Please complete one form for each couple for each treatment cycle and submit the form to HRT Council within three months after the treatment. Please also complete DC Form 4 within 12 months after treatment to report on details concerning outcome of pregnancy.</td>
</tr>
<tr>
<td>(2) “Patient’s clinic record number” should be a record number used by the centre for identification of the patient. Same patient who has undergone several treatment cycles at a centre should have the same record number.</td>
</tr>
<tr>
<td>(3) Please fill in the HKID Card number of patient/husband, or Passport / Other Entry Permit number for non-HKID Card holder. “Other Entry Permit” refers to official document which the donor is holding in entering Hong Kong.</td>
</tr>
<tr>
<td>(4) When stored embryos are used or stored for research, please report the usage in AS Form 10 and return to the HRT Council as required.</td>
</tr>
<tr>
<td>(5) Heterotopic pregnancy refers to simultaneous existence of intrauterine and ectopic pregnancy. For such a case, please only tick against “heterotopic pregnancy” and need not tick against “ectopic pregnancy”.</td>
</tr>
</tbody>
</table>
CONFIDENTIAL

DONOR INSEMINATION TREATMENT FORM

Please complete the form in block letters

1. Name of centre: ............................................................... 3. Patient’s clinic record number Note 2: [ ] [ ] [ ] [ ] [ ] [ ] [ ]
2. Licence number: [ ] [ ] [ ] [ ] [ ] 4. Name of centre where treatment started, if different: ............................................................... 5. FULL NAME of patient: .................................................................
6. Date of birth: [ ] [ ] [ ] [ ] 7. HKID Card / Passport / Other Entry Permit Number Note 3: .................................................................
8. FULL NAME of husband: .................................................................
9. Date of birth: [ ] [ ] [ ] [ ] 10. HKID Card / Passport / Other Entry Permit Number Note 3: .................................................................
11. Reasons for treatment: Obstructive azoospermia YES [ ] NO [ ]
Nonobstructive azoospermia YES [ ] NO [ ]
Severe deficits in semen quality in couples who do not wish to undergo intracytoplasmic sperm injection YES [ ] NO [ ]
Genetic YES [ ] NO [ ]
Infectious disease in the male partner (such as HIV) YES [ ] NO [ ]
Severe rhesus isoimmunisation YES [ ] NO [ ]
Others (please specify) .................................................................................................................................
12. Donor clinic record number: .................................................................
13. Donor’s centre licence number if different from item 2 above: .................................................................
14. The donation is *anonymous/designated. (If the donation is designated, please refer to para. 14.9 of the Code of Practice and report the case with detailed information including detailed justifications to the HRT Council within three months after the treatment.)

*please delete where in appropriate*

15. Dates of treatment(s) (if more than one insemination per treatment cycle, give all dates):

<table>
<thead>
<tr>
<th>Day</th>
<th>Month</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
16. Ovarian stimulation: Yes [ ] No [ ]

Treatment cycle: ........ (e.g. 1st/2nd/3rd cycle for this couple)
**CONFIDENTIAL**

17. Outcome of treatment:

<table>
<thead>
<tr>
<th>Condition</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>No pregnancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ectopic pregnancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy terminated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydatidiform mole</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miscarriage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterotopic pregnancy&lt;sup&gt;Note 4&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ongoing pregnancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lost to follow up</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**

1. Please complete one form for each couple for each treatment cycle and submit the form to HRT Council within three months after the treatment. Please also complete DC Form 4 within 12 months after treatment to report on details concerning outcome of pregnancy.

2. “Patient’s clinic record number” should be a record number used by the centre for identification of the patient. Same patient who has undergone several treatment cycles at a centre should have the same record number.

3. Please fill in the HKID Card number of patient/husband, or Passport / Other Entry Permit number for non-HKID Card holder. “Other Entry Permit” refers to official document which the donor is holding in entering Hong Kong.

4. Heterotopic pregnancy refers to simultaneous existence of intrauterine and ectopic pregnancy. For such a case, please only tick against "heterotopic pregnancy" and need not tick against “ectopic pregnancy".
**PREGNANCY OUTCOME FORM**

**CONFIDENTIAL**

Please complete the form in block letters

1. Name of centre: .................................................................

2. Licence number: | | | | | | | |

3. Patient’s clinic record number: | | | | | | | |

4. Date of gamete transfer / embryo replacement / insemination resulting in pregnancy: Day Month Year

(Please delete where inappropriate)

5. Pregnancy outcome:

<table>
<thead>
<tr>
<th></th>
<th>Fetal heart / Pregnancy sac 1</th>
<th>Fetal heart / Pregnancy sac 2</th>
<th>Fetal heart / Pregnancy sac 3</th>
<th>Fetal heart / Pregnancy sac 4</th>
<th>Fetal heart / Pregnancy sac 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>miscarriage</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>ectopic pregnancy</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>pregnancy terminated</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>reason for termination</td>
<td>.........................</td>
<td>.........................</td>
<td>.........................</td>
<td>.........................</td>
<td>.........................</td>
</tr>
<tr>
<td>hydatidiform mole</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>embryo reduction</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>still birth</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>live birth</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>neonatal death</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>lost to follow up</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>others (describe)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

(Please complete item 6. if outcome is live birth)

6. Baby born:

<table>
<thead>
<tr>
<th></th>
<th>Baby 1</th>
<th>Baby 2</th>
<th>Baby 3</th>
<th>Baby 4</th>
<th>Baby 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>gestation (weeks)</td>
<td>☐ ☐</td>
<td>☐ ☐</td>
<td>☐ ☐</td>
<td>☐ ☐</td>
<td>☐ ☐</td>
</tr>
<tr>
<td>weight (grammes)</td>
<td>☐ ☐ ☐</td>
<td>☐ ☐ ☐</td>
<td>☐ ☐ ☐</td>
<td>☐ ☐ ☐</td>
<td>☐ ☐ ☐</td>
</tr>
<tr>
<td>sex</td>
<td>M F</td>
<td>M F</td>
<td>M F</td>
<td>M F</td>
<td>M F</td>
</tr>
<tr>
<td>date of delivery</td>
<td>Day Month Year</td>
<td>Day Month Year</td>
<td>Day Month Year</td>
<td>Day Month Year</td>
<td>Day Month Year</td>
</tr>
<tr>
<td>method of delivery</td>
<td>.........................</td>
<td>.........................</td>
<td>.........................</td>
<td>.........................</td>
<td>.........................</td>
</tr>
</tbody>
</table>

7. Congenital abnormalities if present please describe:

<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: (1) This form should be returned to the Council within 12 months after the treatment.

(2) “Patient’s clinic record number” should be a record number used by the centre for identification of the patient. Same patient who has undergone several treatment cycles at a centre should have the same record number.
**DONOR INFORMATION FORM**
*(For Gamete Donors)*

Please complete the form in block letters.

Top copy should be returned to the Council within one week of the date when a donor’s gametes are used by a licensed centre. The second copy should be returned to the Council within three weeks of the date this donor’s gametes are used with item 10 completed as appropriate. A “live birth event” will be assumed after use of a donor’s gametes for treatment has been reported unless the Council is informed otherwise. Gametes from any single donor should not be used to produce more than “3 live birth events”. Therefore, apart from reporting on item 10 of this form and reporting pregnancy information in DC Form 2 or 3 and 4, centres are encouraged to inform this Council if at any stage it is known that the treatment ends up with unsuccessful pregnancy.

A new DC Form 5 should be completed and returned to the Council each time when a donor’s gametes are used.

---

1. Name of centre: .................................................................  

2. Licence number: | | | | | | | | |  

3. Donor’s clinic record number: | | | | | | | | |  

4. FULL NAME of donor: | | | | | | | | |  

5. Sex: Male [ ] Female [ ] (Surname first)  

6. Date of Birth: | | | | | | | | |  

7. HKID Card / Passport / Other Entry Permit Number Note 1: | | | | | | | | |  

8. Full Correspondence Address and Contact Telephone Number:  

   Room/Flat: | | | | | | | | |  

   Floor: | | | | | | | | |  

   Block: | | | | | | | | |  

   Name of Building: | | | | | | | | |  

   No. & Name of Street: | | | | | | | | |  

   District: | | | | | | | | |  

   Country (if outside Hong Kong): | | | | | | | | |  

   Tel. Number (Home): | | | | | | | | |  

   Tel. Number (Mobile): | | | | | | | | |  

   *(Please leave this item blank if the donor does not want to be contacted after donation.)*

9. Date when gametes of this donor are used:  

   Day | | | | | | | | |  

   Month | | | | | | | | |  

   Year | | | | | | | | |  

This is the ..........(e.g. 1st/2nd/3rd/...) time of use in this centre.

10. Outcome of treatment:  

   Clinical pregnancy [ ]  

   No pregnancy [ ]  

   Lost to follow up [ ]

11. If this is for designated recipients Note 2, give names of the couple and their HKID Card / Passport / Other Entry Permit Numbers:  

   FULL NAME of wife: | | | | | | | | |  

   HKID Card / Passport / Other Entry Permit Number Note 1: | | | | | | | | |  

   Relationship with donor:  

   FULL NAME of husband: | | | | | | | | |  

   HKID Card / Passport / Other Entry Permit Number Note 1: | | | | | | | | |  

   Relationship with donor:  

---

Note 1:  

Note 2:  

CONFIDENTIAL

Council on Human Reproductive Technology
DC Form 5 (2)

12. Any donation at other centres: YES [ ] NO [ ]

   If yes, name(s) of centre(s): (a) .................................................(b) .................................................(c) .................................................

   (Please use separate sheet if necessary)

---

Particulars of donor:

13. Height (cm): [ ] [ ] [ ]

14. Weight (kgs): [ ] [ ] [ ]

15. Ethnic group: Chinese [ ] Other, describe .................................................

16. Eye Colour: Brown [ ] Other, describe .................................................

17. Hair Colour: Black [ ] Other, describe .................................................

18. Occupation: ........................................................................................................

---

Notes: (1) Please fill in the HKID Card number of donor/recipients, or Passport / Other Entry Permit number for non-HKID Card holder. “Other Entry Permit” refers to official document which the donor is holding in entering Hong Kong.

(2) For designated donation, please submit a report providing detail justifications as to why donation has to be designated (paragraph 14.9 of the Code of Practice on Reproductive Technology & Embryo Research).
**DONOR INFORMATION FORM**  
*(For Embryo Donors)*

Please complete the form in block letters

Top copy should be returned to the Council within one week of the date when a donor’s embryos are used by a licensed centre. The second copy should be returned to the Council within three weeks of the date this donor’s embryos are used with item 12 completed as appropriate. A “live birth event” will be assumed after use of a donor’s embryos for treatment has been reported unless the Council is informed otherwise. Embryos from any donor(s) should not be used to produce more than “3 live birth events”. Therefore, apart from reporting on item 12 of this form and reporting pregnancy information in DC Form 2 and 4, centres are encouraged to inform this Council if at any stage it is known that the treatment ends up with unsuccessful pregnancy.

A new DC Form 6 should be completed and returned to the Council each time when a donor’s embryos are used.

<table>
<thead>
<tr>
<th>No.</th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Name of centre:</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Licence number:</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Donor’s clinic record number:</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>FULL NAME of female donor:</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Date of Birth:</td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>HKID Card / Passport / Other Entry Permit Number:</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>FULL NAME of male donor:</td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Date of Birth:</td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td>HKID Card / Passport / Other Entry Permit Number:</td>
<td></td>
</tr>
<tr>
<td>10.</td>
<td>Full Correspondence Address and Contact Telephone Number of donors:</td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td>Date when embryos of the donors are used:</td>
<td></td>
</tr>
<tr>
<td>12.</td>
<td>Outcome of treatment:</td>
<td></td>
</tr>
<tr>
<td>13.</td>
<td>If this is for designated recipients:</td>
<td></td>
</tr>
</tbody>
</table>

---

**Notes:**
1. 
2. 

---

**Council on Human Reproductive Technology**

*(Set of 3 carbon copies. Top & second copy to be submitted to HRT Council when the donors’ embryos are used and the third copy for the centre’s record)*

**DC Form 6**

For Official Use  
No.  
1st copy received on  
__/__/____  
2nd copy received on  
__/__/____  
Day Month Year  

**Please complete the form in block letters**

Top copy should be returned to the Council within one week of the date when a donor’s embryos are used by a licensed centre. The second copy should be returned to the Council within three weeks of the date this donor’s embryos are used with item 12 completed as appropriate. A “live birth event” will be assumed after use of a donor’s embryos for treatment has been reported unless the Council is informed otherwise. Embryos from any donor(s) should not be used to produce more than “3 live birth events”. Therefore, apart from reporting on item 12 of this form and reporting pregnancy information in DC Form 2 and 4, centres are encouraged to inform this Council if at any stage it is known that the treatment ends up with unsuccessful pregnancy.

A new DC Form 6 should be completed and returned to the Council each time when a donor’s embryos are used.

1. Name of centre: 
2. Licence number: 
3. Donor’s clinic record number: 
4. FULL NAME of female donor: 
   - Day 
   - Month 
   - Year 
   - (Surname first) 
5. Date of Birth: 
6. HKID Card / Passport / Other Entry Permit Number: 
7. FULL NAME of male donor: 
   - Day 
   - Month 
   - Year 
   - (Surname first) 
8. Date of Birth: 
9. HKID Card / Passport / Other Entry Permit Number: 
10. Full Correspondence Address and Contact Telephone Number of donors: 
   - Room/Flat: 
   - Floor: 
   - Block: 
   - Name of Building: 
   - No. & Name of Street: 
   - District: 
   - Country (if outside Hong Kong): 
   - Tel. Number (Home): 
   - Tel. Number (Mobile): 
   - *(Please leave this item blank if the donors do not want to be contacted after donation.)*
11. Date when embryos of the donors are used: 
   - Day 
   - Month 
   - Year 
   - This is the ……..(e.g. 1st/2nd/3rd/….) time of use in this centre. 
12. Outcome of treatment: 
   - Clinical pregnancy 
   - No pregnancy 
   - Lost to follow up 
13. If this is for designated recipients: 
   - FULL NAME of wife: 
   - HKID Card / Passport / Other Entry Permit Number: 
   - Relationship with donor: 
   - FULL NAME of husband: 
   - HKID Card / Passport / Other Entry Permit Number: 
   - Relationship with donor: 
14. Any donation of embryos at other centres: **YES □ NO □**
   If yes, name(s) of centre(s): (a)...........................................(b)...........................................(c).........................................

Any donation of eggs at other centres by the female donor: **YES □ NO □**
If yes, name(s) of centre(s): (a)...........................................(b)...........................................(c).........................................

Any donation of sperm at other centres by the male donor: **YES □ NO □**
If yes, name(s) of centre(s): (a)...........................................(b)...........................................(c).........................................
(Please use separate sheet if necessary)

### Particulars of female donor

<table>
<thead>
<tr>
<th>15. Height (cm):</th>
<th>16. Weight (kgs):</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chinese</td>
<td>Brown</td>
<td>Black</td>
</tr>
<tr>
<td>Other, describe</td>
<td>Other, describe</td>
<td>Other, describe</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>20. Occupation:</th>
</tr>
</thead>
</table>

### Particulars of male donor

<table>
<thead>
<tr>
<th>21. Height (cm):</th>
<th>22. Weight (kgs):</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chinese</td>
<td>Brown</td>
<td>Black</td>
</tr>
<tr>
<td>Other, describe</td>
<td>Other, describe</td>
<td>Other, describe</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>26. Occupation:</th>
</tr>
</thead>
</table>

**Notes:**
1. Please fill in the HKID Card number of donors/recipients, or Passport / Other Entry Permit number for non-HKID Card holder. “Other Entry Permit” refers to official document which the donor is holding in entering Hong Kong.

2. For designated donation, please submit a report providing detail justifications as to why donation has to be designated (paragraph 14.9 of the Code of Practice on Reproductive Technology).
CONFIDENTIAL

ARTIFICIAL INSEMINATION BY HUSBAND
TREATMENT FORM Note 1
(Intravaginal/ Intracervical/ Intrauterine * Insemination) Note 2

*Please delete where inappropriate

Please complete the form in block letters

1. Name of centre: ...........................................................................................................

2. Licence number: | | |

3. Patient’s clinic record number: | | |

4. Age of wife: | | |

5. Age of husband: | | |

6. Infertility Diagnosis (please tick the appropriate option(s)):
   - Male
   - Endometriosis
   - Ovulatory
   - Unexplained
   - Others (please specify): ..................................................................................

<table>
<thead>
<tr>
<th>Treatment cycle: ...... (e.g. 1st/2nd/3rd .... cycle for this couple)</th>
</tr>
</thead>
</table>

7. Ovarian stimulation
   - Yes [ ]
   - No [ ]

8. Sperm washing
   - Yes [ ]
   - No [ ]

9. Outcome of treatment:
   - No pregnancy [ ]
   - Miscarriage [ ]
   - Ectopic pregnancy [ ]
   - Heterotopic pregnancy Note 4 [ ]
   - Pregnancy terminated [ ]
   - Ongoing pregnancy [ ]
   - Hydatidiform mole [ ]
   - Lost to follow up [ ]

Notes: (1) Please complete one form for each couple for each treatment cycle and submit the form to HRT Council within three months after the treatment. Please also complete DC Form 4 within 12 months after treatment to report on details concerning outcome of pregnancy.

(2) Intravaginal insemination refers to the placement of sperm into the vagina. Intracervical insemination refers to the placement of sperm at the cervical os. Intrauterine insemination refers to the placement of sperm (usually after processing) into the uterine cavity.

(3) "Patient’s clinic record number" should be a record number used by the centre for identification of the patient. Same patient who has undergone several treatment cycles at a centre should have the same record number.

(4) Heterotopic pregnancy refers to simultaneous existence of intrauterine and ectopic pregnancy. For such a case, please only tick against "heterotopic pregnancy" and need not tick against "ectopic pregnancy".

For Official Use
No.
Form received on ___/___/______
Day Month Year
Annex IV

Explanatory Notes for Completing
Annual Statistics Forms on Reproductive Technology Treatments
for submission to the Council on Human Reproductive Technology

- All cases whose monitoring or ovarian stimulation started some time in the year (i.e. from January 1 to December 31 of the year) should be included.

- There are nine individual forms numbered as follows -
  1. IVF-ET
  2. GIFT
  3. ZIFT/PROST
  4. Frozen-thawed ET
  5. ICSI
  6. Use of Reproductive Technology for Surrogacy Arrangement
  7. Use of Reproductive Technology for Gender Selection to Avoid Sex-linked Diseases
  8. Others [for any other programmes outside those numbered from 1 to 5. Please give the name of the programme in the bracket.]
  9. Artificial Insemination by Husband (AIH)

- For the brackets or spaces with ‘±’ sign on each form, please provide mean ‘±’ SD (standard deviation) value.

- In the cases where diagnosis(es) is (are) not mentioned under the block-heading of “Infertility Diagnosis” in the forms, tick the “Others” box and state the diagnosis in the space provided.

- The following terminologies used in data collection forms (AS Form 1-10) should be observed and followed –

  **Clinical pregnancy**

  A pregnancy documented by one or more gestational sacs on ultrasound or the histological confirmation of gestational products in miscarriages or ectopic pregnancies.

  **Clinical Pregnancy rate**

  The percentage of treatment cycles that result in a clinical pregnancy, including ectopic pregnancies, spontaneous and induced abortions, and viable pregnancies of at least 20 weeks’ gestation but excluding biochemical pregnancies. Pregnancy rates should be
expressed per 100 treatment cycles started / commenced or per 100 cycles reaching the stage of attempted oocyte recovery / retrieval or embryo transfer.

**Ectopic pregnancy**

A pregnancy in which implantation has taken place outside the uterine cavity.

**Heterotopic pregnancy**

Heterotopic pregnancy refers to simultaneous existence of intrauterine and ectopic pregnancy.

**Neonatal death**

A death of a liveborn infant within 28 days of birth.

**Oocyte recovery (retrieval)**

Procedure undertaken in an attempt to collect oocyte(s) from a woman.

**Ongoing pregnancy**

Ongoing pregnancy with fetal cardiac activity during the period of the year being reported on.

**Ongoing pregnancy rate**

Ongoing pregnancy rates expressed per 100 treatment cycles started/ commenced or per 100 cycles reaching the stage of attempted oocyte retrieval or embryo transfer.

**Spontaneous abortion (miscarriage)**

Loss of an intrauterine pregnancy detected clinically or by ultrasound, and less than 20 weeks’ gestation (as estimated by the day of embryo transfer or day of ovulation).

**Stillbirth**

The birth of an infant after 24 or more weeks of gestation that shows no signs of life.
Treatment cycle

The process in which a reproductive technology (RT) procedure is carried out, where a woman has undergone ovarian stimulation or monitoring with the intent of having RT procedure, or frozen embryos have been thawed with the intent of transferring them to a woman. A treatment cycle starts (a) on the day when superovulatory drugs were commenced or (b) from the date of the last menstrual period.

Number of cycles started (for AS Form 9)

Total number of treatment cycles started during the reporting period, including cycles which finally lead to insemination treatment and the canceled cycles (which do not lead to insemination treatment).

Number of cycles proceeded to IUI (for AS Form 9)

Number of treatment cycles started which finally lead to the intrauterine insemination.
Annual Statistics on Reproductive Technology Treatment
for Submission to the Council on Human Reproductive Technology

Please complete the form in block letter

<table>
<thead>
<tr>
<th>Name of centre</th>
<th>Licence no.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Period covered: [Day] [Month] [Year] to [Day] [Month] [Year]

1. IVF-ET (In-Vitro Fertilization & Embryo Transfer)

### Patients’ Characteristics

<table>
<thead>
<tr>
<th>Infertility diagnosis</th>
<th>No. of patients</th>
<th>Infertility duration (yr)</th>
<th>Age, women</th>
<th>Age, men</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>[cycles]</td>
<td>±</td>
<td>[±]</td>
<td></td>
</tr>
<tr>
<td>Male plus tubal</td>
<td>[cycles]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometriosis</td>
<td>[cycles]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male plus endometriosis</td>
<td>[cycles]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunologic</td>
<td>[cycles]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubo-peritoneal</td>
<td>[cycles]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovulatory</td>
<td>[cycles]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male plus ovulatory</td>
<td>[cycles]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubal plus ovulatory</td>
<td>[cycles]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unexplained</td>
<td>[cycles]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others (please specify):</td>
<td>[cycles]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Infertility Diagnosis vs Stimulation Protocol

<table>
<thead>
<tr>
<th>Infertility Diagnosis</th>
<th>Natural</th>
<th>Stimulated</th>
<th>Stimulation Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>[cycles]</td>
<td>[cycles]</td>
<td></td>
</tr>
<tr>
<td>Male plus tubal</td>
<td>[cycles]</td>
<td>[cycles]</td>
<td></td>
</tr>
<tr>
<td>Endometriosis</td>
<td>[cycles]</td>
<td>[cycles]</td>
<td></td>
</tr>
<tr>
<td>Male plus endometriosis</td>
<td>[cycles]</td>
<td>[cycles]</td>
<td></td>
</tr>
<tr>
<td>Immunologic</td>
<td>[cycles]</td>
<td>[cycles]</td>
<td></td>
</tr>
<tr>
<td>Tubo-peritoneal</td>
<td>[cycles]</td>
<td>[cycles]</td>
<td></td>
</tr>
<tr>
<td>Ovulatory</td>
<td>[cycles]</td>
<td>[cycles]</td>
<td></td>
</tr>
<tr>
<td>Male plus ovulatory</td>
<td>[cycles]</td>
<td>[cycles]</td>
<td></td>
</tr>
<tr>
<td>Tubal plus ovulatory</td>
<td>[cycles]</td>
<td>[cycles]</td>
<td></td>
</tr>
<tr>
<td>Unexplained</td>
<td>[cycles]</td>
<td>[cycles]</td>
<td></td>
</tr>
<tr>
<td>Others (please specify):</td>
<td>[cycles]</td>
<td>[cycles]</td>
<td></td>
</tr>
</tbody>
</table>

### Clinical Results

<table>
<thead>
<tr>
<th>Clinical Results</th>
<th>Natural cycle</th>
<th>Stimulated cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of cycles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of oocyte recoveries (/cycle)</td>
<td>( %)</td>
<td>( %)</td>
</tr>
<tr>
<td>No. of Embryo Transfers (ET)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of oocytes (/recovery)</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>No. of transferred embryos (/ET)</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Fertilization rate</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>No. of clinical pregnancies</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Clinical preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/recovery)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/ET)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>No. of ongoing pregnancies</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Ongoing preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/recovery)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/ET)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Spont. Abortion (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Ectopic preg. (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Heterotopic preg. (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Termination (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Still birth (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Neonatal death (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Lost to follow up (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Multiple preg. (clinical preg.)</td>
<td>cases</td>
<td>%</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------</td>
<td>---</td>
</tr>
<tr>
<td>Embryo reduction (clinical preg.)</td>
<td>cases</td>
<td>%</td>
</tr>
<tr>
<td>Malformation (newborn)</td>
<td>cases</td>
<td>%</td>
</tr>
<tr>
<td>No. of delivered or ongoing preg. (clinical preg.)</td>
<td>cases</td>
<td>%</td>
</tr>
<tr>
<td>Delivery plus ongoing pregnancy rate (cycle started)</td>
<td>cases</td>
<td>%</td>
</tr>
</tbody>
</table>
Annual Statistics on Reproductive Technology Treatment
for Submission to the Council on Human Reproductive Technology

Please complete the form in block letter

Name of centre : [ ]
Licence no. : [ ]

Period covered : Day Month Year to Day Month Year

2. GIFT (Gamete Intra-Fallopian Transfer)

<table>
<thead>
<tr>
<th>Patients' Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
</tr>
<tr>
<td>Infertility duration (yr)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Infertility Diagnosis</th>
<th>Stimulation Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male cycles</td>
<td>Natural cycles</td>
</tr>
<tr>
<td>Endometriosis cycles</td>
<td>Stimulated cycles</td>
</tr>
<tr>
<td>Male plus endometriosis cycles</td>
<td>Cycles ending up with ovarian hyperstimulation cycles</td>
</tr>
<tr>
<td>Immunologic cycles</td>
<td></td>
</tr>
<tr>
<td>Peritoneal cycles</td>
<td></td>
</tr>
<tr>
<td>Ovulatory cycles</td>
<td></td>
</tr>
<tr>
<td>Male plus ovulatory cycles</td>
<td></td>
</tr>
<tr>
<td>Tubal plus ovulatory cycles</td>
<td></td>
</tr>
<tr>
<td>Unexplained cycles</td>
<td></td>
</tr>
<tr>
<td>Others (please specify): cycles</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical Results</th>
<th>Natural cycle</th>
<th>Stimulated cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of cycles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of oocyte recoveries (/cycle)</td>
<td>( )</td>
<td>%</td>
</tr>
<tr>
<td>No. of gamete transfer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of oocytes (/recovery)</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>No. of transferred oocytes (/transfer)</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>No. of clinical pregnancies</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Clinical preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/recovery)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/transfer)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>No. of ongoing pregnancies</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Ongoing preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/recovery)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/transfer)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Spont. abortion (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Ectopic preg. (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Heterotopic preg. (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Termination (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Still birth (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Neonatal death (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Lost to follow up (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td></td>
<td>cases (%)</td>
<td>cases (%)</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>Multiple preg.</td>
<td>(</td>
<td>(</td>
</tr>
<tr>
<td>(/clinical preg.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Embryo reduction</td>
<td>(</td>
<td>(</td>
</tr>
<tr>
<td>(/clinical preg.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malformation</td>
<td>(</td>
<td>(</td>
</tr>
<tr>
<td>(/newborn)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of delivered or ongoing preg.</td>
<td>(</td>
<td>(</td>
</tr>
<tr>
<td>(/clinical preg.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delivery plus ongoing pregnancy rate</td>
<td>(</td>
<td>(</td>
</tr>
<tr>
<td>(/cycle started)</td>
<td>/cycle)</td>
<td>/cycle)</td>
</tr>
</tbody>
</table>
**Annual Statistics on Reproductive Technology Treatment**

*for Submission to the Council on Human Reproductive Technology*

*Please complete the form in block letter*

Name of centre: ____________________________
Licence no.: ____________________________

Period covered: [ ] [ ] [ ] to [ ] [ ] [ ]

<table>
<thead>
<tr>
<th>No. of patients</th>
<th>Age, women</th>
<th>Age, men</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infertility duration (yr)</td>
<td>[ ] ±</td>
<td>[ ] ±</td>
</tr>
</tbody>
</table>

**ZIFT/PROST (Zygote Intra-Fallopian Transfer/Pronuclear Stage Tubal Transfer)**

**Patients' Characteristics**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Infertility Diagnosis</th>
<th>Stimulation Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>[ ] cycles</td>
<td>Natural [ ] cycles</td>
</tr>
<tr>
<td>Male plus tubal</td>
<td>[ ] cycles</td>
<td>Stimulated [ ] cycles</td>
</tr>
<tr>
<td>Endometriosis</td>
<td>[ ] cycles</td>
<td>Cycles ending up with ovarian hyperstimulation [ ] cycles</td>
</tr>
<tr>
<td>Male plus endometriosis</td>
<td>[ ] cycles</td>
<td></td>
</tr>
<tr>
<td>Immunologic</td>
<td>[ ] cycles</td>
<td></td>
</tr>
<tr>
<td>Tubo-peritoneal</td>
<td>[ ] cycles</td>
<td></td>
</tr>
<tr>
<td>Ovulatory</td>
<td>[ ] cycles</td>
<td></td>
</tr>
<tr>
<td>Male plus ovulatory</td>
<td>[ ] cycles</td>
<td></td>
</tr>
<tr>
<td>Tubal plus ovulatory</td>
<td>[ ] cycles</td>
<td></td>
</tr>
<tr>
<td>Unexplained</td>
<td>[ ] cycles</td>
<td></td>
</tr>
<tr>
<td>Others (please specify): [ ] cycles</td>
<td>[ ] cycles</td>
<td>Donor semen [ ] patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Donor oocyte [ ] patients</td>
</tr>
</tbody>
</table>

**Clinical Results**

<table>
<thead>
<tr>
<th></th>
<th>Natural cycle</th>
<th>Stimulated cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of cycles</td>
<td>( )</td>
<td>( )</td>
</tr>
<tr>
<td>No. of oocyte recoveries (cycle)</td>
<td>( ) ± %</td>
<td>( ) ± %</td>
</tr>
<tr>
<td>No. of zygote transfer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of oocytes (recovery)</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>No. of transferred zygotes (transfer)</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>No. of clinical pregnancies</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Clinical preg. rate (cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (recovery)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (transfer)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>No. of ongoing pregnancies</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Ongoing preg. rate (cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (recovery)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (transfer)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Spont. abortion (clinical preg.)</td>
<td>( ) cases</td>
<td>( ) cases</td>
</tr>
<tr>
<td>Ectopic preg. (clinical preg.)</td>
<td>( ) cases</td>
<td>( ) cases</td>
</tr>
<tr>
<td>Heterotopic preg. (clinical preg.)</td>
<td>( ) cases</td>
<td>( ) cases</td>
</tr>
<tr>
<td>Termination (clinical preg.)</td>
<td>( ) cases</td>
<td>( ) cases</td>
</tr>
<tr>
<td>Still birth (clinical preg.)</td>
<td>( ) cases</td>
<td>( ) cases</td>
</tr>
<tr>
<td>Neonatal death (clinical preg.)</td>
<td>( ) cases</td>
<td>( ) cases</td>
</tr>
<tr>
<td>Lost to follow up (clinical preg.)</td>
<td>( ) cases</td>
<td>( ) cases</td>
</tr>
<tr>
<td>Condition</td>
<td>Cases (%)</td>
<td>Cases (%)</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>Multiple preg.</td>
<td>(</td>
<td>(</td>
</tr>
<tr>
<td>(clinical preg.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Embryo reduction</td>
<td>(</td>
<td>(</td>
</tr>
<tr>
<td>(clinical preg.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malformation</td>
<td>(</td>
<td>(</td>
</tr>
<tr>
<td>(newborn)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of delivered or ongoing preg.</td>
<td>(</td>
<td>(</td>
</tr>
<tr>
<td>(clinical preg.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delivery plus ongoing pregnancy rate</td>
<td>(</td>
<td>(</td>
</tr>
<tr>
<td>(cycle started)</td>
<td>/cycle</td>
<td>/cycle</td>
</tr>
</tbody>
</table>
Annual Statistics on Reproductive Technology Treatment
for Submission to the Council on Human Reproductive Technology

Please complete the form in block letter

Name of centre :
Licence no. :
Period covered :

<table>
<thead>
<tr>
<th>Day</th>
<th>Month</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Day Month Year to Day Month Year

4. Frozen-thawed ET (Embryo Transfer)

Patients' Characteristics

<table>
<thead>
<tr>
<th>No. of patients</th>
<th>Age, women</th>
<th>Infertility duration (yr)</th>
<th>Age, men</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ ]</td>
<td>[ ± ]</td>
<td>[ ± ]</td>
<td>[ ± ]</td>
</tr>
</tbody>
</table>

Endometrial Preparation Protocol

<table>
<thead>
<tr>
<th>Natural</th>
<th>Artificial</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ cycles]</td>
<td>[ cycles]</td>
</tr>
</tbody>
</table>

Clinical Results

<table>
<thead>
<tr>
<th>Natural cycle</th>
<th>Artificial cycle</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>No. of cycles</th>
<th>Natural cycle</th>
<th>Artificial cycle</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>No. of Embryo Transfers (ET)</th>
<th>Natural cycle</th>
<th>Artificial cycle</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Survival rate of frozen-thawed embryos</th>
<th>Natural cycle</th>
<th>Artificial cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of storage (month)</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>No. of transferred embryos (/ET)</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No. of clinical pregnancies</th>
<th>Natural cycle</th>
<th>Artificial cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical preg. rate (/cycle started)</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Clinical preg. rate (/recovery)</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Clinical preg. rate (/ET)</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No. of ongoing pregnancies</th>
<th>Natural cycle</th>
<th>Artificial cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing preg. rate (/cycle started)</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Ongoing preg. rate (/recovery)</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Ongoing preg. rate (/ET)</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Spont. abortion</th>
<th>Natural cycle</th>
<th>Artificial cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ectopic preg.</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Heterotopic preg.</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Termination</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Still birth</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Neonatal death</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Lost to follow up</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Multiple preg.</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Embryo reduction</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Malformation</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>(newborn)</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>No. of delivered or ongoing preg.</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
<tr>
<td>Delivery plus ongoing pregnancy rate</td>
<td>Natural cycle</td>
<td>Artificial cycle</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>(cycle started)</th>
<th>(cycle)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(cycle)</td>
<td>(cycle)</td>
</tr>
</tbody>
</table>
Annual Statistics on Reproductive Technology Treatment
for Submission to the Council on Human Reproductive Technology

Please complete the form in block letter

Name of centre: 
Licence no.: 
Period covered: 

<table>
<thead>
<tr>
<th>Day</th>
<th>Month</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>to</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5. ICSI (Intra-Cytoplasmic Sperm Injection)

Patients' Characteristics

| No. of patients | [ ] | Age, women | [ ] ± |
| Infertility duration (yr) | [ ] ± | Age, men | [ ] ± |

Treatment Method

ICSI with IVF [ ] cycles  ICSI with PROST [ ] cycles  ICSI with MIFT [ ] cycles

Clinical Results

<table>
<thead>
<tr>
<th></th>
<th>ICSI with IVF</th>
<th>ICSI with PROST</th>
<th>ICSI with MIFT</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of cycles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of oocyte recoveries (/cycle)</td>
<td>( )</td>
<td>( )</td>
<td>( )</td>
</tr>
<tr>
<td>No. of zygote transfer</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>No. of oocytes (/recovery)</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>No. of transferred zygotes (/transfer)</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Fertilization rate</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>No. of clinical pregnancies</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Clinical preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/recovery)</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/transfer)</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>No. of ongoing pregnancies</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Ongoing preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/recovery)</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/transfer)</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Spont. abortion (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>( %)</td>
<td>( %)</td>
<td>( %)</td>
<td></td>
</tr>
<tr>
<td>Ectopic preg. (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>( %)</td>
<td>( %)</td>
<td>( %)</td>
<td></td>
</tr>
<tr>
<td>Heterotopic preg. (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>( %)</td>
<td>( %)</td>
<td>( %)</td>
<td></td>
</tr>
<tr>
<td>Termination (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>( %)</td>
<td>( %)</td>
<td>( %)</td>
<td></td>
</tr>
<tr>
<td>Still birth (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>( %)</td>
<td>( %)</td>
<td>( %)</td>
<td></td>
</tr>
<tr>
<td>Neonatal death (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>( %)</td>
<td>( %)</td>
<td>( %)</td>
<td></td>
</tr>
<tr>
<td>Lost to follow up (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>( %)</td>
<td>( %)</td>
<td>( %)</td>
<td></td>
</tr>
<tr>
<td>Multiple preg. (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>( %)</td>
<td>( %)</td>
<td>( %)</td>
<td></td>
</tr>
<tr>
<td>Embryo reduction (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>( %)</td>
<td>( %)</td>
<td>( %)</td>
<td></td>
</tr>
<tr>
<td>Malformation (/newborn)</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>( %)</td>
<td>( %)</td>
<td>( %)</td>
<td></td>
</tr>
<tr>
<td>No. of delivered or ongoing preg. (/clinical preg.)</td>
<td>cases</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Delivery plus ongoing pregnancy rate (/cycle started)</td>
<td>( ) /cycle</td>
<td>( ) /cycle</td>
<td>( ) /cycle</td>
</tr>
</tbody>
</table>
Annual Statistics on Reproductive Technology Treatment
for Submission to the Council on Human Reproductive Technology

Please complete the form in block letter

Name of centre: ____________________________
Licence no.: ____________________________

Period covered: [ ] [ ] [ ] [ ] to [ ] [ ] [ ]

6. Use of Reproductive Technology for Surrogacy Arrangement

<table>
<thead>
<tr>
<th>Patients' Characteristics</th>
<th>Infertility Diagnosis</th>
<th>Stimulation Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>Age, women [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Infertility duration (yr)</td>
<td>[ [ ] [ ] [ ] [ ]]</td>
<td>Age, men [ ] [ ] [ ] [ ]</td>
</tr>
</tbody>
</table>

Hysterectomy [ ] cases Natural [ ] cycles
Absent/Abnormal uterus and/or ducts [ ] cases Stimulated [ ] cycles
Others (please specify): ( ) Cycles ending up with ovarian hyperstimulation [ ] cycles

Surrogate Mothers' Characteristics

| No. of surrogate mothers | [ ] [ ] [ ] [ ] | Single but previously married and had one or more than one pregnancy [ ] case |
| Age                     | [ ] [ ] [ ] [ ] | Married [ ] case |
| Unmarried               | [ ] [ ] [ ] [ ] |

Treatment Method

| IVF-ET [ ] cycles | Frozen-thawed ET [ ] cycles |
| ZIFT/PROST [ ] cycles | Others (please specify): [ ] [ ] [ ] [ ] |

Clinical Results

<table>
<thead>
<tr>
<th>No. of cycles</th>
<th>Natural cycle</th>
<th>Stimulated cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of oocyte recoveries (/cycle)</td>
<td>( ) %</td>
<td>( ) %</td>
</tr>
<tr>
<td>No. of embryos/zygotes transfer</td>
<td>( )</td>
<td>( )</td>
</tr>
<tr>
<td>No. of oocytes (/recovery)</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>No. of transferred embryos/zygotes (/transfer)</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Fertilization rate</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>No. of clinical pregnancies cases</td>
<td>cases</td>
<td></td>
</tr>
<tr>
<td>Clinical preg. rate (/cycle started) %</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Clinical preg. rate (/recovery) %</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Clinical preg. rate (/transfer) %</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>No. of ongoing pregnancies cases</td>
<td>cases</td>
<td></td>
</tr>
<tr>
<td>Ongoing preg. rate (/cycle started) %</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Ongoing preg. rate (/recovery) %</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Ongoing preg. rate (/transfer) %</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Spont. abortion (/clinical preg.) cases</td>
<td>cases</td>
<td></td>
</tr>
<tr>
<td>Ectopic preg. (/clinical preg.) cases</td>
<td>cases</td>
<td></td>
</tr>
<tr>
<td>Heterotopic preg. (/clinical preg.) cases</td>
<td>cases</td>
<td></td>
</tr>
<tr>
<td>Termination (/clinical preg.) cases</td>
<td>cases</td>
<td></td>
</tr>
<tr>
<td>Still birth (/clinical preg.) cases</td>
<td>cases</td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>Cases</td>
<td>%</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>-------</td>
<td>---</td>
</tr>
<tr>
<td>Neonatal death</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lost to follow up</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple preg.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Embryo reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malformation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of delivered or ongoing preg.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delivery plus ongoing pregnancy rate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Please complete the form in block letter

Name of centre: _______________________
Licence no. ________________

Period covered: ___________ to ___________

7. Use of Reproductive Technology for Gender Selection to Avoid Sex-linked Diseases

**Patients’ Characteristics**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Affected genes</th>
<th>Husband</th>
<th>Wife</th>
<th>Both</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male lethal sex-linked genetic diseases</td>
<td>[ cases]</td>
<td>[ cases]</td>
<td>[ cases]</td>
<td></td>
</tr>
<tr>
<td>Female lethal sex-linked genetic diseases</td>
<td>[ cases]</td>
<td>[ cases]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male non-lethal sex-linked genetic diseases</td>
<td>[ cases]</td>
<td>[ cases]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female non-lethal sex-linked genetic diseases</td>
<td>[ cases]</td>
<td>[ cases]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Infertility Diagnosis**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Natural</th>
<th>Stimulated</th>
<th>Cycles ending up with ovarian hyperstimulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>With infertility problems</td>
<td>[ cases]</td>
<td>[ cases]</td>
<td>[ cases]</td>
</tr>
<tr>
<td>Without infertility problems</td>
<td>[ cases]</td>
<td>[ cases]</td>
<td>[ cases]</td>
</tr>
</tbody>
</table>

**Gender Selection Methods Used**

<table>
<thead>
<tr>
<th>Method</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sperm treatment with IVF-ET</td>
<td>[ cases]</td>
</tr>
<tr>
<td>Sex-selective abortion</td>
<td>[ cases]</td>
</tr>
<tr>
<td>PGD with sex-selective zygote transfer</td>
<td>[ cases]</td>
</tr>
<tr>
<td>Others (please specify):</td>
<td>[ cases]</td>
</tr>
</tbody>
</table>

**Clinical Results**

<table>
<thead>
<tr>
<th>Results</th>
<th>Natural cycle</th>
<th>Stimulated cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of cycles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of oocyte recoveries (/cycle)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of male embryo/zygote transfer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of female embryo/zygote transfer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of oocytes (/recovery)</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>No. of transferred embryos/zygotes</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Fertilization rate (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of clinical pregnancies</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Clinical preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/recovery)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/transfer)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>No. of ongoing pregnancies</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Ongoing preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/recovery)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/transfer)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Spont. abortion (/clinical preg.)</td>
<td>( %)</td>
<td>( %)</td>
</tr>
<tr>
<td>Ectopic preg. (/clinical preg.)</td>
<td>( %)</td>
<td>( %)</td>
</tr>
<tr>
<td>Heterotopic preg. (/clinical preg.)</td>
<td>( %)</td>
<td>( %)</td>
</tr>
<tr>
<td>Termination (/clinical preg.)</td>
<td>( %)</td>
<td>( %)</td>
</tr>
<tr>
<td>Event</td>
<td>Cases</td>
<td>%</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>-------</td>
<td>------</td>
</tr>
<tr>
<td>Still birth</td>
<td>(</td>
<td>%</td>
</tr>
<tr>
<td>Neonatal death</td>
<td>(</td>
<td>%</td>
</tr>
<tr>
<td>Lost to follow up</td>
<td>(</td>
<td>%</td>
</tr>
<tr>
<td>Multiple preg.</td>
<td>(</td>
<td>%</td>
</tr>
<tr>
<td>Embryo reduction</td>
<td>(</td>
<td>%</td>
</tr>
<tr>
<td>Malformation</td>
<td>(</td>
<td>%</td>
</tr>
<tr>
<td>No. of delivered or ongoing preg.</td>
<td>(</td>
<td>%</td>
</tr>
<tr>
<td>Delivery plus ongoing pregnancy rate</td>
<td>(</td>
<td>/cycle</td>
</tr>
<tr>
<td>No. of fetuses aborted for sex selective abortion:</td>
<td>male</td>
<td>(</td>
</tr>
<tr>
<td>[total cases]</td>
<td>cases</td>
<td></td>
</tr>
</tbody>
</table>
### Annual Statistics on Reproductive Technology Treatment
**AS Form 8**
for Submission to the Council on Human Reproductive Technology

**Please complete the form in block letter**

| Name of centre : |  |
| Licence no. : |  |

**Period covered :**

<table>
<thead>
<tr>
<th>Day</th>
<th>Month</th>
<th>Year</th>
<th>to</th>
<th>Day</th>
<th>Month</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

8. **Others** (* )

#### Patients' Characteristics

<table>
<thead>
<tr>
<th>No. of patients</th>
<th>Age, women</th>
<th>±</th>
</tr>
</thead>
<tbody>
<tr>
<td>infertility duration (yr)</td>
<td>±</td>
<td>Age, men</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Infertility Diagnosis</th>
<th>Stimulation Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>cycles</td>
</tr>
<tr>
<td>Male plus tubal</td>
<td>cycles</td>
</tr>
<tr>
<td>Endometriosis</td>
<td>cycles</td>
</tr>
<tr>
<td>Male plus endometriosis</td>
<td>cycles</td>
</tr>
<tr>
<td>Immunologic</td>
<td>cycles</td>
</tr>
<tr>
<td>Tubo-peritoneal</td>
<td>cycles</td>
</tr>
<tr>
<td>Ovulatory</td>
<td>cycles</td>
</tr>
<tr>
<td>Male plus ovulatory</td>
<td>cycles</td>
</tr>
<tr>
<td>Tubal plus ovulatory</td>
<td>cycles</td>
</tr>
<tr>
<td>Unexplained</td>
<td>cycles</td>
</tr>
<tr>
<td>Others (please specify):</td>
<td>cycles</td>
</tr>
<tr>
<td>( )</td>
<td></td>
</tr>
</tbody>
</table>

#### Clinical Results

<table>
<thead>
<tr>
<th>No. of cycles</th>
<th>Natural cycle</th>
<th>Stimulated cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of oocyte recoveries (/cycle)</td>
<td>( )</td>
<td>( %)</td>
</tr>
<tr>
<td>No. of embryos transferred (ET)</td>
<td>( )</td>
<td>( )</td>
</tr>
<tr>
<td>No. of oocytes (/recovery)</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>No. of transferred embryos (/ET)</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Fertilization rate</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>No. of clinical pregnancies</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Clinical preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/recovery)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/ET)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>No. of ongoing pregnancies</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>Ongoing preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/recovery)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/ET)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Spont. abortion</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>(clinical preg.)</td>
<td>( )</td>
<td>( )</td>
</tr>
<tr>
<td>Ectopic preg.</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>(clinical preg.)</td>
<td>( )</td>
<td>( )</td>
</tr>
<tr>
<td>Heterotopic preg.</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>(clinical preg.)</td>
<td>( )</td>
<td>( )</td>
</tr>
<tr>
<td>Termination</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>(clinical preg.)</td>
<td>( )</td>
<td>( )</td>
</tr>
<tr>
<td>Still birth</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>(clinical preg.)</td>
<td>( )</td>
<td>( )</td>
</tr>
<tr>
<td>Neonatal death</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>(clinical preg.)</td>
<td>( )</td>
<td>( )</td>
</tr>
<tr>
<td>Lost to follow up</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>(clinical preg.)</td>
<td>( )</td>
<td>( )</td>
</tr>
<tr>
<td>Multiple preg. (/clinical preg.)</td>
<td>cases</td>
<td>%</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------</td>
<td>---</td>
</tr>
<tr>
<td>Embryo reduction (/clinical preg.)</td>
<td>(</td>
<td></td>
</tr>
<tr>
<td>Malformation (/newborn)</td>
<td>cases</td>
<td>%</td>
</tr>
<tr>
<td>No. of delivered or ongoing preg. (/clinical preg.)</td>
<td>(</td>
<td></td>
</tr>
<tr>
<td>Delivery plus ongoing pregnancy rate (/cycle started)</td>
<td>(</td>
<td>/cycle</td>
</tr>
</tbody>
</table>

*In the case of micromanipulations, please specify the type of methods (eg. Partial Zona Dissection, Subzonal Sperm Insertion, etc)
### Annual Statistics on Reproductive Technology Treatment
**for Submission to the Council on Human Reproductive Technology**

**Please complete the form in block letter**

<table>
<thead>
<tr>
<th>Name of centre</th>
<th>Licence no.</th>
</tr>
</thead>
</table>

Period covered: 1 1 1 1 3 1 1 2

9. **AIH (Artificial Insemination by Husband)**

#### Patients' Characteristics

<table>
<thead>
<tr>
<th>No. of patients</th>
<th>Age, women</th>
<th>±</th>
<th>Age, men</th>
<th>±</th>
</tr>
</thead>
</table>

#### Infertility Diagnosis

<table>
<thead>
<tr>
<th>Male</th>
<th>Endometriosis</th>
<th>Male plus endometriosis</th>
<th>Ovulatory</th>
<th>Male plus ovulatory</th>
<th>Unexplained</th>
<th>Others (please specify):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Clinical Results

<table>
<thead>
<tr>
<th>No. of cycles started Note 1</th>
<th>IVI and ICI cases</th>
<th>IUI cases</th>
<th>No. of cycle which proceeded to IUI Note 2</th>
<th>cases</th>
<th>cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVI and ICI</td>
<td></td>
<td></td>
<td>IUI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of clinical pregnancies</td>
<td>cases</td>
<td>cases</td>
<td>Clinical preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/cycle started)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of ongoing pregnancies</td>
<td>cases</td>
<td>cases</td>
<td>Ongoing preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/cycle started)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IUI</td>
<td></td>
<td></td>
<td>No. of clinical pregnancies</td>
<td>cases</td>
<td>cases</td>
</tr>
<tr>
<td>No. of clinical pregnancies</td>
<td>cases</td>
<td>cases</td>
<td>Clinical preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Clinical preg. rate (/cycle started)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of ongoing pregnancies</td>
<td>cases</td>
<td>cases</td>
<td>Ongoing preg. rate (/cycle started)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Ongoing preg. rate (/cycle started)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| Spont. abortion (/clinical preg.) | cases | % | cases | % |
| Ectopic preg. (/clinical preg.)  | cases | % | cases | % |
| Heterotopic preg. (/clinical preg.) | cases | % | cases | % |
| Termination (/clinical preg.)    | cases | % | cases | % |
| Still birth (/clinical preg.)    | cases | % | cases | % |
| Neonatal death (/clinical preg.) | cases | % | cases | % |
| Lost to follow up (/clinical preg.) | cases | % | cases | % |
| Multiple preg. (/clinical preg.) | cases | % | cases | % |
| Embryo reduction (/clinical preg.) | cases | % | cases | % |
| Malformation (/newborn)          | cases | % | cases | % |</p>
<table>
<thead>
<tr>
<th>No. of delivered or ongoing preg. (clinical preg.)</th>
<th>cases %</th>
<th>cases %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delivery plus ongoing pregnancy rate (cycle started)</td>
<td>/cycle</td>
<td>/cycle</td>
</tr>
</tbody>
</table>

Notes:

1. "No. of cycles started" means the "Total no. of treatment cycles started during the reporting period, including cycles which finally lead to insemination and the cancelled cycles".

2. "No. of cycles which proceeded to IUI" means cycles started which finally lead to the intrauterine insemination.
Annual Statistics on Reproductive Technology Treatment
for Submission to the Council on Human Reproductive Technology

Please complete the form in Block Letters

Name of centre : ____________________________
Licence no. : _______________________________
Period covered : [ ] [ ] [ ] to [ ] [ ] [ ]

Storage of Gametes / Embryos

A. Total number of gametes / embryos stored at the centre (as at end of the above period)

<table>
<thead>
<tr>
<th>Total number of embryos stored</th>
<th>Total number of eggs (oocytes) stored</th>
<th>Total number of semen samples stored</th>
</tr>
</thead>
</table>

B. Information on Donors and Storage of Donated Materials (for the period covered)

<table>
<thead>
<tr>
<th>Donated materials</th>
<th>Number of Donors Note 1</th>
<th>Number of donations made</th>
</tr>
</thead>
<tbody>
<tr>
<td>Semen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eggs (Oocytes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Embryos</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C. Age Distribution of Donors

<table>
<thead>
<tr>
<th>Age</th>
<th>No. of Female Donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-20</td>
<td></td>
</tr>
<tr>
<td>21-25</td>
<td></td>
</tr>
<tr>
<td>26-30</td>
<td></td>
</tr>
<tr>
<td>31-35</td>
<td></td>
</tr>
<tr>
<td>36 or above</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age</th>
<th>No. of Male Donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-20</td>
<td></td>
</tr>
<tr>
<td>21-25</td>
<td></td>
</tr>
<tr>
<td>26-30</td>
<td></td>
</tr>
<tr>
<td>31-35</td>
<td></td>
</tr>
<tr>
<td>36-40</td>
<td></td>
</tr>
<tr>
<td>41-45</td>
<td></td>
</tr>
<tr>
<td>46-50</td>
<td></td>
</tr>
<tr>
<td>51-55</td>
<td></td>
</tr>
<tr>
<td>56 or above</td>
<td></td>
</tr>
</tbody>
</table>

For Official Use
No.
Form received on [ ] [ ] [ ]
### D. Storage of Donated Materials

**Note:** 2 (No. of sample stored as at the end of the period)

<table>
<thead>
<tr>
<th>Sources</th>
<th>Anonymous</th>
<th>Designated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Local</td>
<td>Import</td>
</tr>
<tr>
<td>Purposes of storage</td>
<td>Treatment</td>
<td>Research</td>
</tr>
<tr>
<td>No. of donated semen samples</td>
<td></td>
<td></td>
</tr>
<tr>
<td>stored</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of donated eggs (oocytes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>stored</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of donated embryos stored</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### E. Donated embryos used for research project

<table>
<thead>
<tr>
<th>Research project licence no.</th>
<th>No. of embryos used</th>
<th>Dates when embryos were used</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Day</td>
</tr>
<tr>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:

1. Same donor giving donation at different time would be counted as one donor.
2. The number should exclude the gametes / embryos stored for own-treatment.